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Cancer is one of the leading causes of death. Studies have shown that vitamin E 
forms including gamma-tocopherol (γT), delta-tocopherol (δT), and gamma-tocotrienol 
(γTE) exhibited potent anticancer activities in various types of cancer cells. But 
molecular mechanisms underlying anticancer actions of γTE are not completely 
understood. 13’-carboxychromanols (13’-COOHs), major fecal excreted long-chain 
metabolites of vitamin E, have recently been shown to induce apoptosis in liver cancer 
cells. However, it is not clear whether 13’-COOHs have anticancer effects on other types 
of cancer. In the current study, we investigated the anticancer effects and mechanisms of 
γTE and 13’-COOHs; δT-13’-COOH and δTE-13’-COOH, which are metabolites of δT 
or delta-tocotrienol (δTE), respectively. Like γTE, 13’-COOHs inhibited the growth and 
induced apoptosis and autophagy in human colon, breast, and pancreatic cancer cells in a 
time- and dose-dependent manner. In these activities, 13’-COOHs were similar or more 
potent than γTE, both of which were much stronger than γT and δT. Since we have 
previously shown that γTE and γT induce prostate cancer cell death by modulation of 




the levels of sphingolipids in cancer cells using liquid chromatography tandem mass 
spectrometry. Treatment of human colon cancer HCT-116 cells with γTE or δT-13’-
COOH significantly increased in intracellular dihydroceramides (dhCers) and 
dihydrosphingosine (dhSph), sphingoid bases in de novo synthesis pathway of 
sphingolipids, but decreased in C16:0-ceramide (Cer) during shorter treatment. During 
longer treatment, γTE or δT-13’-COOH increased in C16:0- and C18:0-Cers while 
decreased in SMs. To investigate potential effects on de novo synthesis of sphingolipids, 
we used 13C3, 15N-labeled L-serine, which condensed with palmitoyl-CoA to form the 
first sphingolipid intermediate in the de novo synthesis pathway. We found that compared 
with controls, γTE or δT-13’-COOH treatment increased labeled dhCers and dhSph, but 
led to decrease in labeled Cers. These results strongly suggest that γTE or δT-13’-COOH 
inhibit dihydroceramide desaturase (DEGS)-catalyzed reactions and may activate 
sphingomyelin hydrolysis to enhance Cer levels. Consistently, we found that γTE or δT-
13’-COOH inhibited the DEGS activity, while they did not affect DEGS expression. The 
importance of sphingolipid modulation was further supported by blocking the increase of 
these sphingolipids, which resulted in a partial counteraction of γTE or 13’-COOHs-
induced cell death. In agreement with these cell-based studies, δTE-13’-COOH showed 
anticancer activities in a preclinical model in mice. In addition, we found that various 
phytochemicals including curcumin, resveratrol, and epigallocatechin gallate, etc. also 
modulated sphingolipid metabolism in cancer cells. Overall, our studies demonstrate that 






CHAPTER 1. LITERATURE REVIEW 
1.1 Vitamin E 
 
1.1.1 Vitamin E Forms and Food Sources 
 
Vitamin E is an important nutrient and is a well-known lipophilic chain-breaking 
antioxidant. In 1922, Evans and Bishop first discovered vitamin E as an essential dietary 
factor for reproduction in rats (Evans and Bishop, 1922). Since the discovery, many 
researchers have focused on the potential health benefits of vitamin E for various 
diseases. Natural forms of vitamin E consist of eight structurally related molecules that 
can be further divided into two major groups, which are tocopherols and tocotrienols. 
Tocopherols and tocotrienols are composed of the same basic chemical structure 
characterized by a 16-carbon phytyl chain which is attached at the 2-position of a 
chromane ring. However, the difference between tocopherols and tocotrienols is that 
tocopherols have a saturated phytyl chain whereas tocotrienols have an unsaturated 
phytyl chain with three double bonds. Individual tocopherols and tocotrienols, which are 
α-, β-, γ- and δ-tocopherol (αT, βT, γT and δT) and α-, β-, γ- and δ-tocotrienol (αTE, 




methyl groups in the chromane ring. The structures of tocopherols and tocotrienols are 




Figure 1.1 Structures of natural forms of vitamin E. (A) Tocopherols and (B) tocotrienols. 
All vitamin E forms contain a 16-carbon phytyl chain which is attached at the 2-position 
of a chromane ring. The difference between tocopherol and tocotrienol is that tocotrienol 











Furthermore, vitamin E is found in both natural and synthetic forms. Natural 
forms of tocopherol have the RRR configuration at the 2, 4’, and 8’-positions of the 
phytyl tail, and natural forms of tocotrienol have the R configuration at the 2-position of 
the phytyl tail. Both natural single stereoisomeric form of α-tocopherol (RRR, formerly 
d-α-tocopherol) and synthetic form of α-tocopherol are available commercially for the 
use as a dietary supplement. When α-tocopherol is synthesized chemically, this synthetic 
form consists of an approximately equimolar mixture of all eight possible stereoisomers 
(all-racemic α-tocopherol, formerly dl-α-tocopherol): RRR, RRS, RSS, RSR, SRR, SSR, 
SRS, and SSS (Brigelius-Flohe and Traber, 1999; Burton et al., 1998). Although they 
have similar structures, the different stereoisomers of vitamin E have different 
bioavailability and bioacitivity, which will be discussed in the next section. In addition, 
as the free forms of vitamin E are easy to be oxidized, more stable forms of vitamin E as 
a dietary supplement have been produced. Since ester forms are very stable, α-tocopherol 
is usually sold either as acetate esters (RRR α-tocopheryl acetate or all-rac α-tocopheryl 
acetate) or as succinate esters (RRR α-tocopheryl succinate or all-rac α-tocopheryl 
succinate). Among them, the acetate ester of all-rac α-tocopherol is the most common 
form of vitamin E supplementation due to the cost and the stability (Vagni et al., 2011). 
Since humans and animals do not make vitamin E, they acquire natural forms of 
vitamin E from plants. Vitamin E is found in various types of foods such as some fruits, 
vegetable oils, green leafy vegetables, plant seeds, corn, barley, oats, and wheat germ. 
Natural sources of tocopherols include vegetable oils, plant seeds and nuts. For instance, 
peanuts, almonds, and sunflower seeds are major sources of αT, whereas γT is rich in 




germ. As the corn and soybean oils are widely used, γT accounts for about 70% of the 
vitamin E in the US diet. On the other hand, tocotrienols are mainly found in palm oil, 
barley, oats and some cereal grains, but in much smaller amounts than tocopherols (Jiang 
et al., 2001; McLaughlin and Weihrauch, 1979; Slover, 1971). 
 
1.1.2 Bioavailability and Metabolites  
 
Vitamin E is a lipophilic (fat-soluble) vitamin, and similar to other lipids, all 
vitamin E forms are absorbed equally into the intestine along with dietary fat, and 
incorporated into chylomicrons. The chylomicron-bound vitamin E is transported through 
lymphatic system to peripheral tissues such as skin, adipose, muscle or brain with the 
help of lipoprotein lipase. The chylomicron remnants are taken up by the liver for 
metabolism or further distribution. In the liver, αT is preferentially incorporated into 
very-low-density lipoproteins due to the high affinity of α-tocopherol transfer protein (α-
TTP) together with ATP-binding cassette transporter A1 (ABCA1), and re-distributed 
throughout the body. Therefore, αT is the predominant form in most human and animal 
tissues and plasma as it is protected by α-TTP from being metabolized (Brigelius-Flohe 
and Traber, 1999; Jiang, 2014; Jiang et al., 2001; Manor and Morley, 2007; Traber, 
2007). 
In contrast, α-TTP has much lower affinity toward other forms of vitamin E. 
Thus, non-αT forms of vitamin E such as β-, γ-, δ-T and α-, β-, γ-, δ-TE are relatively low 
in tissues as they are preferentially catabolized in the liver via cytochrome P450 




then further oxidized to 13’-carboxychromanol (13’-COOH), followed by β-oxidation of 
the phytyl chain to generate various shorter chain length of carboxychromanols including 
11’- and 9’-COOHs, and the terminal product 3’-COOH or (2’-carboxyethyl)-6-
hydroxychromans (CEHCs), which is the water-soluble metabolite of vitamin E, and then 
primarily excreted out of the body by the urine (Fig. 1.2) (Jiang, 2014; Sontag and 
Parker, 2002; Swanson et al., 1999). In parallel with β-oxidation, conjugation such as 
sulfation and glucuronidation of the phenolic on the chromane ring in the intermediate 
metabolites takes place when the intake of vitamin E forms is high (Jiang et al., 2007). 
Therefore, despite γT is the major form of vitamin E in the US diet, αT is the 
predominant form of vitamin E in the body. The plasma concentrations of αT are about 
20~30 μM, but γT is 5-10 times lower than αT in the plasma (Behrens and Madere, 1986; 
Jiang et al., 2001). Also, the bioavailability of γT is suppressed by increased intake of αT 
(Handelman et al., 1985), but γT supplementation increased the levels of both 
tocopherols (Clement and Bourre, 1997).   
 In addition to the different bioavailability of each natural vitamin E form, the 
different stereoisomers of vitamin E have different bioavailability as well as biopotencies. 
Both natural form of vitamin E and synthetic vitamin E are absorbed in the body. 
However, after absorption, RRR-αT, a natural form of vitamin E has a greater 
bioavailability and activities than the all-rac forms due to the higher affinity of RRR-αT 
toward the liver protein named α-TTP over the synthetic forms. Thus, synthetic forms of 
vitamin E are preferentially excreted. The bioavailability of natural vitamin E is about 




synthetic forms of vitamin E are required to match the bioavailability of the natural forms 





Figure 1.2 Metabolism of vitamin E forms and their metabolites. Vitamin E forms are 






1.1.3 Bioactivities of Vitamin E 
 
The biological activity of vitamin E compounds has historically been assessed by 
the rat fetal resorption assay. In this assay, the biological activity of vitamin E is 
measured based on its ability to prevent or reverse the symptoms of vitamin E deficiency 
such as fetal resorption, encephalomalacia and muscular dystrophy, followed by embryo 
death. Among natural forms of vitamin E, αT has been shown to have the highest 
biological acitivity measured by this assay. Studies have also demonstrated that α-TTP is 
present in pregnant rodent uterus, and αT is important during pregnancy (Bieri and 
Evarts, 1974). However, this difference in activity between vitamin E forms appears to be 
caused by the lower concentrations of non-αT forms of vitamin E in tissues and plasma 




Free radicals generated by oxidative stress exert an important role in the 
development of numerous diseases including cancer, atherosclerosis, and 
neurodegenerative diseases. All vitamin E forms have been well recognized as one of the 
most important antioxidants. It has been known to be a potent, lipophilic peroxyl radical 
scavenger that protects biological molecules from oxygen toxicity. In vitamin E studies, 
most researches have primarily focused on αT until recently, because αT is the 
predominant form of vitamin E in tissues and plasma, and due to its highest biological 




vitamin E deficiency-associated ataxia. Moreover, among tocopherols, αT has been 
shown to have the highest antioxidant activities against peroxyl radical (LOO⋅) and delta-
tocopherol is the least active (alpha > beta = gamma > delta). αT terminates the chain 
reaction of free radical mediated lipid peroxidation by donating hydrogens from the 
phenolic group on the chromane ring to lipid radicals. Therefore, αT protects lipid 
membrane from lipid radical damage (Kamal-Eldin and Appelqvist, 1996). After αT 
becomes a free radical itself, it can be recycled back to antioxidant form by vitamin C 
(ascorbic acid) (Traber and Stevens, 2011). In contrast, γT has its unique ability to 
change highly reactive nitrogen back into safe NO, thereby protection against oxidation 
damage by reactive nitrogen species. αT lacks this ability (Cooney et al., 1993; Jiang et 
al., 2001).  
On the other hand, tocotrienols also show antioxidant effects by scavenging the 
chain-propagating peroxyl radical. It has been demonstrated that αTE has a more potent 
antioxidant activity than αT for the scavenging peroxyl radicals in liposomes as it is 
distributed more evenly in the phospholipid bilayer of the plasma membrane, and it 
shows more efficient collision with radicals (Packer et al., 2001; Wong and 
Radhakrishnan, 2012). 
In addition to tocopherols and tocotrienols, 13’-carboxychromanols from δT and 
δTE, which are long-chain metabolites of vitamin E, have been shown to exert stronger 








Besides antioxidant activities of vitamin E, vitamin E isoforms have other 
biological functions independent of their antioxidant properties such as anti-
inflammatory, anticancer, cardioprotective, and antidiabetic effects. Chronic 
inflammation has been recognized to contribute to the development of other chronic 
diseases including cardiovascular diseases and cancer (Balkwill and Mantovani, 2001; 
Libby et al., 2002). Eicosanoids derived from arachidonic acid via cyclooxygenases 
(COX) and 5-lipoxygenase (LOX)-catalyzed reaction play important roles in regulation 
of inflammation and cancer (Vane, 1976; Wang and Dubois, 2010). Mechanistic studies 
have shown that vitamin E forms such as γT, δT, and γTE exert anti-inflammatory 
activities by inhibiting COXs and 5-LOX activities and suppressing nuclear factor κB 
(NF-κB) and Janus kinase (JAK)-signal transducer and activator of transcription (STAT) 
6 or JAK-STAT3 signaling pathways in various types of cells (Jiang, 2014; Jiang et al., 
2000; Wang and Jiang, 2013; Wong and Radhakrishnan, 2012). In particular, recent 
studies in our group found novel mechanisms of anti-inflammatory effects of γTE in 
which γTE inhibited TNFα-stimulated NF-κB, TAK1 and JNK activation by modulation 
of sphingolipids, induction of ER stress followed by up-regulation of A20 (Wang et al., 
2015). In addition, our group have also demonstrated that δT-13’-COOH, a long-chain 
carboxychromanol from δT, competitively inhibited COX-1 and -2 activities, and it was 
much stronger than short-chain carboxychromanols and unmetabolized vitamin E forms 
in these effects (Jiang et al., 2008). δT-13’-COOH also inhibited 5-LOX activity (Jiang et 





In addition to the anti-inflammatory activities of vitamin E forms, αT, γT, and δT 
have been demonstrated to prevent the development of atherosclerosis by inhibiting 
protein kinase C activity and proliferation of smooth muscle cell (Chatelain et al., 1993; 
Tasinato et al., 1995). Several studies have been shown that the plasma concentrations 
and the intake of γT are inversely associated with increased risk of cardiovascular disease 
(CVD), suggesting that γT is important in the defense against CVD (Ohrvall et al., 1996). 
Moreover, tocotrienols have been shown to have cardioprotective effects, which may be 
stem from their blood-pressure-lowering, cholesterol-lowering, and antiatherogenic 
effects of tocotrienols (Wong and Radhakrishnan, 2012). In the cholesterol-lowering 
activities of tocotrienols, tocotrienols affected on the mevalonate pathway by post-
transcriptionally suppressing the 3-hydroxyl-3-methyl-glutaryl CoA reductase (Parker et 
al., 1993). 
Vitamin E forms also showed antidiabetic effects. For example, γT, but not αT, 
partially protected insulin-secreting cells from the nitric oxide-induced functional 
inhibition (Sjoholm et al., 2000) and palm vitamin E (tocotrienol-rich diet; TRF) 
decreased advanced glycosylation end-points in non-diabetic rats and improved glycemic 
control in streptozotocin-induced diabetic rats (Wan Nazaimoon and Khalid, 2002).  
Independent of its antioxidant activity, vitamin E forms also have shown to 
prevent cancer by inhibition of cell-cycle, suppression of DNA synthesis and by inducing 
apoptosis (Wong and Radhakrishnan, 2012). The anticancer activities of each vitamin E 









Cancer, also known as a malignant tumor and a complex disease caused by 
abnormal and uncontrolled cell proliferation, is one of the leading causes of death 
worldwide. Over the past 60 years, death rates from heart diseases and stroke have 
dropped significantly, but the death from cancer has changed little since the 1950s. 
According to World Health Organization (WHO), cancer now accounts for more than 14 
million new cases and 8.2 million deaths per year worldwide (World Cancer Report 
2014). Cumulative cancer risk is estimated to be 30% and 22% in men and women, 
respectively, by age 75 in developed area worldwide (Jemal et al., 2011). Therefore, 
cancer is a growing health problem around the world. Among various cancer types, lung, 
colon, breast, and pancreatic cancers are the major leading causes of cancer-related death 
in the United States (Siegel et al., 2015). However, there is still no effective therapy for 
late-stage cancer as many cancer therapeutic agents have side effects or due to high rates 
of cancer recurrence. Since cancer is a result of a multistep process, which takes years or 
decades to develop, chemoprevention that prevents or delays the onset of late-stage 
cancer can be an attractive strategy for reducing cancer-related death.  
In this regard, natural forms of vitamin E are potentially good chemoprevention 
agents as they are known to be safe and specific forms of vitamin E have been shown to 
have cancer prevention effects. Among them, αT, which is the predominant vitamin E 




degeneration, and infertility when it has deficiency, is the most extensively studied 
vitamin E form in relation to prevention of chronic diseases such as cardiovascular 
diseases and cancer. However, the human clinical studies as well as numerous animal 
studies of αT in cancer prevention resulted in inconsistent and disappointing outcomes 
(Moya-Camarena and Jiang, 2012). In this section, we review the several studies of 
vitamin E forms including αT and non-αT forms of vitamin E in cancer prevention so far. 





Despite eight different forms of vitamin E, most studies have focused on αT for 
the last couple of decades due to its abundance in the body and antioxidant properties. 
Especially, all the human intervention studies for the vitamin E in cancer prevention have 
exclusively focused on αT. Since 1993, eight large randomized clinical trials (RCTs) to 
examine the effect of αT or combinations of αT with other nutrients on cancer incidence 
and cancer mortality have been reported; Linxian study (Blot et al., 1993), the α-
Tocopherol, β-Carotene Cancer Prevention Study (ATBC) (Heinonen et al., 1998), Heart 
Protection Study (HPS) (Heart, 2002), Supple’ mentation en Vitamines et Miéraux 
Antioxydants (SUVIMAX) (Hercberg et al., 2004), Women’s Health Study (WHS) (Lee 
et al., 2005), The Heart Outcomes Prevention Evaluation and The HOPE-The Ongoing 
Outcomes (HOPE and HOPE-TOO) (Lonn et al., 2005), Selenium and vitamin E Cancer 




(Gaziano et al., 2009). However, results from eight large intervention studies that tested 
the anticancer effects of αT have been inconsistent and disappointing. Only three studies 
including the Linxian study, the ATBC study, and the SUVIMAX study have found that 
αT or its combination with other antioxidants reduced total cancer incidence and 
mortality or a risk of prostate cancer. Importantly, these three studies have something in 
common with their population characteristics that they were not general healthy 
populations. Specifically, the Linxian study in China had population with moderate 
micronutrients deficiency, and the ATBC study was conducted in male heavy smokers, 
and the subjects of the SUVIMAX study included men who have low plasma levels of 
antioxidant levels. 
Beside these human clinical studies, several animal studies to test the beneficial 
effects of αT on cancer have also yielded inconsistent and disappointing outcomes. On 
the other hand, recent mechanistic studies and studies using preclinical animal models 
have demonstrated that other forms of vitamin E appear to have different and stronger 
biological properties compared with αT for the prevention and therapy against cancer. 
 
1.2.3 Non-αT Forms of Vitamin E 
 
Despite most studies in the cancer prevention focused exclusively on the αT form 
of vitamin E in the past, recent studies by others and us have shown that other forms of 
vitamin E appear to have unique and stronger anticancer activities.  
γT, the major form of vitamin E in many plant seeds and in the US diet, and the 




for cancer prevention and therapy that are not shared by αT. First of all, as we already 
mentioned in section 1.1.3, γT exerts anti-inflammatory activities, which are known to 
play important roles in cancer prevention. Specifically, our previous studies have shown 
that γT and γ-CEHC, but not αT, exert anti-inflammatory activities by inhibition of 
prostaglandin E2 (PGE2) synthesis, which occurred through COX-catalyzed reaction, in 
activated macrophages and epithelial cells and by inhibition of 5-LOX-catalyzed 
synthesis of leukotriene B4 (LTB4) in carrageenan-induced inflammation in rats (Jiang 
and Ames, 2003; Jiang et al., 2000). We also showed that γT, but not αT, inhibited 
proliferation and induced apoptosis in human prostate cancer cells, but not in normal 
prostate epithelial cells by interrupting sphingolipid metabolism, specifically by 
accumulating dihydrosphingosine and dihydroceramides (Jiang et al., 2004). Follow-up 
studies also reported that γT induced apoptosis in human breast cancer cells by the 
induction of increases in cellular ceramides and dihydroceramides levels and activating c-
Jun N-terminal kinase (JNK)/CCAAT/enhancer-binding protein homologous protein 
(CHOP)/death receptor-5 (DR5) proapoptotic signaling (Gopalan et al., 2012; Yu et al., 
2008b). Moreover, RRR-γT, but not RRR-αT induced apoptosis in multiple colon cancer 
cell lines, but not in normal colon cells (Campbell et al., 2006). In addition to a number 
of cancer cell studies, several animal studies were conducted to investigate whether these 
anticancer effects of γT are also translated into in vivo animal models. Yu et al. reported 
that γT supplementation, but not αT, significantly reduced breast tumor growth compared 
with control diet group in xenograft mouse models (Yu et al., 2009; Yu et al., 2008a). γT, 
but not αT, also suppressed tumor progression, along with activation of caspase-3 and -7 




group recently demonstrated that γT significantly attenuated moderate colitis and 
suppressed inflammation-promoted colon tumorigenesis (Jiang et al., 2013). Furthermore, 
several studies investigated the anticancer effects of γT in vivo using γT-rich mixed 
tocopherols (γ-TmT). γ-TmT supplementation as well as γT or δT produced a significant 
inhibition of azoxymethane (AOM)-induced aberrant crypt foci (ACF; a precancer lesion) 
in the colon of rats (Guan et al., 2012; Newmark et al., 2006). Another study was 
conducted to test the effects of γ-TmT against colon cancer, and in this study, γ-TmT 
suppressed AOM/DSS-induced tumorigenesis in CF-1 mice (Ju et al., 2009). Besides 
colon cancer, γ-TmT was also effective in suppression of breast tumorigenesis in 
preclinical rat models (Lee et al., 2009; Smolarek et al., 2012; Suh et al., 2007). 
Moreover, in a human study, Helzlsouer et al. conducted a nested case-control study to 
investigate the associations of αT, γT, and selenium with incidence of prostate cancer. 
They observed that higher plasma γT concentrations were associated with a statistically 
significant lower risk of developing prostate cancer. Interestingly, this protective 
association against prostate cancer was found with only γT, not with αT or selenium 
(Helzlsouer et al., 2000). 
Besides tocopherols, recent studies suggested that tocotrienols, especially γTE 
and δTE, appear to have potent anticancer effects in various cancer cells. γTE, which is 
an abundant vitamin E form in palm oil, has been shown to have strong anti-
inflammatory activities by inhibition of TNFα-stimulated NF-κB, TAK1 and JNK 
activation via sphingolipid modulation, ER stress induction, and A20 upregulation (Wang 
et al., 2015). γTE inhibited cell proliferation and induced apoptosis in human colon 




activation of caspase-3 (Xu et al., 2009). Our group also showed that γTE induced 
apoptosis and autophagy by interrupting sphingolipid modulation in prostate and breast 
cancer cells (Gopalan et al., 2012; Jiang et al., 2012). Several studies have shown that 
γTE and δTE significantly inhibited cell proliferation and induced apoptosis in both 
estrogen receptor-negative MDA-MB-435 and estrogen receptor-positive MCF-7 human 
breast cancer cells (Guthrie et al., 1997; Loganathan et al., 2013; Park et al., 2010; Yu et 
al., 1999b). Consistent with the results in cancer cell culture studies, γTE and δTE 
showed effective anticancer properties in several in vivo animal studies. For instance, 
several studies have shown that γTE supplementation significantly inhibited prostate 
tumor growth in xenograft models (Jiang et al., 2012; Kumar et al., 2006; Yap et al., 
2010). γTE also showed these anticancer properties against pancreatic cancer, which 
generally shows resistance to chemotherapy, by inhibition of tumor growth and 
sensitization it to gemcitabine (Kunnumakkara et al., 2010). Interestingly, Hiura et al. 
reported that both γTE and δTE supplementation significantly delayed liver tumor 
growth, by particularly being accumulated in tumors, not in normal tissues (Hiura et al., 
2009). In addition, δTE was observed to show potent tumor antiangiogenic potential 
compared with αT (Shibata et al., 2009). 
 
1.2.4 13’-Carboxychromanol, a Long-chain Vitamin E Metabolite 
 
13’-carboxychromanol (13’-COOH) is a long-chain metabolite of vitamin E (Fig. 
1.2). Sontag and Parker first discovered cytochrome P450 ω-hydroxylase pathway of 




chain carboxychromanols and final metabolite, 3’-carboxychromanol in human 
hepatocyte (Sontag and Parker, 2002). Consistently, our group identified these 
intermediates after treatment with γT and δT in human A549 cells, and first discovered 
that in parallel with β-oxidation, sulfation of intermediate metabolites takes place. 
Importantly, these sulfated or non-sulfated long-chain carboxychromanols were found in 
rat plasma and liver upon vitamin E supplementation (Jiang et al., 2007). We also 
observed the similar metabolism of γTE in human A549 cells and in rats (Freiser and 
Jiang, 2009). Bardowell et al. revealed the presence of all six carboxychromanol 
metabolites and 13’-OH in fecal samples from mice fed with 800 mg/kg body weight γT 
and δT for 12 weeks. They also found similar findings in fecal material from an adult 
male supplemented with 400 mg/kg/day γT for 14 days (Bardowell et al., 2012a).  
Recently, our group began to investigate the biological activities of these vitamin 
E metabolites and demonstrated that long-chain carboxychromanols have stronger anti-
inflammatory activities than their unmetabolized vitamin E forms. Particularly, δT-13’-
COOH, a long-chain carboxychromanol from δT, has been shown to exert anti-
inflammatory effects by showing much more potent inhibiting actions on COX-1/COX-2 
and 5-LOX activities than short-chain carboxychromanols and unmetabolized vitamin E 
precursors (Jiang et al., 2008; Jiang et al., 2011). Moreover, Birringer et al. investigated 
the biological activities of long-chain carboxychromanols synthesized from garcinoid 
acid, a δTE derivative extracted from the African bitter nut Garcinia kola, in human 
HepG2 hepatocellular liver carcinoma cells. 13’-COOHs from αT and δT have shown to 
induce mitochondria-mediated apoptosis with increased mitochondrial ROS formation 




results of these studies show that vitamin E metabolites, especially 13’-COOHs exert 
potential anticancer properties, thus may contribute to beneficial effects of vitamin E 
forms in vivo, the effects and the underlying mechanisms by which 13’-COOHs exert 
these beneficial effects are not completely understood yet, thus warranting further 
investigation. 
 
1.3 Phytochemicals in Cancer Prevention 
 
1.3.1 Overview of Phytochemicals 
 
Cancer is the second leading cause of death worldwide, and now many 
researchers have been focusing on the prevention as well as the treatment to overcome 
cancer. The World Health Organization (WHO) indicates that at least one-third of all 
cancer deaths are preventable and that the diet is closely associated with this cancer 
prevention (Bode and Dong, 2009). Epidemiological studies have consistently shown that 
populations consuming high levels of fruits and vegetables have low incidence rates of 
various cancers (Block et al., 1992; Steinmetz and Potter, 1996). Therefore, numerous 
cell culture and animal model studies have been conducted to find biologically active 
compounds from edible plants and evaluate their protective effects against various 
diseases including cancer. This group of plant bioactive compounds now called as 
phytochemicals. Phytochemicals are non-nutritive plant chemicals expressed as 
secondary metabolites (‘phyto’ means ‘plant’ in the Greek word), which have protective 




(NCI) has identified that to date, greater than 1,000 different phytochemicals from plant 
sources have cancer preventive activities. Since phytochemicals are natural products, they 
have been used for the prevention and treatment of cancer for a long time due to their 
safety and general availability, and became important research targets for cancer research 
(Surh, 2003). Phytochemicals are generally classified as phenolics, carotenoids, alkaloids, 
nitrogen-containing compounds, and organosulfur compounds (Liu, 2004). They are 
typically divided into two distinct classes depending on their chemical structure, 
solubility, and physiological absorption properties; water-soluble dietary phytochemicals: 
phenolics and polyphenols, lipid-soluble dietary phytochemicals: carotenoids, 
tocochromanols (vitamin E derivatives), and curcuminoids. Among them, the most 
studied phytochemicals are the phenolics and carotenoids. This review will briefly 
introduce a general classification of phytochemicals and their key phytochemicals from 
each group with their dietary sources and health beneficial properties. Figure 1.3 
illustrates the chemical structures of representative dietary phytochemicals that have been 








Figure 1.3 Chemical structures of representative dietary phytochemicals. Structures of 
curcumin, quercetin, epigallocatechin gallate (EGCG), resveratrol, and sulforaphane. 
 
Phenolics 
Phenolics (also known as polyphenols) are compounds that contain one or more 
hydroxyl groups attached to one or more aromatic rings in their chemical structure. They 
are generally categorized as flavonoids, phenolic acids, stilbenes, curcuminoids, 
coumarins, and tannins, and numerous epidemiological studies have been demonstrated 
that phenolics showed beneficial properties against cancer, CVD, neurodegenerative 
diseases, diabetes, and osteoporosis (Gonzalez-Vallinas et al., 2013). 
Flavonoids represent the 60% of dietary phenolics with more than 4,000 varieties. 
Their chemical structure consists of two benzene rings linked by three carbons that are 
usually in an oxygenated heterocycle ring. Based on the differences in the heterocycle 
ring, they are classified into six groups: flavonols (quercetin and kaempferol), flavanols 




and apigenin), flavanones (naringenin), anthocyanidins, and isoflavonoids (genistain) 
(Liu, 2004). 
Quercetin. Quercetin is the most abundant flavonoids in fruits and vegetables. It is a 
flavonol and the major sources are onion, apple, and broccoli. Quercetin has shown a free 
radical-scavenging activity and health benefits against many diseases including CVD, 
cancer, and neurodegenerative diseases. Quercetin exerts its anticancer effects by its 
antioxidant and antiproliferative activities and by regulating various cell-signaling 
pathways, cell cycle, and apoptosis (Murakami et al., 2008; Okamoto, 2005). 
(-)-Epigallocatechin-3-gallate (EGCG). EGCG is the major catechin and an antioxidant 
polyphenol flavonoid found mostly in green tea. It has been shown to exert health 
beneficial properties for cancer, atherosclerosis, and neurodegenerative diseases (Khan et 
al., 2006). 
Stilbenes are a family of plant secondary metabolites produced in a small number 
of plant species including grapevine in response to environmental stresses which are 
biotic and abiotic stresses. The bioactive stilbenes such as resveratrol and pterostilbene 
possess several health benefits such as antioxidant, cardioprotective, and cancer 
preventive properties (Rimando and Suh, 2008). 
Resveratrol. Among stilbenes, in particular, resveratrol, which is mainly present in grapes 
and red wine, has received much attention because of its anticancer, antioxidant, 
cardioprotective, and lifespan extending properties (Agarwal and Baur, 2011; Bishayee, 
2009). 
 Curcuminoids are components of the cherished Indian spice known as rhizome of 




spice blends, such as curry. Curcumin is the primary curcuminoid and several studies in 
recent years have shown that it has several biological activities, including antioxidant, 




Carotenoids are naturally occurring fat-soluble pigments, and about 600 different 
carotenoids have been identified and they are particularly plentiful in the red, orange, and 
yellow colored fruits and vegetables, and dark leafy green vegetables. There are two 
categories of carotenoids, which are provitamin A carotenoids that the body can turn into 
vitamin A such as β-carotene and β-cryptoxanthin, and non-provitamin A carotenoids 
such as lutein, lycopene, and zeaxanthin. Carotenoids are powerful antioxidant and have 
been implicated in many beneficial effects on human health with anticancer, 
cardioprotective, and immune system enhancing properties (Britton, 1995; Maiani et al., 
2009; Tan et al., 2010) 
 
Organosulfur compounds 
Organosulfur compounds are naturally occrurring organic compounds that contain 
sulfur in their structure. Dietary organosulfur compounds are commonly found in garlic 
and cruciferous vegetables such as broccoli, cabbage, and cauliflower. These compounds 
have been demonstrated that they possess a number of biological activities such as 




studies have suggested that comsumption of organosulfur compounds can decrease the 
incidence of different types of cancer (Moriarty et al., 2007). 
Sulforaphane. Sulforaphane is a compound in the isothiocyanate group of organosulfur 
compounds. It is obtained from cruciferous vegetables such as broccoli and cabbage. 
For example, when fresh broccoli is chopped or chewed, it releases enzyme myrosinase, 
and myrosinase-catalyzed hydrolysis of glucosinolate glucoraphanin occurs to produce 
sulforaphane. It has shown antioxidant and anticancer activities against various types of 
cancer (Clarke et al., 2008). 
 
1.3.2 Molecular and Cellular Targets of Phytochemicals for Cancer Prevention 
 
Carcinogenesis is a multistep process and it consists of three closely linked stages 
that are tumor initiation, promotion and progression. Moreover, as cancer is a multifactor 
disease, it may require treatment with compounds that can alter this multiple process and 
target multiple intracellular components with greater effectiveness and less toxicity. In 
this regard, a large variety of phytochemicals are potential chemopreventive reagents due 
to its safety and numerous recent studies have demonstrated that several phytochemicals 
have anticancer properties by targeting various cellular signaling molecules. These 
chemopreventive phytochemicals can block, reverse or retard the development and 
progression of the cells in premalignant stage into malignant ones. The cellular 
mechanisms that phytochemicals elicit anticancer effects are multi-faceted, thus various 
cellular molecules and signalings could be potential targets of chemopreventive 




kinases and transcription factors that decide the expression of genes involved in cell 
survival or death (Surh, 2003). During the past decades, there has been remarkable 
advances in identifying the molecular and cellular targets that mediate chemopreventive 
effects of specific phytochemicals, but despite this progress, the identification of clear 
mechanisms and targets of these phytochemicals are still incomplete. This section will 
review several identified key cellular signaling pathways and molecular targets by which 
representative phytochemicals exert their chemopreventive effects. Representative 
cellular signaling molecules and pathways targeted by various phytochemicals include 
the NRF/KEAP1 complex, NF-κB and AP1 with MAPK pathways, oncogenic 
AKT/protein kinase B (PKB) signaling pathway, β-catenin, and proteins involved in 
apoptosis induction. 
 
1.3.2.1 NRF-KEAP1 Complex and Activation of NRF 
 
One of the important ways to prevent cancer development is to block the initiation 
stage of carcinogenesis. The exposure to toxic environmental insults which cause DNA 
damage can be blocked and detoxified by phase II enzymes such as glutathione S-
transferase (GST), NAD(P)H:quinone oxidoreductase (NQO) and heme oxygenase-1 
(HO-1), resulting in the removal of toxicants from the cells before they are able to 
damage the DNA (Hayes and McMahon, 2001). The nuclear factor-erythroid 2p45 (NF-
E2)-related factor 2 (NRF2) is a transcription factor that regulates expression of phase II 




(KEAP1) is a negative regulator of NRF2 which inhibits its translocation to the nucleus 
(Itoh et al., 1999). These two proteins interact with each other, but phase II enzyme 
inducers or prooxidants break the link, resulting in the releasement of NRF2 from 
KEAP1. In addition, phosphorylation of NRF2 by several kinases such as 
phosphatidylinositol 3-kinase (PI3K), protein kinase C (PKC), c-Jun NH2-terminal 
kinase (JNK) and extracellular-signal-regulated kinase (ERK) are known to facilitate the 
dissociation of NRF2 and KEAP1 (Huang et al., 2002). The released and translocated 
NRF2 in nucleus binds to the antioxidant-responsive element (ARE) to express genes that 
encode phase II detoxification or antioxidant enzymes.  
Several phytochemicals have been demonstrated to activate NRF. For instance, 
Chen et al. found that EGCG, a major green tea polyphenol, showed potent activation of 
ARE, MAPKs including ERK, JNK and p38, and caspase-3-mediated cell death (Chen et 
al., 2000). Sulforaphane from cruciferous vegetables also activated MAPKs and 
upregulated ARE-dependent phase II detoxifying enzymes (Yu et al., 1999a). 
 
1.3.2.2 Suppressing NF-κB and AP1 Activation 
 
Several chemopreventive agents elicit anticancer effects by modulating cell-
signaling pathways that regulate cell proliferation and differentiation. One of the 
components that play important roles in these pathways is the mitogen-activated protein 
kinases (MAPKs). Abnormal regulation of this MAPK pathway and its downstream 




conversion to malignancy (Zhang and Liu, 2002). These MAPKs and other kinases such 
as PKC and PI3K activate several transcription factors, including nuclear factor κB (NF-
κB) and activator protein 1 (AP1) (Li and Verma, 2002). NF-κB and AP1 are ubiquitous 
eukaryotic transcription factors that regulate various target gene expression and mediate 
pleiotropic effects, thus they are targets of several chemopreventive phytochemicals. 
Overexpression or aberrant activation of NF-κB has been associated with over-
proliferation and malignant transformation. Inactive NF-κB resides in the cytoplasm as a 
complex with the regulatory protein IκB. The activation of NF-κB pathway starts from 
the phosphorylation of IκB by IκB kinase (IKK), leading to IκB phosphorylation, 
ubiquitination and degradation by the 26S proteasome. The released NF-κB from IκB is 
then translocated to the nucleus, and it binds to specific promoter regions of genes, which 
are involved in the regulation of cell proliferation, differentiation, apoptosis and 
inflammation (Li and Verma, 2002). Recent studies have shown that activation of NF-κB 
is also regulated by AKT signaling pathway. PI3K activates AKT via phosphorylation, 
and this leads to NF-κB activation by stimulating IKK activity (Das et al., 2003; Li and 
Sarkar, 2002). AP1 is another transcription factor that is also regulated by the MAPK 
signaling cascade and regulates gene expressions that are involved in cell proliferation 
and differentiation, leading to tumor promotion and malignant transformation (Li and 
Verma, 2002). 
A number of chemopreventive phytochemicals have been shown to suppress NF-
κB and AP1 activation, leading to prevent abnormal cell proliferation and growth. 
Curcumin inhibits TNF-α-induced COX-2 gene transcription and NF-κB activation 




al., 2003; Li and Sarkar, 2002). EGCG inhibits the activities of PI3K and AKT (Pianetti 
et al., 2002). In addition, IKK has shown to be inhibited by several chemopreventive 
phytochemicals, including curcumin (Bharti et al., 2003; Plummer et al., 1999), 
resveratrol (Holmes-McNary and Baldwin, 2000) and EGCG (Yang et al., 2001). 
 
1.3.2.3 Downregulation of β-Catenin-mediated Signaling Pathway 
 
β-Catenin is one of the important targets of numerous chemopreventive 
phytochemicals. It functions as a transcription factor and involves in the regulation of cell 
proliferation and tumorigenesis. Growth factors and WNT proteins stimulate β-catenin-
mediated signaling pathway. The interaction of a WNT protein with its transmembrane 
receptor inactivates glycogen synthase kinase-3β (GSK-3β) by phosphorylation. The 
interaction of a growth factor with receptor kinase (RTK) activates PI3K, leading to AKT 
phosphorylation. Phosphorylated AKT also inactivates GSK-3β by phosphorylation. 
GSK-3β forms a multiprotein complex with adenomatous polyposis coli (APC), axin and 
conductin, and this complex regulates the fate of β-catenein. In the presence of a growth 
factor or WNT signal, the phosphorylated and inactivated GSK-3β stabilizes β-catenin in 
the cytoplasm. The β-catenin translocates to the nucleus and acts as a transcription factor, 
resulting in the activation of gene transcription involved in the cellular proliferation and 
growth. On the other hand, in the absence of stimuli, GSK-3β phosphorylates cytosolic β-
catenin, which is in turn targeted for ubiquitylation followed by proteasomal degradation 




Some chemopreventive phytochemicals have been shown to target and 
downregulate the β-catenin-mediated signaling pathway and exert subsequent anticancer 
activities. For instance, curcumin reduced the cellular levels of β-catenin through 
caspase-mediated degradation of the protein (Mahmoud et al., 2000). Resveratrol has also 
shown to attenuate the expression of β-catenin in human colon cancer cells (Joe et al., 
2002). Inhibition of β-catenin activity and reduction of its protein expression has been 
shown by EGCG treatment (Dashwood et al., 2002). 
 
1.3.2.4 Induction of Apoptosis 
 
Despite the regulation of abnormal cell proliferation and growth may retard or 
block tumor development, the induction of programmed cell death via apoptosis can 
completely remove abnormal cells from a tissue. In contrast to necrosis, apoptosis is a 
tightly regulated mechanism of cell death that can be induced by a variety of signals and 
stimuli. 
Several dietary phytochemicals have been shown to induce apoptosis in cancer 
cells. Sulforaphane, a molecule in the isothiocyanate group of organosulfur compounds, 
induces apoptosis and inhibition of proliferation of human bladder cancer cells (Tang et 
al., 2006). EGCG treatment also inhibits cell growth and induces apoptosis in human 
epidermoid carcinoma cells, but not in normal human epidermal keratinocytes (Ahmad et 




apoptotic proteins such as Bim, Bax, and Bak, and down-regulating the anti-apoptotic 
proteins such as Bcl-2 and Bcl-xL (Shankar and Srivastava, 2007).  
 
1.4 Sphingolipids Metabolism and Their Biological Activities 
 
1.4.1 Overview of Sphingolipids 
 
Over the past twenty years, several groups of lipids and their metabolites have 
started to receive more attention, as they serve as biologically active molecules exerting a 
wide range of biological functions and providing health benefits through modification of 
tissue composition or induction of several cell-signaling pathways. Among a broad 
variety of bioactive lipids, evidences suggested that the polyunsaturated fatty acids 
(PUFAs) and eicosanoids are the most important bioactive lipids. Another well-known 
group of bioactive lipids is the sphingolipids. Sphingolipids were first identified in brain 
extracts at the end of the 19th century and were named after the Greek mythological 
creature, the Sphinx, on the basis of the nature of their enigmatic molecular structure 
(Thudichum, 1884).  
Sphingolipids are a class of natural lipids that primarily have sphingosine as their 
structural backbone, amide-linked long-chain fatty acids, and one of various polar head 
groups. Thus, they are the most structurally diverse class of membrane lipids depending 
on their head groups. Among them, since sphingomyelin (SM) is an essential component 
in the outer leaflet of the plasma membrane and provides a barrier to the extracellular 




evidence also suggests that they are pleiotropic molecules playing important roles in the 
regulation of numerous functions including cell survival, apoptosis, senescence, and 
differentiation. Indeed, sphingolipid metabolism has proved to be a dynamic process, and 
several sphingolipid metabolites are now recognized as second messengers playing 
essential roles in various cell functions (Hannun et al., 1986; Hannun and Obeid, 2008; 
Spiegel and Merrill, 1996). 
The levels of endogenous sphingolipid metabolites are controlled by de novo 
synthesis and dynamic metabolisms involving synthesis of complex sphingolipids and 
catabolic pathways of complex sphingolipids or ceramides (Fig. 1.4) (Gault et al., 2010; 
Hannun and Obeid, 2008). Therefore, this review section will focus on the dynamic 
sphingolipid metabolism and enzymes involved in this pathway. 
 
1.4.1.1 De novo Sphingolipids Biosynthesis 
 
The de novo sphingolipid biosynthesis starts in the endoplasmic reticulum from 
condensation of palmitoyl-CoA and serine into 3-keto-dihydrosphingosine by serine 
palmitoyltransferase (SPT). The intermediate 3-ketosphinganine is rapidly reduced to 
dihydrosphingosine (dhSph) by a NADPH dependent 3-ketosphinganine reductase. An 
acylation by a family of (dihydro)ceramide synthases (CerSs) using fatty acyl-CoAs 
generates dihydroceramide (dhCer) subspecies. Dihydroceramide desaturase (DEGS) 
introduces a 4,5-trans double bond in dhCers to make the final product, Ceramide (Cer) 






Figure 1.4 Sphingolipid metabolism. De novo biosynthesis pathway of sphingolipids, the 
production of complex sphingolipids from ceramide, the degradation of ceramide to 
sphingosine, the formation of sphingosine-1-phosphate (S1P), and the clearance of S1P 
by S1P lyase. SMS, sphingomyelin synthase; SMase, sphingomyelinase; CERK, 
ceramide kinase; GCS, glucosylceramide synthase; GBA, acid glucocerebrosidase; SK, 
sphingosine kinase; SPP, S1P phosphatase 
 
 
Serine Palmitoyltransferase (SPT) 
The first step in the sphingolipid biosynthesis is the condensation of cytosolic 
serine and palmitoyl-CoA, a reaction catalyzed by SPT to produce 3-keto-




However, SPTLC3 has been identified in yeast, but not in mammals (Gable et al., 2000). 
SPT is a member of a pyridoxal 5′-phosphate-dependent α-oxoamine synthases family. 
Mammalian SPT has LCB1 and LCB2 subunits, and each SPT subunit contains several 
transmembrane domains and displays type I topology. Although little is known about 
SPT regulation, many factors have been reported to regulate SPT activity and its activity 
is regulated transcriptionally and post-transcriptionally. The most widely known factor 
that affects SPT activity is the availability of serine and palmitoyl-CoA pool. SPT is 
inhibited by several synthetic and natural products. The selective inhibitors of this 
enzyme are L-cycloserine and beta-chloroalanine. More potent and selective natural 
inhibitors of SPT have been isolated from microorganisms which include sphingofungins, 
lipoxamycin and ISP-1/myriocin. The myriocin is a potent inhibitor of SPT and is widely 
used to block and identify the role of de novo sphingolipid biosynthesis (Hanada, 2003; 
Wadsworth et al., 2013).  
 
(Dihydro)ceramide Synthase (CerS) 
Dihydrosphingosine is further acylated by the action of CerS. Recently, human 
CerS 1-6 have been discovered as yeast homologues of the longevity assurance gene 1-6 
(LASS1-6), and are encoded by six distinct genes, resulting in the generation of huge 
dhCer and Cer profiles (Pewzner-Jung et al., 2006). Each CerS has substrate preference 
for different lengths of fatty acyl-CoAs, thus producing distinct dhCers with different 
acyl-chain lengths. For example, whereas CerS1 prefer stearoyl-CoA as a substrate and 
mainly generate C18-Cer species (Venkataraman et al., 2002), CerS5 and CerS6 both 




(Riebeling et al., 2003). On the other hand, CerS2 prefer C20-C26 acyl-CoA species and 
form long chain Cer species (Laviad et al., 2008). CerS3 utilizes middle and long chain 
acyl-CoA and makes the corresponding Cer species (Mizutani et al., 2006) (Fig. 1.5). 
These CerS proteins are localized mainly to the ER and its activity is inhibited by a 
number of fungal inhibitors such as fumonisin B1 (FB1), a mycotoxin produced by 
Fusarium verticillioides. The nature of the inhibition of CerS by FB1, which contains an 
aminoeicosapentol backbone, is that CerS recognizes the aminopentol moiety of this 
compound, which competes with the binding sites for dhSph and fatty acyl-CoA (Merrill 
et al., 2001). 
 
Dihydroceramide Desaturase (DEGS) 
The last step of the de novo biosynthesis of Cer is the insertion of a 4,5-trans-
double bond into dhCer by dihydroceramide Δ4-desaturase (DEGS) to generate Cer. 
Michel et al. first reported the biochemical characterization of the DEGS reaction in 1997 
using rat liver microsomes (Michel et al., 1997). They have shown that the DEGS uses 
molecular oxygen as electron acceptor to have a hydroxyl group in the C4-position of the 
dhSph, and then with NADP or NADPH as an electron donor, a dehydration reaction 
occurs to produce a double bond in the C4-C5 position of dhCer. Therefore, they 
confirmed that the conversion of dhCer to Cer was occurred by a desaturase and not by a 
dehydrogenase. Two different DEGSs, DEGS1 and DEGS2, have been so far reported. In 
bioinformatics approach, Ternes et al. identified a family of sphingolipid Δ4-desaturases 
(homologs of the Drosophila melanogaster degenerative spermatocyte gene 1 (des-1)) 




desaturase and very low C-4 hydroxylase activities, whereas DEGS2, another ortholog 
identified in mouse and human, is similarly active as both sphinglipid C-4 hydroxylase 
and Δ4-desaturase activities, resulting in the production of either phytoceramide or 
ceramide. Like the previous two enzymes in the de novo sphingolipid biosynthesis 
pathway, DEGS is localized in the ER membrane where it can access to dhCer species. 
DEGS1 activity is largely influenced by a number of factors including the length of the 
alkyl chain of the sphingoid base (C18 > C12 > C8) and fatty acid (C8 > C18), the 
stereochemistry of the dhSph moiety of the substrate (D-erythro-isomer > L- or D-threo-
isomers), and the nature of the headgroup (dhCer: the highest activity, dhSM: some 
(~20%) activity). The activity of DEGS is inhibited by several compounds, including 
cyclopropene-containing ceramide, GT-11 (C8-cyclopropenylceramide; C8-CPPC) 








Figure 1.5 De novo biosynthesis of sphingolipids highlighting the synthesis of many 
ceramides with different fatty acid chain length. Biosynthesis of sphinganine, which can 
be acylated by the CerS/Lass gene products with their specific fatty acyl-CoA preference. 
Each dhCer can be desaturased to the corresponding Cer species, followed by the 
production of more complex sphingolipids. Cer, ceramide; CerS, ceramide synthase; 
dhCer, dihydroceramide; DEGS, dihydroceramide desaturase; SM, sphingomyelin 
 
 
1.4.1.2 Synthesis of Complex Sphingolipids 
 
Cer formed via the de novo sphingolipid biosynthesis pathway in the ER is 




2008). Since Cer is a lipophilic molecule, it needs to be transported either by vesicular 
transport for the delivery of Cer to synthesize glucosyl-Cer (Watson and Stephens, 2005) 
or by the protein Cer transfer protein (CERT), which is a cytosolic protein and 
specifically delivers Cer for SM synthesis (Hanada et al., 2003). In addition, transfer of 
glucosyl-Cer for complex glycosphingolipids synthesis requires FAPP2 transfer protein 
(D'Angelo et al., 2007). Therefore, in the Golgi apparatus, more complex sphingolipids 
such as glucosyl-, or galactosyl-Cers and sphingomyelin (SM) are generated from Cers. 
Glucosyl-Cer and galactosyl-Cer are synthesized by the actions of enzymes glucosyl-Cer 
synthase and Cer galactosyltransferase, respectively. Meanwhile, SM, which is the most 
abundant sphingolipids in mammalian cells, is produced by the action of SM synthases 
(SMS). There are at least two members of the SMS family and SMS1 and 2 are localized 
to the trans-Golgi, but SMS2 is also present in the plasma membrane. The synthesis of 
SM is catalyzed by the SMS enzyme, which transfers the phosphocholine headgroup 
from phosphatidylcholine to Cer yielding the products SM and diacylglycerol (DAG). 
The activity of SMS enzyme is inhibited by tricyclodecan-9-xanthogenate (D609) 
(Amtmann, 1996). The produced SM and complex glycosphingolipids are delivered to 
the plasma membrane by vesicular transport. A majority of the total SM resides at the 
plasma membrane, where it plays important roles structurally and functionally (Huitema 
et al., 2004). 
Moreover, although Cer is mainly converted into complex sphingolipids in the 






1.4.1.3 Catabolism of Complex Sphingolipids and Ceramides 
 
SM is the most abundant complex sphingolipid in mammalian cells, and it can be 
broken down to maintain cellular homeostasis, which occurs by the action of 
sphingomyelinase (SMase) family. The SMase family hydrolyzes phosphocholine 
headgroups in the SM to produce Cer and phosphocholine. The SMase family has two 
major categories based upon their pH optimum, which are the acid and neutral SMases. 
Acid SMases that are present in lysosomes and the outer membrane leaflet or neutral 
SMases in the inner leaflet of the bilayer can metabolize SMs to Cers and other bioactive 
lipids (Marchesini and Hannun, 2004). Although the functions and regulatory 
mechanisms of SMases are not well characterized, some studies have been investigated 
the factors and mechanisms that control the SMases activation. Acid SMases has been 
shown to be activated by the TNF receptor, oxidants, and UV radiation (Henry et al., 
2013; Zhang et al., 2001). Neutral SMases activation has also been investigated that 
serum starvation (Jayadev et al., 1995), oxidative stress (Marchesini and Hannun, 2004), 
treatment of vitamin D (Okazaki et al., 1994), and curcumin (Abdel Shakor et al., 2014) 
activate the enzyme. Neutral SMase activation was also a necessary signaling event for 
the TNF-induced human MCF-7 breast cancer cell death (Luberto et al., 2002). A number 
of compounds that inhibit SMases were also found. Desipramine, which is a member of 
the tricyclic antidepressant family, has been used as a selective acid SMase inhibitor by 
acting on the proteolytic degradation of acid SMase. SR33557 is also a specific acid 
SMase inhibitor, and NB6 is another inhibitor of the SMase gene transcription. GW4869 




Catabolism of Cer occurs by the action of ceramidases (CDases) to form 
sphingosine. There are two major CDases, which are acid CDase localized in the 
lysosomes and neutral CDase localized in the ER and the mitochondria. After Cer is 
deacylated into sphingosine, sphingosine-1-phosphate (S1P) is synthesized from 
sphingosine and ATP by the action of one of the sphingosine kinases (SphK); SphK1 or 
SphK2. Meanwhile, the sphingosine produced from Cer hydrolysis by acid CDase in 
lysosome may exit the lysosome and salvaged into Cer and sphingolipid pathways. The 
last step of the sphingolipid catabolic pathway is the degradation of S1P by S1P lyase, a 
microsomal enzyme to produce 2-hexadecenal and phosphoethanolamine (Gault et al., 
2010). 
 
1.4.2 Bioactive Sphingoid Bases and Their Roles in Cell Growth, Survival, and Death  
 
Sphingolipids are diverse groups of lipids that play a variety of essential roles as 
components of cell membrane structure and cell signaling molecules, thus affecting on 
the mammalian development and physiology. Moreover, dysregulated sphingolipids 
metabolism is known to occur in some diseases such as cancer, diabetes, atherosclerosis, 
and neurodegenerative diseases. Over the past two decades, several sphingolipids 
metabolites, such as sphingosine, Cer, and S1P were defined as bioactive lipid 
messengers and regulatory molecules, and many researchers have begun to investigate 
their various roles and functions. These metabolites are now clearly known to play 
critical roles in regulating various cellular events including differentiation, proliferation, 




sphingolipid metabolism is complex and dynamic processes, and the produced 
metabolites have different or opposite functions, their relative levels and balance between 
each other are important for the regulation of survival and death within the cells. For 
instance, while Cer has antiproliferative and proapoptotic properties, S1P involves in 
cellular proliferation and survival. Thus, a model has been previously proposed in which 
the equilibrium between these two molecules, the ‘Cer/S1P rheostat’, could determine 
cell fate (Cuvillier, 2002). Besides this model, recent studies have suggested that 
sphingolipid metabolites are interconvertible and each metabolite has its distinct 
functions. For example, Cer can be further metabolized to sphingosine by ceramidase, 
which has been shown to induce apoptosis in many cell types. This sphingosine can be 
further phosphorylated to form S1P by sphingosine kinase. In addition, Cer can be 
generated from SM via SMases. Therefore, now it is important to understand this 
complexity of sphingolipid metabolism and specific enzymes that are involved in the 
pathway, and define the roles and regulation of each metabolite by the application of the 
comprehensive ‘sphingodynamic’ model. This present review will focus on the roles of 




The first sphingolipid identified that exerts pleiotropic effects on protein kinase C 
and other targets was sphingosine (Hannun et al., 1986; Merrill et al., 1986; Wilson et al., 




phosphorylated by sphingosine kinase to form S1P. Sphingosine has been shown to be 
produced during the early stages of apoptosis, and the exogenously added sphingosine 
itself also induced apoptosis in many cell types (Ahn and Schroeder, 2002; Cuvillier, 
2002). Although the role of sphingosine in apoptosis was not extensively studied 
compared with that of Cer, there are several defined mechanisms that could account for 
sphingosine to mediate apoptosis. Treatment of sphingosine has been shown to inhibit 
MAPKs, Erk-1 and Erk-2 activities, and activate JNK and p38, which are stress-activated 
protein kinases. Moreover, several studies have revealed that caspases, cysteine 
proteases, are activated during sphingosine-induced apoptosis. In addition, sphingosine 
induces apoptosis by the mitochondrial pathway, particularly by down-regulating the 




After sphingosine was recognized as a second messenger, Cer also became 
another candidate for the sphingolipid metabolite, which may act as bioactive cellular 
signaling molecule (Goldkorn et al., 1991). Cer has a variable length of fatty acid chain 
attached at the carbon 2 position of long-chain sphingosine by an amide bond. It is either 
synthesized via de novo synthesis by condensation of serine and palmitoyl-CoA or 
generated by sphingomyelin catabolism by the action of sphingomyelinases. Now, due to 
its diverse roles including the regulation of cell death and senescence, even more 




are influenced by Cer, interest has focused on defining the direct targets of Cer. Several 
proteins such as Cer-activated protein phosphatases (CAPPs), various protein kinases and 
cathepsin D, have been identified that interact directly with Cer. The CAPPs which are 
serine/threonine phosphatase, such as PP1 and PP2A, are bound and activated by Cer and 
induce growth arrest or apoptosis. Targets of these CAPPs for dephosphorylation include 
the retinoblastoma gene product (Rb), PKCα, protein kinase B (PKB or AKT) and Bcl-2 
(Hannun and Obeid, 2008; Kolesnick, 2002; Ohanian and Ohanian, 2001). Moreover, 
kinase suppressor of ras (KSR), which is a Cer-activated protein kinase (CAPK), has also 
been identified. KSR is a serine/threonine kinase that phosphorylates and activate Raf to 
initiate MAPK signaling cascade. In addition, PKCζ and the protease cathepsin D have 
been shown to be direct targets for Cer. Activation of PKCζ by Cer has been linked 
cytokines to NFκB signaling (Ohanian and Ohanian, 2001) and implicated in 
proapoptotic functions. Cathepsin D has been proposed as a specific target for acid 
SMase-generated Cer in lysosome and implicated in subsequent induction of 
mitochondrial apoptosis.  
While Cer has been proposed as an important cell-signaling messenger for the 
regulation of diverse events such as differentiation, proliferation and senescence, it has 
received much attention as a potential mediator of apoptosis. Intensive investigation in 
the past decade has firmly established that Cer could play a key role in apoptosis 
signaling in response to cytokines, anticancer drugs, or environmental stresses. Treatment 
of cells with Cer has been shown to induce apoptosis by the mitochondria-mediated 
pathway and down-regulation of the PI3K-Akt pathway (Ahn and Schroeder, 2002; 




membranes after chemotherapeutic drugs or TNFα treatment and caused mitochondrial 
outer membrane permeabilization by making pore, resulting in the induction of 
mitochondrial apoptosis (Siskind, 2005). Recent studies have shown that addition of 
exogenous Cer also induced autophagy, and the autophagy was induced by compounds 
treatment such as tamoxifen, a chemotherapeutic drug, and 4-HPR in which endogenous 
Cer increase was involved (Scarlatti et al., 2004; Zheng et al., 2006). In addition to the 
proapoptotic and proautophagic effects of Cer, it has been implicated in the inhibitory 
properties of inflammation. Treatment of Cer has been found to inhibit phosphorylation 
of pro-inflammatory kinases and production of cytokines, and also decrease the 
inflammatory interleukin 6 (Kitatani et al., 2009; Sun et al., 2008).  
Recently, emerging results suggest that endogenous Cers with different fatty acyl-
chain lengths appear to have distinct bioactivities. Thus, many researchers have been 
investigating the role of CerS family that makes Cers as well as specific functions of 
individual Cer species. These researches were enabled by the development of mass 
spectrometry (MS)-based approaches for the direct quantitation of Cers over the past 15 
years, instead of using a variety of indirect assays, such as enzymatic assays or TLC 
separations. With the highly sensitive and specific MS-based method, each individual Cer 
species with different mass could be effectively quantified even in a mixture at low nM 
concentrations. Watts et al. applied this technique to investigate the changes of individual 
Cer levels during apoptosis in cells for the first time, and observed specific elevations of 
C16:0-Cer (Watts et al., 1999). One study found that B-cell receptor-triggered cell death 
was associated with an elevation in C16:0-Cer in Ramos B-cells. The increase of this Cer 




hallmarks such as activation of caspases, mitochondrial damage followed by induction of 
cell death, suggesting that de novo generated C16:0-Cer is involved in mitochondrial 
apoptosis (Kroesen et al., 2001). More recently, numerous studies have been revealed the 
changes of individual Cer levels in specific cancers, and reported the distinct functions of 
each individual Cer species in the regulation of tumor growth and therapy using the 
sphingolipidomic analysis. Koybasi et al. first found that only one specific Cer, C18:0-Cer 
was selectively down-regulated in human head and neck squamous cell carcinoma 
(HNSCC) tissues, and this Cer involved in the inhibition of cancer cell growth and may 
play an important role in the regulation of cell fate (Koybasi et al., 2004). Consistently, 
Karahatay et al. also found the significantly decreased levels of C18:0-Cer in HNSCC 
tumors. (Karahatay et al., 2007). In contrast, this group found an increase in the levels of 
C16:0-, C24:0- and C24:1-Cers in the same cancer patients. The increased levels of these Cer 
species were also observed in malignant breast cancer tissues compared with benign and 
normal tissues (Schiffmann et al., 2009a). One study has shown that SW620 colon cancer 
cells had lower expression levels of CerS6 and significantly decreased C16:0-Cer which 
resulted in the resistance to the tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL)-induced apoptosis. Moderate elevation in CerS6 expression reversed the 
apoptotic response to TRAIL in this cell line (White-Gilbertson et al., 2009). Schiffmann 
et al. also implicated an increase of C16:0-Cer by CerS6 activation from the salvage 
pathway in a selective COX-2 inhibitor, celecoxib-induced toxic effects in HCT-116 
colon cancer cells (Schiffmann et al., 2009b). Recent study has found that the 
accumulation of long-chain Cers by CerS5 and 6 through the salvage pathway play 




cancer cells (Mullen et al., 2011). However, interestingly, another recent study by Senkal 
et al. revealed novel prosurvival role of C16:0-Cer against ER stress-induced apoptosis in 
HNSCCs. They found that whereas C18:0-Cer showed proapoptotic roles, C16:0-Cer 
showed antiapoptotic and prosurvival roles, suggesting that C16:0-Cer and C18:0-Cer 
generated by CerS1 or CerS5, respectively, play opposite roles in determining cancer cell 
survival or apoptosis (Senkal et al., 2010). In addition to the proapoptotic roles of C18:0-
Cer, it has been shown to mediate lethal autophagy induction, independent of apoptosis in 
HNSCC cell lines (Sentelle et al., 2012). Taken together, although there is still 
controversy in the roles of each individual Cer species, recent studies have demonstrated 
the distinct roles of individual Cer species, and Cers with different fatty acyl chain 
lengths may contribute to tumor growth and therapy. 
 
1.4.2.3 Dihydrosphingosine and Sphingosine-1-phosphate 
 
Although sphingosine and Cer have been recognized and studied as pivotal 
apoptosis-inducing molecules for a long time, emerging evidence suggests that other 
sphingolipid intermediates in the de novo synthesis of sphingolipid pathway also play 
important roles in cell survival and death.   
First, dihydrosphigosine (dhSph or sphinganine), an intermediate upstream of 
CerS an enzyme sensitive to fumunosin B1, has been shown to induce apoptosis in 
human colon cancer cells (Ahn and Schroeder, 2002), activation-induced T cells 




1996; Ohta et al., 1995). Moreover, our group found that the treatment of γT, the 
predominant form of vitamin E in US diet, or mixed vitamin E forms induced huge 
accumulation of dhSph, resulting in the induction of human prostate cancer cell death 
(Jiang et al., 2004). We also found that γTE enhanced the intracellular levels of dhSph 
and inhibited PI3K-mediated Akt phosphorylation followed by induction of apoptosis and 
autophagy in human prostate cancer cells (Jiang et al., 2012). In addition, safingol, the 
synthetic L-threo-stereoisomer of endogenous (D-erythro-) dhSph, has been shown to 
induce autophagy through inhibition of PKCs and PI3K in various cancer cells (Coward 
et al., 2009). Interestingly, fumonisin B1, an inhibitor of CerS, caused the accumulation 
of dhSph in tissues, serum, and urine, which appear to be responsible for the toxicity of 
this mycotoxin (Merrill et al., 2001). 
 Sphingosine and Cer are representative sphingolipid metabolites, which are 
typically associated with induction of cell death, while S1P is involved in opposite roles 
such as cell proliferative, mitogenic, survival, antiapoptotic and drug resistant actions. 
S1P is produced through the action of SphK from sphingosine, which is generated via 
deacylation of Cer. SphK activity is increased by a number of stimuli such as growth 
factors, cytokines and G protein-coupled receptors (GPCRs), but the mechanisms 
regulating the activity of SphK are not yet clearly understood. The increased S1P by the 
action of SphK interacts with GPCRs as extracellular signals. S1P signaling through 
these GPCRs has been implicated in various cellular responses including differentiation, 
migration, and mitogenesis. S1P has also been proposed to play as an intracellular second 
messenger, which activate calcium release, MAPKs, phospholipase D, and p125FAK 




increases in proliferation of cancer cells (Pyne and Pyne, 2000). Several studies suggest 
that the levels of S1P are closely linked to resistance to the cancer cell death induction, 
and the apoptosis-inducing action of Cer is antagonized by S1P. S1P also increased 
platelet-derived growth factor and vascular endothelial growth factor which are 
associated with angiogenesis and metastasis of tumor (Catarzi et al., 2007; Heo et al., 
2009). Interestingly, S1P has been shown to induce COX-2 expression, which activates 
inflammatory response and has been recognized to be linked to the cancer progression 




Dihydroceramide (DhCer) is another sphingolipid metabolite which is converted 
to Cer via DEGS. The only structural difference between Cer and dhCer is the presence 
or absence of a 4, 5-trans-double bond, respectively. Whereas Cer is well known 
sphingolipid involved in cell death, dhCer was thought to be an inactive precursor of Cer 
and a non-signaling molecule. In the early 1990’s, a study demonstrated that dhCers were 
inactive in inhibition of cell growth and induction of apoptosis, in which Cers were active 
in HL-60 cells (Bielawska et al., 1993). Ahn et al. also have shown that sphingosine, 
dhSph, and C2-Cer inhibited growth, caused apoptosis and death of colon cancer cells, 
whereas dhCer had no effect on these (Ahn and Schroeder, 2002). Several other previous 
studies also have revealed and confirmed that dhCers have not been found to mimic the 




However, these studies used unnatural C2 or C6 short-chain analogs instead of natural 
long-chain Cer and dhCer. Stiban et al. first investigated the effects of their long-chain 
analogs, and found that dhCer are not ineffective. In this study, dhCer hindered Cer 
channel formation in mitochondria, resulting in the inhibition of apoptotic cell death 
(Stiban et al., 2006). 
 On the other hand, technology used in the previous studies showing the important 
roles of Cer in the induction of cell death was limited in that it could not distinguish 
between Cer and dhCer. The potential effects of dhCer were recognized with the use of 
liquid chromatography tandem mass spectrometry (LC-MS/MS) technology, which can 
identify even different species of Cer and dhCer. For example, 4-hydroxy 
phenylretinamide (4-HPR or fenretinide), a synthetic retinoid, had been thought to cause 
large elevation of Cer to induce growth arrest and apoptosis in numerous cancer cells 
(Erdreich-Epstein et al., 2002; Wang et al., 2003; Wang et al., 2001). However, the LC-
MS/MS analysis revealed that 4-HPR did not increase in Cer, but rather accumulate 
dhCer by inhibiting DEGS.  
DhCers are now considered as one of the bioactive sphingolipid metabolites and 
have shown to be involved in important cellular responses such as cell cycle arrest 
(Kraveka et al., 2007), apoptosis (Gopalan et al., 2012; Jiang et al., 2012; Jiang et al., 
2004), autophagy (Jiang et al., 2012; Signorelli et al., 2009; Zheng et al., 2006), and 
oxidative stress (Idkowiak-Baldys et al., 2010). Recently, several compounds including 
natural bioactives such as vitamin E forms, resveratrol, and cancer chemotherapeutic 
agents have been shown to inhibit DEGS and induce subsequent increases in dhCer levels 




the first natural compound that has been shown to induce apoptotic cell death by 
increasing intracellular dhCer and dhSph in human prostate cancer cells (Jiang et al., 
2004). Since then, subsequent studies have reported several compounds that can 
modulate intracellular levels of dhCer. Fenretinide, a vitamin A analog with 
chemotherapeutic properties, also enhanced intracellular dhCer by inhibition of DEGS 
activity, leading to cell cycle arrest and inhibition of cell growth in human neuroblastoma 
cells (Kraveka et al., 2007). Following studies from this group found that fenretinide, 
which bears a structural resemblance to dhCer, directly and irreversibly inhibited DEGS 
activity (Rahmaniyan et al., 2011). Moreover, resveratrol treatment showed an increase in 
dhCers levels, which resulted in the induction of autophagy in gastric cancer cells. 
Importantly, XM462, an inhibitor of DEGS, caused the accumulation of dhCer and it was 
sufficient to have autophagy (Signorelli et al., 2009). Consistently, in the earlier studies, 
Zheng et al. also showed the induction of autophagy in C2-dhCer-treated prostate cancer 
cells (Zheng et al., 2006). Celecoxib, a selective COX-2 inhibitor, induced various cancer 
cell death by promoting dhCer and dhSph accumulation through the inhibition of DEGS 
and activation of sphingolipid biosynthesis, while depleting cells of Cers. DEGS activity 
was also found to be inhibited by oxidative stress (Idkowiak-Baldys et al., 2010) or 
hypoxic environment (Devlin et al., 2011), resulting in significant elevation in dhCer 
levels and inhibition of cell proliferation. Again, our group has recently shown that γTE, 
an analog of γT, also enhanced dhCer as well as dhSph, which lead to the induction of 
apoptosis and autophagy in human cancer cells (Gopalan et al., 2012; Jiang et al., 2012). 
On the other hand, γTE did not significantly affect Cer or sphingosine levels, and γTE 




importance of dhCer increase in the γTE-mediated NFκB inhibition through increase of 




CHAPTER 2.  SPHINGOLIPID METABOLISM IS THE INITIAL PRIMARY 




Our previous studies suggest that gamma-tocotrienol (γTE) has potent anticancer 
activities in cancer cells via modulation of sphingolipid metabolism. Here, by employing 
liquid chromatography tandem mass spectrometry, we investigated temporal changes in 
levels of sphingolipids by γTE treatment in human colon cancer HCT-116 cells. 
Incubation with γTE for 16 h resulted in accumulation of dihydrosphingosine (dhSph) 
and dihydroceramides (dhCer), and these changes intensified during prolonged treatment. 
In contrast, γTE treatment led to a significant decrease in C16:0-ceramide (Cer) levels at 8 
h, but showed no difference at 16 h or increase at 24 h, compared with controls. 
Meanwhile, γTE led to a decrease in C24:1-Cer and C24:0-Cer from 8 to 24 h, but an 
increase in C18:0-Cer from 16 h. Interestingly, sphingomyelins (SM) declined from 8 h but 
cells showed obvious apoptosis (PARP cleavage) or autophagy (LC3 increase) only at 16 
h or longer treatment with γTE. Using 13C3, 15N-labeled L-serine, we further evaluated the 
effect of γTE on de novo synthesis of sphingolipids. We observed that γTE had no effect 
on total de novo sphingolipid biosynthesis, but induced increases in labeled dhCers and 




inhibit dhCer desaturase (DEGS). Consistent with these results, γTE inhibited the DEGS 
activity as indicated in situ assay and in vitro assay with microsomes. The importance of 
sphingolipids modulation in γTE-induced cancer cell death such as the accumulation of 
dhCers and dhSph during the initial phase, and the increase of Cers and decrease of SMs 
during the prolonged treatment period was supported by blocking these enhancements 
using each individual enzyme inhibitors, myriocin and desipramine, respectively. Co-
treatment of cells with myriocin or desipramine partially but significantly reversed the 
γTE-induced cancer cell death. These results indicate that γTE exerts anticancer effects 
by modulating enzyme activities in sphingolipid metabolism, specifically, by inhibition 




Natural forms of vitamin E consist of α-, β-, γ- and δ-tocopherols (αT, βT, γT and 
δT) and α-, β-, γ- and δ-tocotrienols (αTE, βTE, γTE and δTE). Although these forms 
share the similar structures, different forms of vitamin E appear to have distinct activities 
and metabolism. Among them, αT, which is the predominant vitamin E form in tissues 
and plasma, and the form that is the least catabolized, is the most extensively studied. 
However, the human clinical studies as well as numerous animal studies of αT in cancer 
prevention resulted in inconsistent and disappointing outcomes. On the other hand, other 
forms of vitamin E, although they are low in tissues due to the extensive catabolism, 
appeared to have unique and strong anticancer activities. Especially, γTE has been shown 




Camarena and Jiang, 2012). However, the molecular mechanism by which γTE exerts its 
anticancer effects are not understood yet. 
Recently, our group has shown that γT and γTE induced apoptosis and autophagy 
through mechanisms involving dhCer and dhSph accumulation in prostate and breast 
cancer cells, and this modulation of sphingolipid played an important role in γT and γTE-
induced cell death (Gopalan et al., 2012; Jiang et al., 2012; Jiang et al., 2004). 
Sphingolipids constitute an essential component of cell membrane and also are important 
signaling molecules that regulate cell growth, differentiation, senescence and apoptosis 
(Hannun and Obeid, 2008; Ryland et al., 2011; Zheng et al., 2006). The levels of 
endogenous sphingolpids are controlled by de novo synthesis pathway and dynamic 
metabolisms involving catabolic pathways and synthetic pathways of complex 
sphingolipids. Briefly, de novo sphingolipid synthesis begins in the endoplasmic 
reticulum from condensation of palmitoyl-CoA and serine into 3-keto-
dihydrosphingosine by serine palmitoyltransferase (SPT). The intermediate 3-
ketodihydrosphingosine is rapidly reduced to dihydrosphingosine (dhSph), followed by 
acylation by a family of (dihydro)ceramide synthases (CerSs) using fatty acyl-CoAs to 
generate the corresponding dihydroceramide (dhCer) subspecies. In mammals, there are 
six identified genes that encode CerS, and each CerS has substrate preference for 
different lengths of fatty acyl CoAs, thus producing distinct dhCers with different acyl-
chain lengths. Dihydroceramide desaturase (DEGS) inserts a 4,5-trans double bond in 
dhCers to make the final product, ceramide (Cer). In the Golgi apparatus, more complex 
sphingolipids such as glucosyl- or galactosyl-Cers and sphingomyelin (SM) by the 




repectively, can be generated from Cers (Fig. 2.3A). As for the degradation pathways, 
Cer is broken down by ceramidases into sphingosine (Sph), which may be salvaged into 
sphingolipid pathways or can be phosphorylated to form sphingosine-1-phosphate (S1P). 
Also, Cer can be generated by breakdown of SM through the action of acid or neutral 
SMases, which operate at different pH optima (Hannun and Obeid, 2008; Hannun and 
Obeid, 2011; Kitatani et al., 2008; Marchesini and Hannun, 2004).  
Among different species of sphingolipids, only Cers and S1P have been focused 
to be bioactive molecules. On the other hand, dhCers were thought to be an inactive 
precursor of Cer, which is a well-known sphingolipid metabolite involved in cell death 
(Zheng et al., 2006). However, technology used in the previous studies showing the 
important roles of Cer in the induction of cell death was limited in that it could not 
distinguish between Cer and dhCer. Recent studies, using liquid chromatography tandem 
mass spectrometry (LC-MS/MS) technology which can identify even different species of 
Cer and dhCer, have shown dhCers to be involved in important cellular responses such as 
cell cycle arrest (Kraveka et al., 2007), apoptosis (Gopalan et al., 2012; Jiang et al., 2012; 
Stiban et al., 2006), autophagy (Jiang et al., 2012; Signorelli et al., 2009; Zheng et al., 
2006), and oxidative stress (Idkowiak-Baldys et al., 2010).  
Therefore, we hypothesize that the sphingolipid pathway may be also an important 
target for the anti-proliferative effects of γTE in other cancer cells. In this study, we 
investigated the anticancer effects and mechanisms of γTE in human cancer cells and our 
study revealed that modulation of sphingolipid was the primary target of γTE in the 





2.3 Materials and Methods 
 
2.3.1 Materials and reagents 
γTE (97-99%), a gift from BASF (Ludwigshafen, Germany), was dissolved in 
DMSO at 100 mM and then diluted to 5 mM in fatty acid-free BSA (10 mg/ml). 
Sphingolipid standards were obtained from Avanti Polar Lipids (Alabaster, AL). CHAPS 
was purchased from Thermo Fisher Scientific. C8-cyclopropenylceramide (C8-CPPC) 
was purchased from Matreya LLC (Pleasant Gap, PA). Myriocin from Mycelia Sterilia, 
desipramine, GW4869, 13C3, 15N-labeled L-serine, N-acetyl cysteine (NAC), dimethyl 
sulfoxide (DMSO), [3-(4,5)-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide] 
(MTT), and all other chemicals were from Sigma (St Louis, MO). 
 
2.3.2 Cell culture and treatment 
Human colon cancer HCT-116 and breast cancer MCF-7 cells were obtained from 
American Type Culture Collection (Manassas, VA). Cells were routinely cultured in 
growth media containing 10% fetal bovine serum (FBS) at 37 °C in 5% CO2. HCT-116 
cells were cultured in McCoy’s 5A modified medium. MCF-7 cells were incubated in 
Dulbecco’s modified eagle medium (DMEM) supplemented with 0.1% insulin. At the 
time of experiments, cells were seeded in each medium with 10% FBS either at a density 
of 4 x 104 cells/well in 24-well plates or at a density of 7-8 x 105 cells in 10-cm dishes. 
Unless otherwise indicated, for experiment, cells were seeded in 10-cm dishes except 




containing 1% FBS and γTE or other compounds. All the treatment solutions were 
freshly prepared for each experiment. 
 
2.3.3 MTT assay 
Cell viability was examined by MTT assay to estimate mitochondrial 
dehydrogenase activity. In living cells, the enzyme reduces MTT to form formazan which 
was dissolved in DMSO and measured the absorbance at 570 nm by using a microplate 
reader (SpectraMax 190, Molecular Devices, Sunnyvale, CA). 
 
2.3.4 Lipid extraction 
Total lipids were extracted as previously described (Merrill et al., 2005). Briefly, 
cell pellets were resuspended in methanol/chloroform/water (10:5:1 [v/v/v]) after the 
addition of internal standard mixture containing 0.5 nmol C12:0/C25:0-Cers, C12:0-SM, and 
C17-Sph/dhSph (Avanti Polar Lipids, Alabaster, AL). The suspension was dispersed 
fully by tip sonication for 20 sec and then incubated overnight at 48 °C. 100 µL of 
solvent was used to determine the amount of total choline-containing phospholipids by an 
enzymatic colorimetric assay (Wako chemicals, Osaka, Japan) (Jiang et al., 2004). 75 µL 
of 1 M KOH in methanol was added to the rest of the solvent and sonicated for 30 min. 






2.3.5 Measurement of sphingolipids using liquid chromatography tandem mass 
spectrometry (LC-MS/MS) 
Samples for sphingolipids analysis were resolved again in methanol and sonicated 
to disperse, then centrifuged to clarify before transferring to test vials for quantification. 
The LC-MS/MS method was slightly modified based on the method of Merrill et al. 
(Merrill et al., 2005). Analyses were performed using the Agilent 6460 triple quadrupole 
mass spectrometer coupled with the Agilent 1200 Rapid Resolution HPLC (Agilent 
Technologies, Santa Clara, CA) with detection of sphingolipids in positive mode by 
multiple reaction monitoring (MRM) technique. The HPLC mobile phases consisted of 
methanol-H2O-formic acid (74:25:1, v/v/v; RA) and methanol-formic acid (99:1, v/v; 
RB); both RA and RB contain 5 mM ammonium formate. For measurement of ceramides 
and sphingoid bases, Agilent column XDB-C18 (4.6 x 50 mm) with particle size of 1.8 
μm, was used with isocratic run (100% B) or gradient (0-1 min, 20% B, 10-13 min, 100% 
B and 15-20 min at 20% B), respectively. For measurement of sphingomyelins, Agilent 
Zorbax XDB-C8 (2.1 x 50 mm) with particle size of 3.4 μm, was used with gradient (0-1 
min, 20% B, 10-20 min, 100% B, 22-30 min, 20% B). The MS/MS parameters were as 
follows: gas temperature, 325-350 °C; gas flow rate, 7-10 L/min; nebulizer pressure, 45-
50 psi; capillary voltage, 3500 V; The fragmentor voltage was 100 V and collision energy 
was 12-20 V. Precursor-to-product ion transitions for each sphingolipid were used 





2.3.6 De novo sphingolipids analysis 
HCT-116 cells were treated with either 400 μM 13C3, 15N-labeled L-serine alone 
or with a combination of 400 μM 13C3, 15N-labeled L-serine and 20 μM of γTE for 30 
min, 2 h, 3 h and 6 h. Lipids were extracted and de novo synthesized sphingolipids were 
measured using LC-MS/MS. 
 
2.3.7 In Situ dihydroceramide desaturase assay 
C8:0-dihydroceramide (C8:0-dhCer) was used as the substrate for the DEGS. HCT-
116 cells were pretreated with either γTE or C8-CPPC as a positive control, followed by 
10 μM of C8:0-dhCer incubation for 1 h. The cells were collected and lipids were 
extracted. The levels of products (C8:0-ceramide and C8:0-sphingomyelin) were detected 
by LC-MS/MS. 
 
2.3.8 In Vitro dihydroceramide desaturase assay 
Microsomes were prepared and used as the DEGS enzyme source for this assay 
(Rahmaniyan et al., 2011). Livers from male Wistar rats were rinsed in ice-cold PBS and 
homogenized in buffer (0.25 M sucrose, 10 mM HEPES, 1 mM EDTA, pH 7.4) with a 
homogenizer in ice. The homogenate was centrifuged at 800 x g for 10min first and the 
supernatant was re-centrifuged at 10,000 x g for 15 min followed by ultracentrifugation 
of the resulting supernatant at 104,000 x g for 1 h. The microsomal pellet was 
resuspended in potassium phosphate buffer (50 mM, pH 7.4) and aliquots were stored at -
80 °C until use. Protein amount was quantified by using a bicinchoninic acid (BCA) 




compounds were dried under a stream of nitrogen, followed by resuspension in CHAPS 
(1.1 mg/10 μl of water). 500 μg of microsomal protein was mixed with reaction buffer 
(20 mM bicine, pH 8.5, 50 mM NaCl, and 50 mM sucrose) and then the tested 
compounds were added, followed by 30 min pre-incubation at room temperature. 2 mM 
of NADH and 10 μM of C8:0-dhCer were added and the mixture was incubated for 20 min 
at 37 °C with shaking. Lipid extraction was conducted directly after reaction and the 
product (C8:0-ceramide) was quantified by LC-MS/MS. 
 
2.3.9 Transmission Electron Microscopy (TEM) 
After treatment, cells were fixed with 2% glutaldehyde in 0.1 M cacodylate buffer 
(pH 7.4) for 1 h at room temperature. After primary fixation, the attached cells were 
scraped and pooled together with the floating cells. All the cells were then centrifuged 
and washed twice with cacodylate buffer and once with water. A secondary fixation in 
reduced osmium containing 1% OsO4 and 1.5% agarose and then diced and dehydrated in 
ethanol with a concentration gradient. The ultrathin sections were stained with 2% 
uranylacetate in 70% methanol for 5 min and lead citrate for 3 min. Finally, the cell 
images were taken by a FEI/Philips CM-10 bio-twin transmission electron microscope 
(FEI Company, Hillsboro, OR) using an acceleration voltage of 80 kV. Cells and the 
inner ultrastructure were observed in different magnification. 
 
2.3.10 Western Blotting 
Cells were lysed in lysis buffer containing Tris-EDTA, 1% SDS, 2 mM Na3VO4 




protein assay kit were denatured by boiling in Laemmli buffer for 5 min at 95 °C. Equal 
amount of proteins (15-30 µg) were separated on acrylamide gels by SDS-electrophoresis 
and then transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore, 
Bilerica, MA, USA), and probed by antibodies. Membranes were exposed to 
chemiluminescent reagent (PerkinElmer) and visualized on Kodak film with an M35A X-
Omat processor (Kodak). The antibodies used in the study were as follows: DEGS1 
(Novus Biologicals, Littleton, CO), membrane bound microtubule-associated protein 
light chain 3 (LC3; MBL international, Woburn, MA), poly (ADP-ribose) polymerase-1 
(PARP-1) and Actin (Santa Cruz Biotechnology, Santa Cruz, CA), phosphorylated JNK 




Statistical significance was determined using a Student’s t-test. p-values of < 0.05 




2.4.1 Temporal changes of sphingolipids induced by γTE 
We investigated the effects of γTE on sphingolipid metabolism using LC-MS/MS 
in human colon HCT-116 cancer cells. During the initial 8 h treatment, γTE caused 
significant decreases of C16:0-Cer, C18:0-Cer, C24:1-Cer and C24:0-Cer, resulting in the 




have distinct bioactivities (Hannun and Obeid, 2011; Senkal et al., 2010; Sentelle et al., 
2012), appeared to respond differently to γTE in the longer time treatment. For example, 
C16:0-Cer in γTE-treated cells returned to the control levels at 16 h but exceeded the 
control at 24 h. Compared with controls, C18:0-Cer was enhanced in γTE-treated cells at 
16 h, whereas C24-Cers remained lower than controls during the prolonged treatment 
period (Fig. 2.1A). Meanwhile, γTE induced significant increases of dhCers and dhSph 
starting at 16 h, thus cells accumulated high levels of dhCers and dhSph at 16 h and 24 h 
treatment with γTE (Figs. 2.1B and C). As to SM, while dhSMs increased during 16-24 h 
incubation, SMs declined at 8 h compared with controls (Figs. 2.1D and E; Table 2.1). 
Furthermore, we observed similar sphingolipid modulatory effects of γTE on human 
breast MCF-7 cancer cells (Fig. 2.2; Table 2.2). 
These data suggest that the initial action of γTE is likely to inhibit DEGS, which 
is evident by the increase of dhSph and dhCers and decrease of Cers, similar phenomena 
reported with DEGS knockout model (Ruangsiriluk et al., 2012; Siddique et al., 2013). 
During prolonged treatment, γTE may induce C16:0-SM hydrolysis, which explains the 
subsequent increase of C16:0-Cer during prolonged incubation times. On the other hand, 
another possible explanation for increased C16:0-Cer and decreased SM is that the 

























Figure 2.1 Effects of γTE on sphingolipid metabolism in HCT-116 cells. HCT-116 cells 
were treated with 20 μM of γTE for 8, 16, and 24 h. The sphingolipid levels including 
(A) total Cers, C16:0-Cer, C18:0-Cer, C24:1-Cer, and C24:0-Cer, (B) total dhCers, (C) dhSph, 
(D) total SMs, C16:0-SM, and C24:1-SM, and (E) total dhSMs were determined by LC-
MS/MS. Results are shown as mean ± SEM for at least three independent experiments. 


















Figure 2.2 Effects of γTE on sphingolipid metabolism in MCF-7 cells. MCF-7 cells were 
treated with 20 μM γTE for 8 h or 16 h. The sphingolipid levels including (A) total 
dhCers, (B) C16:0-dhCer, (C) dhSph, (D) C16:0-Cer, C18:0-Cer, C24:1-Cer, and C24:0-Cer, (E) 
total dhSMs, and (F) total SMs were determined by LC-MS/MS. Results are shown as 
mean ± SEM for five independent experiments. *p < 0.05 and **p < 0.01 indicate a 


















2.4.2 De novo synthesis of sphingolipids with labeled serine 
To evaluate whether γTE has impact on de novo sphingolipid biosynthesis (Fig. 
2.3A), 13C3, 15N- L-serine was added to culture media to trace only newly synthesized 
sphingolipids. Similar to those observed effects of γTE on sphingolipid metabolism 
above, γTE led to an increase of de novo synthesized dhCers and decrease in de novo 
Cers after 2 h, supporting the notion that DEGS is inhibited (Figs. 2.3B and C). 
Interestingly, compared with control cells, labeled dhSM and SM, which represented 
newly synthesized dhSM and SM, also significantly increased at 2 h in γTE-treated cells, 
while SMs returned to the control levels at 3 h (Figs. 2.3D and E). These results indicate 
that the conversion of C16:0-Cer to C16:0-SM was stimulated at the initial stage of 
treatment, despite the decrease of C16:0-Cer in cells. As a result, the decrease of Cers due 
to inhibition of DEGS was intensified by increased SM synthesis. The continuous 
increase of de novo dhSM was probably a result of enhanced de novo dhCer, which led to 
limited accumulation of dhCer during the first few hours (Figs. 2.1B and E). On the other 
hand, we did not see significant difference between control and γTE-treated cells in total 
labeled sphingolipids (Fig. 2.1F), suggesting that the overall sphingolipid synthesis was 
not enhanced (Table 2.3).     
Since labeled C16:0-Cer is decreased, the increase of overall C16:0-Cer in the 
subsequent time (24 h) and decrease of SM is likely due to hydrolysis of C16:0-SM, which 






















Figure 2.3 Effects of γTE on de novo sphingolipid biosynthesis in HCT-116 cells. (A) 
The de novo biosynthesis pathway of sphingolipids (SMS, sphingomyelin synthase; 
SMase, sphingomyelinase). HCT-116 cells were treated with either 400 μM 13C3, 15N-
labeled L-serine alone as control or with a combination of 400 μM 13C3, 15N-labeled L-
serine and 20 µM γTE for 0.5, 2, 3, and 6 h. The amount of each labeled de novo 
sphingolipid including (B) total and C16:0-dhCers, (C) total, C16:0-, C24:1- and C24:0-Cers, 
and (D) total, C16:0- and C24:1-SMs, and (E) total and C16:0-dhSMs were determined by 
LC-MS/MS. (F) Total amounts of all the de novo synthesized sphingolipids were 
calculated. Results are shown as mean ± SEM for three independent experiments. *p < 














2.4.3 Direct evidence that γTE inhibits DEGS 
We found that γTE treatment increased de novo synthesized dhCers, but led to 
decrease in de novo Cers, suggesting that γTE decreases DEGS protein expression or 
inhibits DEGS-catalyzed enzyme reactions. γTE treatment did not affect the DEGS 
protein expression on HCT-116 cells as determined by western blotting (Fig. 2.4A). Next, 
to determine whether the observed sphingolipid change results from inhibition of DEGS 
enzyme activity, both in situ and in vitro assays were conducted. In the assays, the non-
physiological C8:0-dhCer was used as a substrate for the DEGS, and measured the C8:0-
sphingolipid products by LC-MS/MS; specifically C8:0-Cer with C8:0-SM or C8:0-Cer for 
in situ and in vitro DEGS assays, respectively. In situ DEGS activity was evaluated in 
intact HCT-116 cells. C8-CPPC, a known competitive inhibitor of DEGS (Triola et al., 
2003), inhibited DEGS activity, and showed ~75% reduction of the C8:0-sphingolipids 
production. The relative inhibition of DEGS activity by 20 µM of γTE for 6 h and 8 h 
was ~40% and ~45%, respectively (Fig. 2.4B). In addition, the direct effect of γTE on 
DEGS activity was determined using rat liver microsomes. In this direct in vitro DEGS 
assay, γTE showed a modest DEGS activity inhibition by only ~10% at a concentration 
of 20 μM, and ~25% at 100 μM (Fig. 2.4C). The requirement of higher concentration of 
γTE for the DEGS inhibitory effects in in vitro assay could be due to limitation in 
permeability through the cell membrane of γTE. These results indicated that γTE inhibits 








Figure 2.4 Effects of γTE on DEGS expression and activity. (A) HCT-116 cells were 
treated with 20 μM γTE for 8, 16, and 24 h and the protein levels of DEGS-1 were 
detected by western blotting. (B) In situ DEGS assay: HCT-116 cells were pretreated 
with either 20 μM γTE or 1 μM C8-CPPC as a positive control, followed by 10 μM C8:0-
dhCer incubation as a substrate for the enzyme for 1 h. The cells were collected and 
lipids were extracted. The levels of C8:0-sphingolipid products were detected by LC-
MS/MS. (B) In vitro DEGS assay using rat liver microsomes: Microsomes were used as 
the enzyme source for this assay. The microsomal proteins in reaction buffer were pre-
mixed with either 20 or 100 μM γTE or 10 μM C8-CPPC for 30 min, followed by 
addition of 2 mM NADH and 10 μM C8:0-dhCer and incubation for 20 min at 37 °C. 
Total lipids were extracted immediately after reaction, and the product was quantified by 
LC-MS/MS. The data are mean ± SD of three independent experiments. *p < 0.05 and 





2.4.4 Temporal changes of cell death markers 
γTE treatment caused PARP cleavage, as indicated by the appearance of the 89 
kDa cleavage product from 16 h in HCT-116 cells. γTE treatment also increased levels of 
p-JNK, which is a stress marker, in HCT-116 cells, as consistent with the p-JNK 
upregulation by γTE in MCF-7 cells (Gopalan et al., 2012). The induction of autophagy 
in γTE-treated HCT-116 cells was first investigated by using LC3-II, a marker of 
autophagy. Interestingly, γTE treatment also led to an increase of LC3-II expression from 
16 h (Fig 2.5A). It is important to note that the initial autophagy or apoptosis (at 16 h but 
not 8 h) is not due to decrease of C16:0-Cer or C24-Cers, but might be facilitated by 
increased dhSph, dhCer and increased C18:0-Cer.  
We further examined the morphological analysis using TEM. As shown in Fig. 
2.5B, control HCT-116 cells appeared normal, displaying abundant microvilli at the cell 
surface, abundant organelles in the cytoplasm, and well-organized nuclei with clear 
nuclear membrane. However, cells treated with γTE for 21 h showed evidence of 
apoptosis characterized by cell shrinkage, loss of microvilli, loss of nuclear membrane 














Figure 2.5 Induction of apoptosis and autophagy by γTE in HCT-116 cells. (A) HCT-116 
cells were treated with 20 μM of γTE for 6, 8, and 16 h. Expression levels of full-length 
and cleaved PARP, LC3-II, Actin as a loading control, and levels of p-JNK and JNK 
were examined by western blotting. (B) HCT-116 cells were treated with 20 μM of γTE 
for 21 h. The morphology of HCT-116 cells was imaged by TEM. Representative TEM 






2.4.5 The role of sphingolipid modulation in γTE-induced cell death 
To evalulate the involvement and importance of de novo sphingolipid modulation 
in γTE-induced cancer cell death, we used two inhibitors of enzymes in sphingolipid 
biosynthesis pathway to block the specific effects of γTE on sphingolipid metabolism. 
Since the above results (Figs. 2.1B and C) have shown that γTE treatment induced 
accumulation of intracellular dhCers and dhSph, which are known to be toxic to cancer 
cells (Ahn and Schroeder, 2002; Jiang et al., 2004), we used myriocin, a specific inhibitor 
of serine palmitoyltransferase to inhibit the increase of these sphingoid bases. 
Interestingly, co-treatment of cells with myriocin showed partial but significant 
protection from the γTE-caused cancer cell death, as assayed by MTT assay. The 
importance of sphingolipid modulation in γTE-induced cell death was further confirmed 
by western blot experiments. Co-incubation of myriocin with γTE slightly but clearly 
prevented the γTE-induced PARP cleavage and LC3-II induction (Fig. 2.6A). These data 
suggest that the accumulation of dhSph and dhCers plays an important role in γTE-
induced apoptosis, autophagy and subsequent cancer cell death. 
 During the prolonged treatment time, γTE led to an increase of Cers, but induced 
a significant decrease in SMs (Fig. 2.1) with the still lower de novo synthesized Cers 
compared with control (Fig. 2.2B), suggesting that γTE may induce SM hydrolysis by 
activating SMases. As Cers have been known to induce apoptosis, autophagy and cell 
death, we investigated the role of the increased Cers from SMs via SMases in γTE-
induced cancer cell death by using desipramine and GW4869 to inhibit acid or neutral 




shown) with γTE partially but significantly reversed γTE-induced cancer cell death (Fig. 
2.6B), suggesting that the increase of Cers from SMs through the acid SMase activation 















Figure 2.6 Protective effects of inhibitors of enzymes in sphingolipid metabolism on 
γTE-induced cancer cell death. (A) HCT-116 cells were treated with 10 or 20 μM of γTE 
with or without 3-6 μM of myriocin, a specific inhibitor of serine palmitoyltransferase to 
block the de novo sphingolipid pathway. After 48 h of treatment, relative cell viability 
was measured by MTT assay compared with control. In addition, after 16 h of treatment, 
the cells were collected and analyzed for detection of PARP cleavage and LC3-II 
expression. Western blots in this figure are representative of three or more independent 
experiments. (B) HCT-116 cells were treated with 15 μM of γTE with or without 10 μM 
of desipramine, an inhibitor of acid SMase for 24 h. Relative cell viability was measured 
by MTT assay compared with control. The data are mean ± SEM of at least three 













Figure 2.7 NAC, an antioxidant, did not reverse γTE-induced modulation of 
sphinoglipids in HCT-116 cells. HCT-116 cells were treated with either 20 μM γTE or 1 
mM NAC alone or with a combination of γTE and NAC for 8 h. The sphingolipid levels 
including (A) C16:0-dhCer, C24:1-dhCer, C24:0-dhCer, and dhSph, (B) C16:0-Cer, C24:1-Cer, 
and C24:0-Cer, (C) C16:0-dhSM, C24:1-dhSM, C16:0-SM, and C24:1-SM were determined by 











Table 2.1 Effect of γTE on sphingolipid metabolism in HCT-116 cells. HCT-116 cells 
were treated with 20 µM γTE for 8, 16, and 24 h. The amount of each sphingolipid was 
determined by LC-MS/MS. Data are mean ± SEM of 5 independent experiments. *p < 
0.05, **p < 0.01, significant difference between control and γTE-treated cells. Cer, 
ceramide; dhCer, dihydroceramide; Sph, sphingosine; dhSph, dihydrosphingosine; S1P, 
sphingosine-1-phosphate; SM, sphingomyelin; dhSM, dihydrosphingomyelin 
 
Ceramides (pmol/µg PC) 
C16:0-Cer     
Hours Control γTE 20 µM 
8 2.19 ± 0.23 0.95 ± 0.22** 
16 2.41 ± 0.22 2.17 ± 0.24 
24 2.09 ± 0.17 3.96 ± 0.76** 
C18:0-Cer     
Hours Control γTE 20 µM 
8 0.038 ± 0.006 0.033 ± 0.006* 
16 0.028 ± 0.003 0.082 ± 0.013** 
24 0.025 ± 0.003 0.14 ± 0.027** 
C20:0-Cer     
Hours Control γTE 20 µM 
8 0.023 ± 0.004 0.017 ± 0.005* 
16 0.020 ± 0.003 0.042 ± 0.009** 
24 0.018 ± 0.003 0.065 ± 0.014** 
C22:0-Cer     
Hours Control γTE 20 µM 
8 0.20 ± 0.031 0.068 ± 0.010** 
16 0.26 ± 0.086 0.095 ± 0.018** 
24 0.21 ± 0.056 0.15 ± 0.030 
C24:1-Cer     
Hours Control γTE 20 µM 
8 1.02 ± 0.26 0.47 ± 0.16** 
16 1.79 ± 0.22 0.66 ± 0.082** 
24 1.47 ± 0.18 0.94 ± 0.20** 
C24:0-Cer     
Hours Control γTE 20 µM 
8 1.22 ± 0.22 0.30 ± 0.10** 
16 2.56 ± 0.29 0.35 ± 0.057** 




C26:1-Cer     
Hours Control γTE 20 µM 
8 0.096 ± 0.008 0.067 ± 0.013* 
16 0.23 ± 0.036 0.11 ± 0.021** 
24 0.18 ± 0.027 0.15 ± 0.040 
C26:0-Cer     
Hours Control γTE 20 µM 
8 0.090 ± 0.006 0.031 ± 0.015* 
16 0.15 ± 0.046 0.043 ± 0.014** 
24 0.13 ± 0.037 0.049 ± 0.018** 
Total Cers     
Hours Control γTE 20 µM 
8 4.88 ± 0.25 1.93 ± 0.18** 
16 7.44 ± 0.75 3.54 ± 0.29** 
24 6.22 ± 0.56 5.88 ± 1.04 
 
Dihydroceramides (pmol/µg PC) 
C16:0-dhCer     
Hours Control γTE 20 µM 
8 0.091 ± 0.030 0.31 ± 0.036 
16 0.18 ± 0.027 2.22 ± 0.18** 
24 0.21 ± 0.031 4.09 ± 0.78** 
C18:0-dhCer     
Hours Control γTE 20 µM 
8 0.0018 ± 0.0003 0.011 ± 0.003* 
16 0.0010 ± 0.0001 0.1 ± 0.025** 
24 0.0013 ± 0.0002 0.17 ± 0.034** 
C20:0-dhCer     
Hours Control γTE 20 µM 
8 0.00029 ± 0.0002 0.0066 ± 0.0026 
16 0.00092 ± 0.0003 0.042 ± 0.013** 
24 0.0011 ± 0.0003 0.06 ± 0.013** 
C22:0-dhCer     
Hours Control γTE 20 µM 
8 0.0038 ± 0.0014 0.018 ± 0.0046* 
16 0.0074 ± 0.0037 0.033 ± 0.0077** 
24 0.0090 ± 0.0034 0.042 ± 0.0082** 




Hours Control γTE 20 µM 
8 0.010 ± 0.004 0.060 ± 0.010* 
16 0.021 ± 0.006 0.14 ± 0.016** 
24 0.031 ± 0.003 0.17 ± 0.026** 
C24:0-dhCer     
Hours Control γTE 20 µM 
8 0.010 ± 0.004 0.035 ± 0.007* 
16 0.046 ± 0.011 0.075 ± 0.004* 
24 0.059 ± 0.014 0.084 ± 0.015 
C26:1-dhCer     
Hours Control γTE 20 µM 
8 0.00063 ± 0.0004 0.0093 ± 0.002 
16 0.0025 ± 0.001 0.037 ± 0.010** 
24 0.0027 ± 0.001 0.034 ± 0.011* 
C26:0-dhCer     
Hours Control γTE 20 µM 
8 0.00069 ± 0.0007 0.0022 ± 0.0011 
16 0.00092 ± 0.0007 0.011 ± 0.0060 
24 0.0013 ± 0.0008 0.0063 ± 0.0054 
Total dhCers     
Hours Control γTE 20 µM 
8 0.12 ± 0.035 0.45 ± 0.045 
16 0.26 ± 0.029 2.66 ± 0.16** 
24 0.32 ± 0.035 4.65 ± 0.82** 
 
Sphingoid bases (pmol/µg PC) 
Sph     
Hours Control γTE 20 µM 
8 0.42 ± 0.18 0.40 ± 0.11 
16 0.30 ± 0.080 0.40 ± 0.053 
24 0.30 ± 0.067 0.48 ± 0.048* 
dhSph     
Hours Control γTE 20 µM 
8 0.046 ± 0.013 0.12 ± 0.015 
16 0.043 ± 0.007 2.46 ± 0.39* 
24 0.051 ± 0.007 5.89 ± 0.98** 
S1P     




8 0.021 ± 0.002 0.019 ± 0.004 
16 0.0087 ± 0.001 0.012 ± 0.002 
24 0.013 ± 0.005 0.016 ± 0.002 
 
Sphingomyelins (pmol/µg PC) 
C16:0-SM     
Hours Control γTE 20 µM 
8 39.09 ± 8.17 26.99 ± 4.48** 
16 56.18 ± 6.99 37.93 ± 4.40** 
24 52.58 ± 7.07 37.78 ± 5.14** 
C18:0-SM     
Hours Control γTE 20 µM 
8 0.47 ± 0.19 0.44 ± 0.14 
16 0.63 ± 0.15 1.12 ± 0.20** 
24 0.53 ± 0.12 1.55 ± 0.32** 
C20:0-SM     
Hours Control γTE 20 µM 
8 0.43 ± 0.18 0.40 ± 0.17* 
16 0.53 ± 0.12 0.81 ± 0.22* 
24 0.51 ± 0.13 0.95 ± 0.25* 
C22:0-SM     
Hours Control γTE 20 µM 
8 1.62 ± 0.69 1.57 ± 0.66 
16 2.17 ± 0.45 2.65 ± 0.72 
24 2.64 ± 1.03 3.20 ± 1.29 
C24:1-SM     
Hours Control γTE 20 µM 
8 6.23 ± 2.44 6.32 ± 2.22 
16 8.72 ± 1.66 9.65 ± 2.07 
24 10.37 ± 3.44 10.50 ± 3.77 
C26:1-SM     
Hours Control γTE 20 µM 
8 0.29 ± 0.13 0.36 ± 0.16** 
16 0.40 ± 0.094 0.76 ± 0.18** 
24 0.60 ± 0.27 1.00 ± 0.44* 
Total SMs     
Hours Control γTE 20 µM 




16 68.62 ± 9.02 52.91 ± 7.62** 
24 67.23 ± 11.73 54.99 ± 10.54* 
 
Dihydrosphingomyelins (pmol/µg PC) 
C16:0-dhSM     
Hours Control γTE 20 µM 
8 5.25 ± 1.88 6.48 ± 2.13 
16 7.32 ± 1.58 18.73 ± 3.42** 
24 7.72 ± 1.62 26.29 ± 4.98** 
C18:0-dhSM     
Hours Control γTE 20 µM 
8 0.13 ± 0.074 0.19 ± 0.093 
16 0.11 ± 0.032 1.13 ± 0.25** 
24 0.12 ± 0.030 1.54 ± 0.37** 
C20:0-dhSM     
Hours Control γTE 20 µM 
8 0.24 ± 0.20 0.15 ± 0.092 
16 0.10 ± 0.035 0.56 ± 0.14** 
24 0.12 ± 0.038 0.74 ± 0.23** 
C22:0-dhSM     
Hours Control γTE 20 µM 
8 0.30 ± 0.20 0.35 ± 0.24 
16 0.26 ± 0.11 0.82 ± 0.27** 
24 0.34 ± 0.12 0.96 ± 0.38** 
C24:0-dhSM     
Hours Control γTE 20 µM 
8 0.41 ± 0.33 0.41 ± 0.32 
16 0.37 ± 0.22 0.73 ± 0.27** 
24 0.51 ± 0.21 0.94 ± 0.36* 
C26:0-dhSM     
Hours Control γTE 20 µM 
8 0.031 ± 0.027 0.032 ± 0.025 
16 0.025 ± 0.013 0.15 ± 0.052** 
24 0.034 ± 0.015 0.24 ± 0.094* 
Total dhSMs     
Hours Control γTE 20 µM 
8 6.37 ± 2.72 7.61 ± 2.89 




24 8.84 ± 1.98 30.71 ± 6.19** 
 
 
Table 2.2 Effect of γTE on sphingolipid metabolism in MCF-7 cells. MCF-7 cells were 
treated with 20 µM γTE for 8, and 16 h. The amount of each sphingolipid was determined 
by LC-MS/MS. Data are mean ± SEM of 5 independent experiments. *p < 0.05, **p < 
0.01, significant difference between control and γTE-treated cells.  
 
Ceramides (pmol/µg PC) 
C16:0-Cer     
Hours Control γTE 20 µM 
8 1.68 ± 0.28 1.32 ± 0.29* 
16 1.90 ± 0.30 3.61 ± 0.89** 
C18:0-Cer     
Hours Control γTE 20 µM 
8 0.15 ± 0.030 0.12 ± 0.023 
16 0.16 ± 0.029 0.39 ± 0.13** 
C20:0-Cer     
Hours Control γTE 20 µM 
8 0.039 ± 0.009 0.035 ± 0.009 
16 0.039 ± 0.008 0.10 ± 0.031** 
C22:0-Cer     
Hours Control γTE 20 µM 
8 0.20 ± 0.040 0.16 ± 0.042 
16 0.22 ± 0.057 0.34 ± 0.12* 
C24:1-Cer     
Hours Control γTE 20 µM 
8 6.08 ± 1.91 4.44 ± 1.11 
16 6.98 ± 2.22 7.66 ± 2.29 
C24:0-Cer     
Hours Control γTE 20 µM 
8 1.32 ± 0.41 0.75 ± 0.18** 
16 1.44 ± 0.42 0.99 ± 0.31** 
C26:1-Cer     
Hours Control γTE 20 µM 
8 0.12 ± 0.037 0.092 ± 0.022 
16 0.18 ± 0.043 0.11 ± 0.036** 




Hours Control γTE 20 µM 
8 0.019 ± 0.011 0.018 ± 0.009 
16 0.028 ± 0.015 0.017 ± 0.009 
Total Cers     
Hours Control γTE 20 µM 
8 9.61 ± 2.41 6.93 ± 1.38 
16 10.96 ± 2.70 13.21 ± 3.26 
 
Dihydroceramides (pmol/µg PC) 
C16:0-dhCer     
Hours Control γTE 20 µM 
8 0.11 ± 0.030 0.22 ± 0.047 
16 0.15 ± 0.036 1.76 ± 0.43** 
C18:0-dhCer     
Hours Control γTE 20 µM 
8 0.0036 ± 0.001 0.0056 ± 0.001 
16 0.0033 ± 0.0005 0.10 ± 0.036* 
C20:0-dhCer     
Hours Control γTE 20 µM 
8 0.00058 ± 0.0001 0.0016 ± 0.0003* 
16 0.00090 ± 0.0002 0.022 ± 0.0080** 
C22:0-dhCer     
Hours Control γTE 20 µM 
8 0.0017 ± 0.0003 0.0041 ± 0.001 
16 0.0029 ± 0.0005 0.030 ± 0.009* 
C24:1-dhCer     
Hours Control γTE 20 µM 
8 0.025 ± 0.010 0.098 ± 0.026* 
16 0.036 ± 0.016 0.33 ± 0.095* 
C24:0-dhCer     
Hours Control γTE 20 µM 
1 0.00093 ± 0.0009 0.0061 ± 0.0053 
2 0.0019 ± 0.0012 0.028 ± 0.016 
Total dhCers     
Hours Control γTE 20 µM 
8 0.14 ± 0.036 0.34 ± 0.064* 





Sphingoid bases (pmol/µg PC) 
Sph     
Hours Control γTE 20 µM 
8 0.72 ± 0.14 0.40 ± 0.10* 
16 0.80 ± 0.17 0.58 ± 0.11** 
dhSph     
Hours Control γTE 20 µM 
8 0.047 ± 0.014 0.054 ± 0.019 
16 0.059 ± 0.016 0.21 ± 0.058** 
S1P     
Hours Control γTE 20 µM 
8 0.019 ± 0.004 0.021 ± 0.003 
16 0.019 ± 0.005 0.017 ± 0.005 
 
Sphingomyelins (pmol/µg PC) 
C16:0-SM     
Hours Control γTE 20 µM 
8 20.72 ± 7.15 19.42 ± 4.81 
16 25.80 ± 7.59 20.93 ± 5.51** 
C18:0-SM     
Hours Control γTE 20 µM 
8 1.46 ± 0.34 1.51 ± 0.19 
16 1.79 ± 0.21 1.70 ± 0.22 
C20:0-SM     
Hours Control γTE 20 µM 
8 1.02 ± 0.13 1.16 ± 0.030 
16 1.37 ± 0.073 1.50 ± 0.088 
C22:0-SM     
Hours Control γTE 20 µM 
8 1.44 ± 0.67 1.54 ± 0.57 
16 1.86 ± 0.67 2.05 ± 0.85 
C24:1-SM     
Hours Control γTE 20 µM 
8 10.15 ± 3.43 10.40 ± 2.67 
16 12.38 ± 3.41 11.44 ± 2.94 
C26:1-SM     




8 3.32 ± 0.53 3.84 ± 0.42 
16 4.29 ± 0.89 5.23 ± 0.48 
Total SMs     
Hours Control γTE 20 µM 
8 38.11 ± 12.10 37.86 ± 8.36 
16 47.50 ± 12.38 42.85 ± 9.89 
 
Dihydrosphingomyelins (pmol/µg PC) 
C16:0-dhSM     
Hours Control γTE 20 µM 
8 3.69 ± 1.00 5.66 ± 0.95** 
16 4.81 ± 0.94 10.91 ± 1.51** 
C18:0-dhSM     
Hours Control γTE 20 µM 
8 0.29 ± 0.078 0.50 ± 0.067 
16 0.36 ± 0.045 1.10 ± 0.037** 
C20:0-dhSM     
Hours Control γTE 20 µM 
8 0.29 ± 0.044 0.48 ± 0.078** 
16 0.41 ± 0.064 1.09 ± 0.092** 
C22:0-dhSM     
Hours Control γTE 20 µM 
8 0.17 ± 0.048 0.23 ± 0.048 
16 0.21 ± 0.042 0.43 ± 0.11* 
C24:0-dhSM     
Hours Control γTE 20 µM 
8 0.13 ± 0.031 0.21 ± 0.023 
16 0.17 ± 0.011 0.41 ± 0.031** 
C26:0-dhSM     
Hours Control γTE 20 µM 
8 0.056 ± 0.014 0.069 ± 0.025 
16 0.11 ± 0.057 0.17 ± 0.043 
Total dhSMs     
Hours Control γTE 20 µM 
8 4.62 ± 1.16 7.14 ± 1.03* 








Table 2.3 Effect of γTE on de novo sphingolipid biosynthesis in HCT-116 cells. HCT-
116 cells were treated with either 400 µM 13C3, 15N-labeled L-serine alone as control or 
with a combination of 400 µM 13C3, 15N-labeled L-serine and 20 µM γTE for 0.5, 2, 3, 
and 6 h. The amount of each labeled de novo sphingolipid was determined by LC-
MS/MS. Data are mean ± SEM of 3 independent experiments. *p < 0.05, **p < 0.01, 
significant difference between control and γTE-treated cells. 
 
Ceramides (pmol/µg PC) 
De novo C16:0-Cer   
Hours Control γTE 20 µM 
0.5 0.10 ± 0.018 0.090 ± 0.015 
2 0.54 ± 0.025 0.44 ± 0.023** 
3 0.65 ± 0.045 0.35 ± 0.033** 
6 0.64 ± 0.004 0.19 ± 0.008** 
De novo C24:1-Cer   
Hours Control γTE 20 µM 
0.5 0.16 ± 0.024 0.15 ± 0.008 
2 0.69 ± 0.087 0.78 ± 0.15 
3 0.85 ± 0.096 0.80 ± 0.029 
6 0.89 ± 0.029 0.55 ± 0.029** 
De novo C24:0-Cer   
Hours Control γTE 20 µM 
0.5 0.13 ± 0.020 0.12 ± 0.003 
2 0.52 ± 0.069 0.55 ± 0.10 
3 0.68 ± 0.087 0.57 ± 0.049* 
6 0.88 ± 0.086 0.43 ± 0.027** 
De novo total Cers   
Hours Control γTE 20 µM 
0.5 0.38 ± 0.058 0.36 ± 0.023 
2 1.75 ± 0.18 1.77 ± 0.27 
3 2.18 ± 0.20 1.71 ± 0.060* 
6 2.41 ± 0.12 1.18 ± 0.050** 
 
Dihydroceramides (pmol/µg PC) 
De novo C16:0-dhCer   
Hours Control γTE 20 µM 




2 0.026 ± 0.005 0.039 ± 0.011* 
3 0.030 ± 0.006 0.052 ± 0.012** 
6 0.042 ± 0.007 0.11 ± 0.022** 
De novo C24:1-dhCer   
Hours Control γTE 20 µM 
0.5 0.00094 ± 0.0003 0.0015 ± 0.0006 
2 0.0025 ± 0.001 0.0062 ± 0.003 
3 0.0025 ± 0.0009 0.0074 ± 0.002 
6 0.0038 ± 0.0009 0.021 ± 0.004* 
De novo C24:0-dhCer   
Hours Control γTE 20 µM 
0.5 0.0010 ± 0.001 0.0018 ± 0.001 
2 0.0031 ± 0.002 0.0033 ± 0.002 
3 0.0025 ± 0.001 0.0048 ± 0.003 
6 0.0051 ± 0.003 0.012 ± 0.006 
De novo total dhCers   
Hours Control γTE 20 µM 
0.5 0.013 ± 0.003 0.014 ± 0.003 
2 0.032 ± 0.007 0.049 ± 0.015* 
3 0.035 ± 0.008 0.064 ± 0.016** 
6 0.051 ± 0.010 0.15 ± 0.032** 
 
Sphingoid bases (pmol/µg PC) 
De novo Sph     
Hours Control γTE 20 µM 
0.5 0.038 ± 0.024 0.022 ± 0.011 
2 0.072 ± 0.021 0.062 ± 0.005 
3 0.065 ± 0.008 0.054 ± 0.021 
6 0.078 ± 0.008 0.034 ± 0.012** 
 
Sphingomyelins (pmol/µg PC) 
De novo C16:0-SM   
Hours Control γTE 20 µM 
0.5 0.35 ± 0.10 0.31 ± 0.071 
2 0.77 ± 0.21 0.97 ± 0.29* 
3 1.18 ± 0.40 1.43 ± 0.32 
6 2.74 ± 0.64 2.61 ± 0.50 




Hours Control γTE 20 µM 
0.5 0.011 ± 0.003 0.011 ± 0.002 
2 0.013 ± 0.002 0.012 ± 0.004 
3 0.012 ± 0.004 0.016 ± 0.005 
6 0.024 ± 0.004 0.045 ± 0.014* 
De novo C24:1-SM   
Hours Control γTE 20 µM 
0.5 0.11 ± 0.031 0.14 ± 0.029 
2 0.18 ± 0.051 0.24 ± 0.077** 
3 0.27 ± 0.090 0.38 ± 0.16 
6 0.54 ± 0.12 1.47 ± 0.73 
De novo total SMs   
Hours Control γTE 20 µM 
0.5 0.47 ± 0.13 0.45 ± 0.10 
2 0.96 ± 0.27 1.22 ± 0.37** 
3 1.46 ± 0.50 1.83 ± 0.48 
6 3.31 ± 0.76 4.13 ± 1.22 
 
Dihydrosphingomyelins (pmol/µg PC) 
De novo C16:0-dhSM   
Hours Control γTE 20 µM 
0.5 0.10 ± 0.020 0.10 ± 0.012 
2 0.18 ± 0.029 0.27 ± 0.055* 
3 0.24 ± 0.039 0.39 ± 0.084** 


















Our current study demonstrates that γTE induced apoptosis and autophagy in 
human colon cancer cells by modulating sphingolipids metabolism. γTE treatment caused 
huge accumulation of intracellular dhSph and dhCers, important sphingolipid 
intermediates in de novo biosynthesis pathway, which appear to mediate cell death (Ahn 
and Schroeder, 2002; Jiang et al., 2004). In particular, γTE led to increase in de novo 
dhCers and decrease in de novo Cers as early as after 2 h incubation and these changes 
intensified during prolonged treatment, supporting the notion that DEGS is inhibited by 
γTE. Consistently, γTE inhibited DEGS activity without affecting its protein expression. 
Importantly, the modulation of these sphingolipids by γTE occurred prior to any signs of 
cell death. Moreover, individual Cers, which appear to have distinct bioactivities 
(Hannun and Obeid, 2011; Senkal et al., 2010; Sentelle et al., 2012), showed different 
responses by γTE treatment. γTE treatment led to significant decrease in C16:0-Cer at 8 h, 
but showed no difference at 16 h or increase at 24 h, compared with controls. On the 
other hand, while C24-Cers decreased from 8 to 24 h, C18:0-Cer increased from 16 h by 
γTE. Interestingly, SM decreased from 8 h but cells showed obvious apoptosis or 
autophagy only at 16 h or longer treatment with γTE. In addition, chemically blocking the 
increase of dhSph and dhCers, or the increase of Cers via SM hydrolysis by myriocin or 
desipramine, repectively, partially counteracted γTE-caused cell death, indicating that 
modulation of sphingolipids plays an important role in γTE-induced cancer cell death. 
 We showed that γTE led to marked accumulation of dhSph and dhCers in human 




of total Cers until the prolonged treatment with γTE. Although sphingosine and Cer have 
long been recognized and studied as pivotal apoptosis-inducing molecules (Woodcock, 
2006), emerging evidence suggests that other sphingolipid intermediates in the de novo 
biosynthesis pathway also play important roles in determining cell fate (Ahn and 
Schroeder, 2002; Jarvis et al., 1996; Kraveka et al., 2007; Ohta et al., 1995; Signorelli et 
al., 2009; Solomon et al., 2003; Zheng et al., 2006). For instance, previous studies in our 
group found that γT, the predominant form of vitamin E in US diet, as well as γTE 
enhanced the intracellular levels of dhSph and dhCers which played significant roles in 
the induction of apoptosis and autophagy in human prostate and breast cancer cells 
(Gopalan et al., 2012; Jiang et al., 2012; Jiang et al., 2004). Consistent with these studies, 
co-treatment of cells with myriocin, a specific inhibitor of the first reaction in the de novo 
sphingolipid synthesis pathway to block the increase of these two sphingoid bases, 
partially but significantly reversed γTE-induced colon cancer cell death, indicating that 
the accumulation of dhSph and dhCers plays important roles in γTE-induced colon cancer 
cell death. 
We identified that DEGS, an enzyme for the conversion of dhCer to Cers, is the 
initial target of γTE in its modulation of sphingolipid metabolism followed by cancer cell 
death. Specifically, in the serine-labeled study with γTE to only trace the effect of γTE on 
de novo biosynthesis pathway of sphingolipids, γTE caused rapid increase of de novo 
dhCers, but significant decrease of de novo Cers as early as after 2 h incubation, 
suggesting that DEGS-catalyzed reaction is likely to be inhibited as a result of γTE 
treatment (Fig. 2.3). Consistently, γTE inhibited DEGS activity in both in situ and in vitro 




that higher concentration of γTE was needed to have its inhibitory effect on DEGS 
activity when we used rat liver microsomes as an enzyme source. It may be due to 
limitation in permeability through the microsomal membrane of γTE under the cell-free 
environment.  
DEGS is a key enzyme regulating the balance of dhCer and Cer as it catalyzes the 
insertion of a 4,5-trans-double bond into dhCer to generate Cer. Michel et al. first 
reported the biochemical characterization of the DEGS reaction in 1997 using rat liver 
microsomes (Michel et al., 1997). They have shown that the DEGS uses molecular 
oxygen as electron acceptor to have a hydroxyl group into the C4-position of the dhSph, 
and then with NADH or NADPH as electron donor, a dehydration reaction occurs to 
produce a double bond in the C4-C5 position of dhCer. Therefore, they confirmed that 
the conversion of dhCer to Cer was occurred by a desaturase, not by a dehydrogenase. 
Two different DEGSs, DEGS1 and DEGS2, have been so far reported. In bioinformatics 
approach, Ternes et al. identified a family of sphingolipid Δ4-desaturases (homologs of 
the Drosophila melanogaster degenerative spermatocyte gene 1 (des-1)). DEGS-1, the 
human homolog of des-1, exhibits high dhCer Δ4-desaturase and very low C-4 
hydroxylase activities, whereas DEGS2, another ortholog identified in mouse and human, 
is similarly active as both sphinglipid C-4 hydroxylase and Δ4-desaturase activities, 
resulting in the production of either phyto-Cer or Cer. Recently, DEGS activity was also 
found to be inhibited by resveratrol (Signorelli et al., 2009), celecoxib (Schiffmann et al., 
2009b), fenretinide (Rahmaniyan et al., 2011), hydrogen peroxide (Idkowiak-Baldys et 
al., 2010) or hypoxic environment (Devlin et al., 2011). Furthermore, as several 




Fujisawa et al., 2004; Galati et al., 2002) and oxidative stress can inhibit DEGS activity 
followed by dhCer accumulation (Idkowiak-Baldys et al., 2010), we investigated whether 
γTE also inhibits DEGS activity by acting as prooxidant. However, we found that N-
acetylcysteine (NAC), an antioxidant, did not reverse γTE-induced modulation of 
sphingolipid metabolism (Fig. 2.7), suggesting that the inhibition of DEGS by γTE is not 
affected by NAC and these sphingolipid modulation did not caused by prooxidant effects 
of γTE. 
 In addition to the accumulation of dhSph and dhCers, γTE treatment had an 
impact on Cer species. Interestingly, the effects of γTE on specific Cer species were 
different. For instance, γTE treatment led to significant decrease in C16:0-Cer during the 
initial phase, but increase in the longer time treatment. While γTE caused increase in 
C18:0-Cer, it led to continuous decreases in C24:1- and C24:0-Cers. Interestingly, recent 
emerging results suggest that endogenous Cers with different fatty acyl-chain lengths 
appear to have distinct bioactivities. C18:0-Cer generated by CerS1 has been found to 
induce apoptosis and lethal autophagy (Senkal et al., 2010; Sentelle et al., 2012). In 
contrast, C16:0-Cer generated by CerS5/6 have been proposed to have opposed roles of 
anti-apoptosis to C18:0-Cer (Senkal et al., 2010). However, several other studies found 
that this Cer also plays important roles in apoptotic cell death (Mullen et al., 2011; 
Schiffmann et al., 2009b; White-Gilbertson et al., 2009). Therefore, further investigation 
should be conducted to determine the role of individual Cer species and to characterize 
the effects of γTE on individual CerSs and Cers. 
 During prolonged treatment, γTE led to increase in Cers, especially C16:0- and 




and SMs, which are SMSs in the de novo synthesis pathway and SMases in the SM 
hydrolysis. In our de novo sphingolipids studies using 13C3, 15N- L-serine, we found that 
since labeled C16:0-Cer is still decreased and the conversion of C16:0-Cer to C16:0-SM is 
stimulated at the initial stage of γTE treatment, we reason that the increase of Cers in the 
longer time treatment is likely caused by SM hydrolysis via the action of SMases. Co-
treatment of cells with desipramine but not GW4869 partially but significantly 
counteracted γTE-induced cancer cell death, indicating that the increase of Cers from 
SMs through acid SMase-catalyzed SM hydrolysis may in part involved in γTE-induced 
colon cancer cell death. 
In summary, our data strongly suggest that γTE-induced apoptosis, autophagy and 
cell death are mediated by modulation of sphingolipid metabolism as its primary target. 
The lipidomic analysis using LC-MS/MS reveals that γTE-exerted anticancer effects are 
caused by initial inhibition of DEGS activity and subsequent activation of SM hydrolysis 











CHAPTER 3. 13’-CARBOXYCHROMANOLS, LONG-CHAIN VITAMIN E 
METABOLITES, INDUCE APOPTOSIS AND AUTOPHAGY BY 




13’-Carboxychromanol (13’-COOH) is a major vitamin E metabolite excreted in 
feces. Here we investigated anticancer activities of δT-13’-COOH and δTE-13’-COOH, 
which are metabolites of delta-tocopherol (δT) or delta-tocotrienol (δTE), respectively. 
Both 13’-COOHs inhibited the growth and induced apoptosis and autophagy in human 
colon (HCT-116, HT-29), breast (MCF-7), and pancreatic (PANC-1, MiaPaca-2) cancer 
cells with the IC50 of 8-20 µM. In these activities, 13’-COOHs were much stronger than 
tocopherols. Using liquid chromatography tandem mass spectrometry, we found that δT-
13’-COOH increased intracellular dihydrosphingosin and dihydroceramides but 
decreased C16:0-ceramide within 2 h treatment. During longer treatment, δT-13’-COOH 
enhanced all sphingoid bases including ceramides while decreased sphingomyelins. 
Modulation of sphingolipids by 13’-COOHs was observed prior to or coinciding with 
appearance of cell death markers including PARP cleavage and LC3-II increase. The 
importance of sphingolipid modulation was supported by the observation that 




COOH-induced cell death. Further mechanistic studies indicated that 13’-COOH 
inhibited dihydroceramide desaturase without affecting its protein expression and may 
activate sphingomyelin hydrolysis to enhance ceramides. In agreement with these cell-
based studies, δTE-13’-COOH significantly decreased colon tumor multiplicity induced 
by AOM with two cycles of 1.5% DSS without any apparent toxicity even when the 
dietary supplementation was started after AOM injection. Moreover, δTE-13’-COOH 
attenuated 1.8% DSS-induced colon inflammation, indicating that δTE-13’-COOH is 
able to attenuate colitis and its promoted tumorigenesis in vivo. Our mechanistic study 
demonstrates that 13’-COOHs have potent anticancer effects by modulating enzyme 




Cumulative cancer risk is estimated to be 30% and 22% in men and women, 
respectively, by age 75 in developed area worldwide (Jemal et al., 2011). Natural forms 
of vitamin E that consist of α-, β-, γ- and δ-tocopherol (αT, βT, γT and δT) and α-, β-, γ- 
and δ-tocotrienol (αTE, βTE, γTE and δTE), are potentially good cancer 
chemoprevention agents as they are known to be safe and specific forms of vitamin E 
have been shown to have cancer prevention effects. Specifically, γT, mixed tocopherols 
and tocotrienols have been demonstrated to inhibit the development of colon, prostate 
and breast cancer in various preclinical models (Jiang, 2014; Moya-Camarena and Jiang, 




in vitamin E alone because many forms of vitamin E are not highly bioavailable as a 
result of their extensive metabolism in vivo.   
Tocopherols and tocotrienols, with exception for αT, are readily metabolized by 
cytochrome P450-catalyzed ω-hydroxylation and oxidation to 13’-carboxychromanols 
(13’-COOH), which are then further catabolized via β-oxidation to generate various 
shorter chain carboxychromanols or sulfation to form sulfated carboxychromanols (Jiang, 
2014; Jiang et al., 2007; Sontag and Parker, 2002). Importantly, carboxychromanols and 
their sulfated counterparts have been detected in rodent plasma and liver upon 
supplementation of γT and γTE (Freiser and Jiang, 2009; Jiang et al., 2007). Recently, 
long-chain carboxychromanols are found at high levels in feces from mice fed diet 
supplemented with γT or δT, and 13’-COOHs appear to be major fecal excreted 
carboxychromanols (Bardowell et al., 2012a; Bardowell et al., 2012b; Jiang et al., 2013). 
Considering significant quantities of carboxychromanols in vivo, it is of importance to 
examine potential bioactivities of these metabolites. 
Emerging studies have demonstrated that long-chain carboxychromanols have 
interesting bioactivities that are relevant to disease prevention and therapy (Jiang, 2014). 
In particular, we have demonstrated that δT-13’-COOH, a long-chain carboxychromanol 
from δT, competitively inhibits cyclooxygenase (COX-1 and COX-2) (Jiang et al., 2008) 
and is much stronger than short-chain carboxychromanols and unmetabolized vitamin E 
forms in these effects. δT-13’-COOH also inhibits 5-lipoxygenase (5-LOX) activity, 
whereas vitamin E forms do not inhibit the enzyme directly (Jiang et al., 2011). These 
results indicate that δT-13’-COOH is a unique dual inhibitor of COX-1/COX-2 and 5-




inflammatory and anticancer agents as both COXs and 5-LOX have been recognized to 
play significant roles in inflammation and cancer (Wang and Dubois, 2010). In addition, 
Birringer et al. (Birringer et al., 2010) demonstrated that 13’-COOHs metabolized from 
αT or δT induced apoptosis in human HepG2 cells. However, the anticancer study of 
13’-COOHs was limited to this liver cell line and the underlying mechanism was not 
completely understood. In the present study, we investigated the effect of δT-13’-COOH 
and δTE-13’-COOH (a metabolite from δTE) (Fig. 3.1) on the proliferation of various 
types of cancer cells including colon, pancreas, and breast. Since vitamin E forms have 
been shown to exert anticancer effects via modulating sphingolipids (Jiang et al., 2012; 
Jiang et al., 2004), we further investigated whether 13’-COOHs are capable of altering 
sphingolipid metabolism and the role of modulation of sphingolipids in 13’-COOH-
exerted anticancer activities. We also examined the anti-inflammatory effects and 
anticancer efficacy of δTE-13’-COOH supplementation against DSS-caused colon 

















Figure 3.1 The structures of (A) natural forms of vitamin E and (B) 13’-COOHs, vitamin 








3.3 Materials and Methods 
 
3.3.1 Materials and reagents 
δT-13’-COOH and δTE-13’-COOH (>95% pure) were synthesized as previously 
described (Maloney and Hecht, 2005). γT (≥96%) and δT (93-97%) were purchased from 
Sigma (St Louis, MO) and Suppleco (Bellefonte, PA), and γTE (97-99%) was a gift from 
BASF (Ludwigshafen, Germany). C8-cyclopropenylceramide (C8-CPPC) was purchased 
from Matreya LLC (Pleasant Gap, PA). All sphingolipid standards were obtained from 
Avanti Polar Lipids (Alabaster, AL). CHAPS (3-((3-cholamidopropyl) 
dimethylammonio)-1-propanesulfonate) was purchased from Thermo Fisher Scientific. 
Myriocin from Mycelia Sterilia, 13C3, 15N-labeled L-serine, dimethyl sulfoxide (DMSO), 
[3-(4,5)-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide] (MTT), and all other 
chemicals were from Sigma.  
 
3.3.2 Cell culture and treatment 
Human colon (HCT-116 and HT-29), breast (MCF-7), and pancreatic (PANC-1 
and MiaPaCa-2) cancer cells, and human normal colonic epithelial CCD841CoN cells 
were obtained from American Type Culture Collection (Manassas, VA). Cells were 
routinely cultured in growth media containing 10% fetal bovine serum (FBS) at 37 °C in 
5% CO2. HT-29 and PANC-1 cells were cultured in Dulbecco’s modified eagle medium 
(DMEM), and HCT-116 cells were cultured in McCoy’s 5A modified medium. MCF-7 
and MiaPaCa-2 cells were incubated in DMEM supplemented with 2.5% horse serum or 




essential medium (EMEM). For experiments, cells were seeded in the corresponding 
medium with 10% FBS either at a density of 4 x 104 cells/well in 24-well plates or at a 
density of 7-8 x 105 cells in 10-cm dishes. After overnight attachment, media were 
replaced with fresh DMEM containing 1% FBS and 13’-COOHs or other compounds. All 
the treatment solutions were freshly prepared for each experiment. Vitamin E forms were 
dissolved in DMSO at 100 mM and then diluted to fatty acid-free BSA (10 mg/ml). 
 
3.3.3 MTT assay 
Cell viability was examined by MTT assay to estimate mitochondrial 
dehydrogenase activity as previously described (Jiang et al., 2004).  
 
3.3.4 Flow cytometry with Annexin V and Propidium Iodide staining 
Both floating and attached cells were collected by trypsinization after treatment. 
Cells were stained with Annexin-V-Flous staining kit (Roche Applied Science, 
Indianapolis, IN), and apoptosis (Annexin V: Ex = 488 nm; Em = 518 nm) and necrosis 
(Propidium Iodide: Ex = 488-540 nm; Em = 617 nm) were evaluated by Beckman 
Coulter FC500 (Beckman Coulter, Miami, FL) and BD FACS Aria III cell sorter (BD 
Biosciences, San Jose, CA) with FlowJo software system.   
 
3.3.5 Western Blotting 
Cells were lysed in lysis buffer containing Tris-EDTA, 1% SDS, 2 mM Na3VO4 
and protease inhibitor cocktails (Sigma). Total proteins were quantified by bicinchoninic 




Laemmli buffer (Bio-rad, Hercules, CA) for 5 min at 95 °C. Equal amount of proteins 
(15-30 µg) were separated on acrylamide gels by SDS-electrophoresis and then 
transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore, Bilerica, MA), 
and probed by antibodies. Membranes were exposed to chemiluminescent reagent 
(PerkinElmer, Waltham, MA) and visualized on Kodak film with an M35A X-Omat 
processor (Kodak, Rochester, NY). The antibodies used in the study were as follows: 
membrane bound microtubule-associated protein light chain 3 (LC3; MBL international, 
Woburn, MA), Caspase-9, poly (ADP-ribose) polymerase-1 (PARP-1) and Actin (Santa 
Cruz Biotechnology, Santa Cruz, CA), and DEGS1 (Novus Biologicals, Littleton, CO). 
 
3.3.6 Lipid extraction 
Lipid was extracted as previously described (Merrill et al., 2005). Briefly, cell 
pellets were resuspended in 500 µL of methanol, 250 µL of chloroform and 50 µL of 
water after the addition of 20 µL of internal standard mixture containing 25 µM of C12:0-
ceramide, C25:0-ceramide, C17-sphingosine, C17-sphinganine, and C12:0-sphingomyelin 
(Avanti Polar Lipids, Alabaster, AL). The suspension was dispersed fully by tip 
sonication for 20 sec and then incubated overnight at 48 °C. 100 µL of solvent was used 
to determine the amount of total choline-containing phospholipids by an enzymatic 
colorimetric assay (Wako chemicals, Osaka, Japan) (Jiang et al., 2004). 75 µL of 1M 
potassium hydroxide in methanol was added to the rest of the solvent and sonicated for 
30 min. After sonication, samples were incubated at 37 °C for 2 h and evaporated under a 





3.3.7 Measurement of sphingolipids using liquid chromatography tandem mass 
spectrometry (LC-MS/MS) 
Samples were resolved in methanol and sonicated to disperse, then centrifuged to 
clarify before transferring to test vials for quantification. The LC-MS/MS analyses were 
performed using the Agilent 6460 triple quadrupole mass spectrometer coupled with the 
Agilent 1200 Rapid Resolution HPLC (Agilent Technologies, Santa Clara, CA) with 
detection of sphingolipids in positive mode by multiple reaction monitoring (MRM) 
technique (Merrill et al., 2005). The HPLC mobile phases consisted of methanol-H2O-
formic acid (74:25:1, v/v/v; RA) and methanol-formic acid (99:1, v/v; RB); both RA and 
RB contain 5 mM ammonium formate. For measurement of Cers and sphingoid bases, 
Agilent column XDB-C18, particle size 1.8 µm, 4.6 x 50 mm was used with isocratic run 
(100% B) or gradient (0-1 min, 20% B, 10-13 min, 100% B and 15-20 min at  20% B), 
respectively. For measurement of SMs, Agilent Zorbax XDB-C8, particle size 3.5 µm, 
2.1 x 50 mm was used with gradient (0-1 min, 20% B, 10-20 min, 100% B, 22-30 min, 
20% B). The MS/MS parameters were as follows: gas temperature, 325-350 °C; gas flow 
rate, 7-10 L/min; nebulizer pressure, 45-50 psi; capillary voltage, 3500 V; The 
fragmentor voltage was 100 V and collision energy was 12-20 V. Precursor-to-product 
ion transitions for each sphingolipid were used according to the method of Merrill et al. 
(Merrill et al., 2005). 
 
3.3.8 De novo sphingolipids analysis 
HCT-116 cells were treated with either 400 µM 13C3, 15N-labeled L-serine alone 




for 0.5, 1, 1.5, 2 and 4 h. Lipid was extracted and de novo synthesized sphingolipids were 
measured using LC-MS/MS. 
 
3.3.9 Dihydroceramide desaturase (DEGS) assay 
For the in vitro assay of DEGS, HCT-116 cells were treated with either 20 µM 
δT-13’-COOH or 1 µM C8-CPPC for 1 or 2 h. Cells were collected and homogenized in 
a buffer (5 mM Hepes, pH 7.4, containing 50 mM sucrose) and kept on ice for 10 min. 
The cell homogenate was centrifuged at 250 x g for 5 min at 4 °C to remove unbroken 
cells. Reaction was started by addition of C8:0-dhCer as a non-physiological substrate for 
DEGS and NADH for an hour at 37 °C.   
In another in vitro assay, rat liver microsomes were prepared as described 
(Rahmaniyan et al., 2011).  Briefly, livers from male Wistar rats were rinsed in ice-cold 
PBS and homogenized in buffer (0.25 M sucrose, 10 mM HEPES, 1 mM EDTA, pH 7.4) 
in ice. The homogenate was centrifuged at 800 x g for 10 min and the supernatant was 
centrifuged at 10,000 x g for 15 min. The resulting supernatant was ultracentrifuged at 
104,000 x g for 1 h to obtain microsomal pellet, which was then resuspended in 
potassium phosphate buffer (50 mM, pH 7.4) and stored at -80 °C until use. In 
preparation for the assay, C8:0-dhCer and tested compounds were dried under a stream of 
nitrogen, followed by resuspension in CHAPS (1.1 mg/10 µl of water). Microsomal 
fraction (500 µg of protein) was mixed with reaction buffer (20 mM bicine, pH 8.5, 50 
mM NaCl, and 50 mM sucrose) and added with tested compounds, followed by 30 min 
pre-incubation at room temperature. 2 mM of NADH and 10 µM of C8:0-dhCer were 




was conducted directly after reaction and the products (C8:0-Cer and C8:0-SM) were 
quantified by LC-MS/MS. 
 
3.3.10 Animal studies 
The animal use protocol was approved by the Animal Care and Use Committee at 
Purdue University. δTE-13’-COOH was isolated from the African Garcinia kola bitter 
nut according to the method described by Terashima et al. (Terashima et al., 1997), and 
modified δTE-13’-COOH-enriched AIN-93G purified diet was prepared by adding 0.22 
g/kg δTE-13’-COOH.  
In animal study 1 (AOM-DSS study), colon tumorigenesis was initiated by 
injection of azoxymethane (AOM; Sigma) and promoted by two cycles of dextran sodium 
sulfate (DSS; molecular weight of 36,000-50,000, MP Biochemicals, Solon, OH) at 1.5% 
in drinking water. Male Balb/c mice at 5-6 weeks of age from Harlan (Indianapolis, IN) 
were injected a dose of AOM (9.5 mg/kg body weight, i.p.) or the vehicle (sterile saline) 
after a week of acclimatization. A week later, AOM-injected mice were randomized into 
control or δTE-13’-COOH-supplemented groups, and they were given 1.5% DSS in 
drinking water for 1 week. The mice were started to be supplemented with either AIN-
93G diet (for Non-AOM/DSS group; n=6, and AOM/DSS control diet group; n=17) or 
δTE-13’-COOH-enriched AIN-93G diet (for AOM/DSS δTE-13’-COOH 
supplementation group; n=15). Two weeks after first cycle of DSS administration, mice 
in AOM/DSS groups were again given the 2nd cycle of 1.5% DSS in drinking water for a 
week (Fig. 3.10A). Animals were observed and weighed daily and food intake was 




rectal bleeding and stool consistency was evaluated daily and scored as follows (rectal 
bleeding: 0 = no blood, 0.5 = feces with tiny spots of bleeding, 1 = feces with blood less 
than 50% of area, 2 = feces with half-sized bleeding, and 3 = feces with blood more than 
50% of area; stool consistency: 0 = normal, 1 = a little bit soft, 2 = soft, and 3 = very soft 
and diarrhea). During tissue harvest, colons were removed, rinsed with cold saline, cut 
open longitudinally from rectum to cecum. Lengths and weights of each colon tissue 
were measured and tumors were examined. 
In animal study 2 (DSS study), to investigate the anti-inflammatory effects of 
δTE-13’-COOH against colitis, colon inflammation was induced by feeding mice with 
one cycle of 1.8% DSS in drinking water for 8 days in 5-6-week-old male Balb/c mice 
(Harlan). On the same day of DSS feeding started, the mice were supplemented with 
either AIN-93G diet (for Non-DSS group; n=8, and DSS control diet group; n=12) or 
δTE-13’-COOH-enriched AIN-93G diet (for DSS δTE-13’-COOH supplementation 
group; n=12; Fig 3.11A). During the study, animals were observed and weighed, and 
their fecal scorings were evaluated daily as described above, and food intake was 
measured once at the end of the study.  
 
3.3.11 Statistics 
Statistical significance was determined using a Student’s t-test.  P < 0.05 was 








3.4.1 13’-COOHs inhibited proliferation of various human cancer cells 
We investigated the effect of δT- or δTE-13’-COOH on cell proliferation using 
MTT assays in various human cancer cell lines. We found that δT-13’-COOH inhibited 
the growth of human colon (HCT-116, HT-29), breast (MCF-7) and pancreatic (PANC-1, 
MiaPaCa-2) cancer cells in a time- and dose-dependent manner (Fig. 3.2A) with the IC50 
values (estimated after 24 h incubation) of 8.9 µM, 8.6 µM and 13.5 µM in HCT-116, 
HT-29, and MCF-7 cells, respectively. In addition, δTE-13’-COOH also showed 
antiproliferative effects with IC50 values (at 24 h) of 16 µM, 17 µM and 19.7 µM in 
HCT-116, HT-29, and MCF-7 cells, respectively (Fig. 3.2B). In these activities, δT-13’-
COOH was more potent than δTE-13’-COOH, and both 13’-COOHs were stronger than 
tocopherols (Fig. 3.2C). Interestingly, although human colon HT-29 cancer cells showed 
more resistance than HCT-116 cells to the treatment of γT and γTE (Fig. 3.2C), 13’-
COOHs showed similar anticancer effects in both cell lines (Figs. 3.2A and B). In 
addition, human normal colonic epithelial cells, CCD841CoN, were used as a control cell 
line. δT-13’-COOH and δTE-13’-COOH showed about 2-fold higher IC50 values (at 24 



















Figure 3.2 Anti-proliferative effects of 13’-COOHs derived from δT or δTE on various 
cancer cells. (A) The effects of δT-13’-COOH on human colon (HCT-116, HT-29), 
breast (MCF-7) and pancreatic (PANC-1, MiaPaCa-2) cancer cells. (B) The effects of 
δTE-13’-COOH on human colon (HCT-116, HT-29) and breast (MCF-7) cancer cells. 
(C) The effects of natural forms of vitamin E on human colon (HCT-116, HT-29) and 
pancreatic (PANC-1) cancer cells. (D) The effects of δT-13’-COOH and δTE-13’-COOH 
on human normal colonic epithelial (CCD841CoN) cells. Relative cell viability was 
measured after treatment with 13’-COOHs or natural forms of vitamin E at the stated 
concentrations and time by MTT assay compared with control. IC50 of 24 h is shown. The 
data are mean ± SD for at least three independent experiments, each performed in 
duplicate. *p < 0.05 and **p < 0.01 indicate a significant difference between treated and 
control cells.  
 
 
3.4.2 13’-COOHs induced apoptosis and autophagy in various types of cancer cells 
Based on microscopic examination, 13’-COOHs appeared to induce cell death as 
indicated by detachment and shrinkage of cells during prolonged treatment. Consistently, 
both δT-13’-COOH and δTE-13’-COOH induced early and late-stage apoptosis in HCT-
116 cells compared with controls, as indicate by enhanced annexin V staining that is 
associated with externalization of phosphatidylserine to the cytoplasmic membrane (Fig. 
3.3A). Furthermore, 13’-COOHs caused PARP cleavage and caspase-9 activation (Fig. 




than δTE-13’-COOH in the induction of apoptosis. In addition to apoptosis, δT- and 
δTE-13’-COOHs treatment led to an increase of LC3-II, a marker of autophagy (Fig. 
3.3C). We also observed similar biochemical changes in MCF-7 cells (data not shown). 
These results demonstrated that δT- and δTE-13’-COOH induced apoptosis and 











Figure 3.3 Induction of apoptosis and autophagy by 13’-COOHs in cancer cells. (A) 
HCT-116 cells were treated with 20 μM δT-13’-COOH or δTE-13’-COOH for 24 h. 
Induction of apoptosis and necrosis was quantified by annexin V and PI staining. 
Representative diagrams of FACS are shown here. Expression levels of (B) full-length 
and cleaved caspase-9 and PARP, and (C) LC3-II in HCT-116 cells after treatment with 
10 or 20 μM of δT-13’-COOH or δTE-13’-COOH were examined by western blotting. 








3.4.3 13’-COOHs modulated sphingolipids in HCT-116 and MCF-7 cells 
We have demonstrated that modulation of sphingolipid pathway plays a role in γT 
and γTE-induced death in human prostate and breast cancer cells (Gopalan et al., 2012; 
Jiang et al., 2012; Jiang et al., 2004). Here we investigated effects of 13’-COOHs on 
sphingolipid metabolism using LC-MS/MS. Compared with controls, δT-13’-COOH 
dose-dependently increased total dihydroceramides (dhCers) (Fig. 3.4A), individual 
dhCer including C16:0- (Fig. 3.4B), C18:0-, C24:1- and C24:0-dhCers (data not shown), and 
dihydrosphingosine (dhSph) (Fig. 3.4C). Interestingly, δT-13’-COOH (20 μM) enhanced 
C16:0-dhCer and dhSph at 1 h after incubation, which was prior to any signs of cell 
morphological changes. Consequently, cells accumulated high levels of dhCers and 
dhSph after incubation for 8-16 h.  In contrast to dhCer, the effect of 13’-COOHs on 
individual ceramides (Cer) varied with treatment time, concentrations, and specific 
ceramide species. Specifically, compared with controls, δT-13’-COOH induced a 
significant decrease of C16:0-Cer after 2 h incubation, but enhanced this sphingoid base 
during longer treatment (8 h or 16 h incubation). δT-13’-COOH at 20 μM increased C18:0-
Cer after 4 h treatment, while treatment of δT-13’-COOH at 10 and 20 μM caused 
opposite effects on C24-Cers (Fig. 3.4D). For sphingomyelin (SM), δT-13’-COOH led to 
persistent decrease in all types of SM species starting at 2 h (Fig. 3.4E; Table 3.1). 
Besides HCT-116 cells, we observed similar modulatory effects of δT-13’-COOH on 
MCF-7 cells (Fig. 3.5; Table 3.2). Furthermore, δTE-13’-COOH at 20 µM induced 
similar modulation of sphingolipids to that by δT-13’-COOH (Fig. 3.6; Table 3.3), 









Figure 3.4 Effects of δT-13’-COOH on sphingolipid metabolism in HCT-116 cells. HCT-
116 cells were treated with 10 or 20 μM δT-13’-COOH with increasing treatment times 
as indicated (1, 2, 4, 8, or 16 h). The sphingolipid levels including (A) total dhCers, (B) 
C16:0-dhCer, (C) dhSph, (D) total, C16:0-, C18:0-, C24:1-, and C24:0-Cers and (E) total SMs 
were determined by LC-MS/MS. Results are shown as mean ± SEM for at least three 
independent experiments. *p < 0.05 and **p < 0.01 indicate a significant difference 














Figure 3.5 Effects of δT-13’-COOH on sphingolipid metabolism in MCF-7 cells. MCF-7 
cells were treated with 10 or 20 μM δT-13’-COOH for 4 h or 8 h. The sphingolipid levels 
including (A) total dhCers, (B) C16:0-dhCer, (C) C16:0-Cer, C18:0-Cer, C24:1-Cer, and C24:0-
Cer and (D) total SMs were determined by LC-MS/MS. Results are shown as mean ± SD 












Figure 3.6 Effects of δTE-13’-COOH on sphingolipid metabolism in HCT-116 cells. 
HCT-116 cells were treated with 10 or 20 μM δTE-13’-COOH for 8 h or 16 h. The 
sphingolipid levels including (A) total dhCers, (B) C16:0-dhCer, (C) dhSph, (D) C16:0-Cer, 
C18:0-Cer, C24:1-Cer, and C24:0-Cer and (E) total SMs were determined by LC-MS/MS. 
Results are shown as mean ± SD for two independent experiments. 
 
3.4.4 13’-COOHs modulated de novo biosynthesis of sphingolipids 
Since 13’-COOHs elevated dhCer and dhSph that are important sphingoid bases 
in de novo synthesis of sphingolipid pathway (Fig. 3.7A), we used 13C3, 15N-labeled L-
serine, a substrate for making sphingolipids with palmitoyl-CoA, to trace the effect on the 
newly synthesized sphingolipids. We observed that δT-13’-COOH treatment induced a 
significant increase in labeled dhCers in a time-dependent manner (Fig. 3.7B) but 
resulted in decrease of Cers including C16:0-, C24:1- and C24:0-Cers as early as 0.5 h to 2 h 
(Fig. 3.7C). δT-13’-COOH significantly suppressed de novo synthesis of C16:0- and C24:1-
SMs (Fig. 3.7D). Despite elevation of newly-made dhCer, δT-13’-COOH significantly 
reduced the total amount of newly synthesized sphingolipids (Fig. 3.7E; Table 3.4) as a 
result of diminished synthesis of SM and Cer that are much more abundant than dhCer. 

















Figure 3.7 Effects of δT-13’-COOH on de novo sphingolipid biosynthesis in HCT-116 
cells. (A) The de novo biosynthesis pathway of sphingolipids (SMS, sphingomyelin 
synthase; SMase, sphingomyelinase). HCT-116 cells were treated with either 400 μM 
13C3, 15N-labeled L-serine alone as control or with a combination of 400 μM 13C3, 15N-
labeled L-serine and 20 μM δT-13’-COOH for 0.5, 1, 1.5, 2, and 4 h. The amount of each 
labeled de novo sphingolipid including (B) total dhCers, (C) total, C16:0-, C24:1- and C24:0-
Cers, and (D) total, C16:0- and C24:1-SMs were determined by LC-MS/MS. (E) Total 
amounts of all the de novo synthesized sphingolipids were calculated. Results are shown 
as mean ± SEM for three independent experiments. *p < 0.05 and **p < 0.01 indicate a 




3.4.5 13’-COOHs inhibited DEGS activity without affecting its protein expression 
Based on the observation that δT-13’-COOH increased newly synthesized dhCers 
but decreased Cers, we reason that δT-13’-COOH likely inhibits the enzyme reaction or 
protein expression of dihydroceramide desaturase (DEGS), which is responsible for 
addition of the 4,5-trans-double bond of dhCer (Fig. 3.7A). The western blot data 
revealed that δT-13’-COOH had no effect on DEGS-1 protein expression in HCT-116 
cells (Fig. 3.8A). We then examined potential effect of δT-13’-COOH on the DEGS 
enzyme activity. In the in vitro DEGS assay with cell homogenates, 1 or 2 h pre-
incubation of δT-13’-COOH inhibited DEGS activity by about 38% or 47%, respectively. 
C8-CPPC, a known competitive inhibitor of DEGS (Triola et al., 2003), inhibited the 
enzyme activity by about 95% (Fig. 3.8B). On the other hand, δT-13’-COOH did not 
show the inhibition of DEGS enzyme activity in another in vitro DEGS assay using rat 







Figure 3.8 Effects of δT-13’-COOH on DEGS expression and activity. (A) HCT-116 
cells were treated with 10 or 20 μM δT-13’-COOH for 8 or 16 h and the protein levels of 
DEGS-1 and actin as a loading control were detected by western blotting. (B) HCT-116 
cells were treated with either 20 μM δT-13’-COOH or 1 μM C8-CPPC as a positive 
control for indirect in vitro DEGS assay. After 1 h or 2 h of treatment, cells were 
collected and homogenized. Using the homogenates, reaction was started for an hour in 
37 °C followed by addition of C8:0-dhCer as a substrate for DEGS with NADH. The 
levels of products which are C8:0-sphingolipids were analyzed by using LC-MS/MS. The 
data are mean ± SD of three independent experiments. *p < 0.05 and **p < 0.01 indicate 






3.4.6 The role of sphingolipid modulation in 13’-COOH-induced cell death 
Since 13’-COOHs induced accumulation of intracellular dhCer and dhSph, which 
are known to induce cell stress and/or death (Ahn and Schroeder, 2002; Jiang et al., 2012; 
Jiang et al., 2004), we used myriocin, a specific inhibitor of serine palmitoyltransferase, 
to block the increase of these sphingoid bases. Interestingly, co-treatment of cells with 
myriocin showed partial reversion of 13’-COOH-induced LC3-II expression (Fig. 3.9A), 
but had no effect on PARP-1 cleavage (data not shown). These data suggest that 
elevation of dhCer and dhSph may play a role in 13’-COOHs-induced autophagy. 
Cers have been known to be potent inducer of apoptosis (Kolesnick, 2002; Radin, 
2001; Woodcock, 2006). Because 13’-COOHs decreased Cers synthesis in the de novo 
pathway (Fig. 3.7C), we reason that the increase of Cers (Fig. 3.4D) after longer 
treatment is likely caused by hydrolysis of SM via sphingomyelinase (SMase). To 
establish the role of Cers from SMs in 13’-COOH-induced cancer cell death, we used 
desipramine and GW4869 to inhibit acid or neutral SMases, respectively. Co-treatment of 
GW4869 but not desipramine (data not shown) with 13’-COOHs partially counteracted 
anti-proliferation by 13’-COOHs (Fig. 3.9B). These data suggest that SM hydrolysis 










Figure 3.9 Protective effects of inhibitors of enzymes in sphingolipid metabolism on 13’-
COOHs-induced cancer cell death. (A) HCT-116 cells were treated with 20 μM δT- or 
δTE-13’-COOH with or without 3 μM myriocin, a specific inhibitor of serine 
palmitoyltransferase to block the de novo sphingolipid pathway. After 16 h of treatment, 
the cells were collected and analyzed for detection of LC3-II expression. Western blots in 
this figure are representative of three or more independent experiments. LC3-II protein 
levels were quantified from the blots. The data are mean ± SEM of three or four 
independent experiments. *p < 0.05 and **p < 0.01; #p < 0.05 and ##p < 0.01 versus 
control indicate a significant difference. (B) HCT-116 cells were treated with 5 or 10 μM 
δT-13’-COOH or 10 μM δTE-13’-COOH with or without 5 μM GW4869, an inhibitor of 
neutral SMase for 24 h. Relative cell viability was measured by MTT assay compared 
with control. The data are mean ± SD of three independent experiments. *p < 0.05 and 





3.4.7 δTE-13’-COOH supplementation attenuated colon inflammation and inhibited 
tumorigenesis induced by AOM with two cycles of 1.5% DSS in mice 
To examine whether the anticancer effect of 13’-COOH can be translated into 
whole body system, we investigated the effectiveness of δTE-13’-COOH 
supplementation against AOM-induced and DSS-promoted colon tumorigenesis in male 
Balb/c mice. The body weights and the amounts of food intake of AOM/DSS-treated 
δTE-13’-COOH-supplemented group were similar to those of the control diet group, and 
δTE-13’-COOH supplementation showed no apparent signs of toxicity throughout the 
experiment (Figs. 3.10B and C). δTE-13’-COOH supplementation attenuated colon 
inflammation induced by two-cycles of 1.5% DSS as indicated by significantly attenuated 
scores of rectal bleeding on day 6 of 2nd cycle DSS administration (Fig. 3.10D), and 
significantly attenuated DSS-caused colon L/W ratio reduction compared with the control 
diet group (Fig. 3.10E). After 43 days, AOM/DSS-treated control diet group had 4.7 ± 
0.3 tumors per mouse in the colon, but AOM/DSS-δTE-13’-COOH supplementation 
group showed beneficial effects with a significantly lower number of colon tumors (3.1 ± 
0.3; p < 0.01; Fig. 3.10F) even the supplementation was started 7 days after AOM 
injection. Interestingly, when the tumors were categorized as small (< 2 mm2) or large (> 
2 mm2) sizes, supplementation of δTE-13’-COOH after AOM/DSS treatment 
significantly decreased the number of large tumors by 58% (p < 0.05), which are closely 
associated with the development of malignancy, although it did not significantly decrease 
the number of small tumors. All these tumors were primarily found in the middle to rectal 









Figure 3.10 Effects of δTE-13’-COOH on colon tumorigenesis induced by AOM with 
two cycles of 1.5% DSS. (A) The design of AOM/DSS study. (B) Body weight and (C) 
food intake of each group during the days after supplementation started. The effects of 
δTE-13’-COOH on (D) fecal scorings during DSS cycle 1 and 2, and (E) ratio of colon 
L/W. (F) The effects of δTE-13’-COOH on colon tumor multiplicity and polyps with 
sizes of < 2 mm2 or > 2 mm2 in the AOM/DSS study (mean ± SEM, n = 15-17). *p < 




3.4.8 δTE-13’-COOH supplementation attenuated colon inflammation induced by one 
cycle of 1.8% DSS in mice 
We further examined whether δTE-13’-COOH has any direct effects on colon 
inflammation caused by one cycle of 1.8% DSS. Similar to the results from AOM/DSS 
study above, the body weights and the amount of food intake were not different between 
groups (Figs. 3.11B and C). Treatment with one cycle of 1.8% DSS resulted in colon 
bleeding and diarrhea, and δTE-13’-COOH supplementation significantly decreased this 
fecal scoring compared with the control-diet group (Figs. 3.11D-F), indicating that δTE-








Figure 3.11 Effects of δTE-13’-COOH on colon inflammation induced by one cycle of 
1.8% DSS. (A) The design of DSS study. (B) Body weight and (C) food intake of each 
group during the study. The effects of δTE-13’-COOH on (D) rectal bleeding, (E) stool 
consistency, and (F) total fecal scorings during the DSS study (mean ± SEM, n = 12). *p 







3.4.9 Combined treatment of specific natural vitamin E forms with their long-chain 
metabolites exhibited synergistic or additive antiproliferative effects 
Since parental vitamin E forms and their metabolites coexist in in vivo system, we 
evaluated whether the combined treatment of vitamin E forms and their long-chain 
metabolites has synergistic antiproliferative effects in colon cancer cells using MTT 
assay. Human colon HCT-116 cancer cells were treated with lower doses of δT or δT-
13’-COOH alone or with their combination for 72 h. Treatment of cells with 5-10 μM δT 
or 2.5-5 μM δT-13’-COOH had no or little effect on cell growth, but combinded 
treatment of δT with δT-COOH induced a significant inhibition of cell growth in a dose-
dependent manner (Fig. 3.12A). HCT-116 cells were also treated with lower doses of 
δTE or δTE-13’-COOH alone or with their combination for 72 h. Similar to the combined 
effects of δT and δT-13’-COOH, 2.5-5 μM δTE or 2.5-5μM had no effect on cell growth, 
but their combination exhibited a significant additive or synergistic antiproliferative 















Figure 3.12 Effects of combined treatment of specific vitamin E forms with their long-
chain metabolites on cancer cell growth. HCT-116 cells were treated with (A) δT, δT-
13’-COOH, and their combination or (B) δTE, δTE-13’-COOH, and their combination 
for 72 h. Relative cell viability was measured after treatment with individual natural 
forms of vitamin E or their metabolites alone or with a combination at the stated 
concentrations by MTT assay compared with control. The data are mean ± SD for three 





Table 3.1 Effect of δT-13’-COOH on sphingolipid metabolism in HCT-116 cells. HCT-
116 cells were treated with 10 or 20 µM δT-13’-COOH for 1, 2, 4, 8 and 16 h. The 
amount of each sphingolipid was determined by LC-MS/MS. Data are mean ± SEM of at 
least 3 independent experiments. *p < 0.05, **p < 0.01, significant difference between 
control and δT-13’-COOH-treated cells. Cer, ceramide; dhCer, dihydroceramide; Sph, 
sphingosine; dhSph, dihydrosphingosine; S1P, sphingosine-1-phosphate; SM, 
sphingomyelin; dhSM, dihydrosphingomyelin 
 
Ceramides (pmol/µg PC)   
C16:0-Cer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 2.33 ± 0.40 1.96 ± 0.12 1.84 ± 0.15 
2 3.04 ± 0.06 1.92 ± 0.10** 2.15 ± 0.13** 
4 2.27 ± 0.26 1.81 ± 0.19** 2.36 ± 0.23 
8 2.41 ± 0.18 2.00 ± 0.28* 2.76 ± 0.21* 
16 2.91 ± 0.15 3.36 ± 0.05* 6.23 ± 0.47* 
C18:0-Cer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.061 ± 0.005 0.062 ± 0.007 0.076 ± 0.014 
2 0.063 ± 0.004 0.052 ± 0.002 0.072 ± 0.004 
4 0.051 ± 0.012 0.050 ± 0.013 0.079 ± 0.021** 
8 0.041 ± 0.004 0.037 ± 0.003 0.064 ± 0.003** 
16 0.040 ± 0.002 0.052 ± 0.001** 0.091 ± 0.005** 
C20:0-Cer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.043 ± 0.012 0.039 ± 0.007 0.044 ± 0.008 
2 0.045 ± 0.006 0.038 ± 0.005** 0.059 ± 0.006** 
4 0.036 ± 0.003 0.044 ± 0.017 0.085 ± 0.024** 
8 0.028 ± 0.003 0.029 ± 0.002 0.063 ± 0.005** 
16 0.028 ± 0.000 0.046 ± 0.002** 0.081 ± 0.005** 
C22:0-Cer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.45 ± 0.14 0.52 ± 0.096 0.60 ± 0.11 
2 0.55 ± 0.074 0.56 ± 0.063 0.77 ± 0.069** 
4 0.30 ± 0.092 0.58 ± 0.19** 0.83 ± 0.23** 
8 0.27 ± 0.043 0.36 ± 0.027 0.53 ± 0.17 
16 0.26 ± 0.010 0.51 ± 0.020** 0.78 ± 0.049** 
C24:1-Cer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 2.62 ± 0.55 2.13 ± 0.52** 2.35 ± 0.46 




4 1.06 ± 0.03 0.90 ± 0.07* 1.32 ± 0.07** 
8 1.48 ± 0.40 1.03 ± 0.30** 1.87 ± 0.42** 
16 2.00 ± 0.34 1.43 ± 0.27** 2.65 ± 0.42 
C24:0-Cer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 2.74 ± 0.50 2.64 ± 0.62 2.63 ± 0.55 
2 3.48 ± 1.10 2.93 ± 0.73 2.81 ± 0.69 
4 1.25 ± 0.16 1.66 ± 0.22** 1.24 ± 0.11 
8 1.70 ± 0.29 2.20 ± 0.42** 1.51 ± 0.27 
16 2.92 ± 0.28 3.59 ± 0.51* 2.11 ± 0.33* 
C26:1-Cer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.27 ± 0.044 0.22 ± 0.045** 0.23 ± 0.034 
2 0.36 ± 0.13 0.23 ± 0.064** 0.27 ± 0.063 
4 0.12 ± 0.013 0.11 ± 0.011 0.14 ± 0.012 
8 0.15 ± 0.016 0.097 ± 0.015** 0.18 ± 0.017** 
16 0.23 ± 0.009 0.13 ± 0.010** 0.29 ± 0.013 
C26:0-Cer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.14 ± 0.076 0.11 ± 0.064 0.12 ± 0.063 
2 0.19 ± 0.12 0.12 ± 0.068 0.13 ± 0.072 
4 0.11 ± 0.009 0.097 ± 0.009 0.098 ± 0.008 
8 0.13 ± 0.016 0.11 ± 0.020** 0.12 ± 0.019 
16 0.24 ± 0.005 0.13 ± 0.014** 0.16 ± 0.010** 
Total Cers       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 8.66 ± 0.71 7.68 ± 1.02 7.89 ± 0.84  
2 10.97 ± 2.57 7.97 ±1.30**  8.91 ± 1.27  
4 5.20 ± 0.57 5.25 ±0.71 6.16 ± 0.67**  
8 6.21 ±0.90 5.87 ±1.03 7.08 ± 0.86** 
16 8.63 ±0.78 9.24 ± 0.86 12.39 ± 0.84 
 
Dihydroceramides (pmol/µg PC)   
C16:0-dhCer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.073 ± 0.009 0.092 ± 0.004 0.12 ± 0.017* 
2 0.11 ± 0.004 0.13 ± 0.015 0.28 ± 0.031* 
4 0.060 ± 0.005 0.13 ± 0.024* 0.33 ± 0.017** 
8 0.087 ± 0.007 0.26 ± 0.031** 1.13 ± 0.092** 
16 0.23 ± 0.022 1.04 ± 0.060** 3.40 ± 0.43** 




Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.0016 ± 0.0001 0.0017 ± 0.0003 0.0025 ± 0.0005 
2 0.0016 ± 0.0001 0.0015 ± 0.0001 0.0035 ± 0.0003* 
4 0.0016 ± 0.0003 0.0022 ± 0.0007 0.0041 ± 0.0005 
8 0.0015 ± 0.0002 0.0023 ± 0.0004 0.011 ± 0.0024* 
16 0.0017 ± 0.0003 0.0060 ± 0.0008** 0.027 ± 0.0024** 
C20:0-dhCer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.0008 ± 0.0003 0.0007 ± 0.0001 0.0012 ± 0.0005 
2 0.0009 ± 0.0002 0.0012 ± 0.0003 0.0020 ± 0.0002 
4 0.0006 ± 0.0001 0.0013 ± 0.0006 0.0038 ± 0.0009* 
8 0.0006 ± 0.0001 0.0020 ± 0.0005* 0.143 ± 0.14 
16 0.0011 ± 0.0000 0.0058 ± 0.0006** 0.013 ± 0.003** 
C22:0-dhCer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.0035 ± 0.0012 0.0035 ± 0.001 0.0059 ± 0.0012 
2 0.0037 ± 0.001 0.0053 ± 0.001* 0.012 ± 0.0016** 
4 0.0030 ± 0.001 0.0098 ± 0.004 0.032 ± 0.0084** 
8 0.0034 ± 0.0002 0.014 ± 0.0024** 0.279 ± 0.23 
16 0.0059 ± 0.001 0.048 ± 0.0060** 0.069 ± 0.011** 
C24:1-dhCer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.0065 ± 0.001 0.0058 ± 0.001 0.0079 ± 0.001 
2 0.0080 ± 0.003 0.0068 ± 0.014 0.015 ± 0.003 
4 0.0045 ± 0.001 0.0105 ± 0.001** 0.025 ± 0.001** 
8 0.0079 ± 0.001 0.024 ± 0.004** 0.082 ± 0.007** 
16 0.025 ± 0.004 0.071 ± 0.005* 0.15 ± 0.013** 
C24:0-dhCer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.0078 ± 0.001 0.0060 ± 0.0004 0.0067 ± 0.001 
2 0.0080 ± 0.001 0.011 ± 0.003 0.017 ± 0.004 
4 0.0056 ± 0.0004 0.020 ± 0.003* 0.025 ± 0.001** 
8 0.011 ± 0.001 0.053 ± 0.009** 0.074 ± 0.004** 
16 0.039 ± 0.005 0.22 ± 0.014** 0.13 ± 0.013** 
C26:1-dhCer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.00025 ± 0.0002 0.00016 ± 0.0002 0.00054 ± 0.0005 
2 0.00022 ± 0.0002 0.00023 ± 0.0002 0.00054 ± 0.0005 
4 0.00064 ± 0.0003 0.00060 ± 0.0004 0.0015 ± 0.001 
8 0.00073 ± 0.0004 0.0017 ± 0.001 0.0088 ± 0.001 




Total dhCers       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.093 ± 0.009 0.11 ± 0.005 0.15 ± 0.021 
2 0.13 ± 0.007 0.16 ± 0.017 0.33 ± 0.036* 
4 0.075 ± 0.004 0.17 ± 0.033* 0.42 ± 0.027** 
8 0.11 ± 0.008 0.35 ± 0.047** 1.73 ± 0.44** 
16 0.31 ± 0.032 1.44 ± 0.10** 3.82 ± 0.47** 
 
Sphingoid bases (pmol/µg PC)   
Sph       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.80 ± 0.10 1.00 ± 0.31 1.01 ± 0.33 
2 1.03 ± 0.32 0.85 ± 0.22* 0.92 ± 0.29 
4 0.63 ± 0.14 0.56 ± 0.14 0.62 ± 0.14 
8 0.40 ± 0.057 0.38 ± 0.064 0.41 ± 0.035 
16 0.43 ± 0.023 0.37 ± 0.027 0.45 ± 0.037 
dhSph       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.057 ± 0.017 0.068 ± 0.009 0.11 ± 0.032** 
2 0.062 ± 0.008 0.067 ± 0.007* 0.12 ± 0.015 
4 0.054 ± 0.012 0.064 ± 0.003 0.14 ± 0.016* 
8 0.064 ± 0.003 0.060 ± 0.009 0.51 ± 0.18* 
16 0.059 ± 0.005 0.12 ± 0.006** 1.90 ± 0.24** 
S1P       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.025 ± 0.007 0.019 ± 0.005 0.029 ± 0.008 
2 0.016 ± 0.006 0.015 ± 0.004 0.019 ± 0.003 
4 0.011 ± 0.002 0.0065 ± 0.001 0.012 ± 0.001 
8 0.014 ± 0.005 0.021 ± 0.006 0.014 ± 0.004 
16 0.013 ± 0.003 0.013 ± 0.002 0.015 ± 0.002 
 
Sphingomyelins (pmol/µg PC)   
C16:0-SM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 54.41 ± 4.37 56.25 ± 5.70 54.49 ± 6.22 
2 64.18 ± 6.12 55.41 ± 1.62 54.51 ± 2.77* 
4 51.09 ± 3.76 52.39 ± 2.37 40.89 ± 2.23 
8 64.19 ± 3.16 49.32 ± 5.61** 39.78 ± 2.80** 
16 100.55 ± 13.49 58.11 ± 7.22** 48.45 ± 5.62** 




Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.69 ± 0.068 0.69 ± 0.079 0.66 ± 0.092 
2 0.78 ± 0.079 0.68 ± 0.046 0.68 ± 0.062* 
4 0.67 ± 0.037 0.66 ± 0.030 0.54 ± 0.009** 
8 0.69 ± 0.025 0.59 ± 0.055* 0.53 ± 0.020** 
16 0.74 ± 0.078 0.58 ± 0.043** 0.54 ± 0.083** 
C20:0-SM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.57 ± 0.092 0.60 ± 0.095* 0.56 ± 0.11 
2 0.68 ± 0.089 0.62 ± 0.052 0.60 ± 0.068 
4 0.62 ± 0.051 0.66 ± 0.046 0.55 ± 0.017 
8 0.62 ± 0.029 0.57 ± 0.030 0.49 ± 0.040** 
16 0.63 ± 0.047 0.53 ± 0.027* 0.46 ± 0.064* 
C22:0-SM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 3.31 ± 0.87 3.31 ± 0.75 3.21 ± 0.71 
2 3.89 ± 0.73 3.56 ± 0.41 3.50 ± 0.52* 
4 2.84 ± 0.35 3.28 ± 0.49* 2.56 ± 0.29* 
8 2.73 ± 0.19 2.93 ± 0.32 2.23 ± 0.16* 
16 3.11 ± 0.19 3.00 ± 0.02 2.32 ± 0.41* 
C24:1-SM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 15.13 ± 3.31 14.55 ± 3.49 14.25 ± 3.49 
2 17.69 ± 3.23 15.92 ± 1.41 15.63 ± 2.12 
4 14.94 ± 3.03 15.76 ± 3.46 12.65 ± 2.28** 
8 12.66 ± 1.51 10.88 ± 1.47* 8.92 ± 1.22** 
16 13.11 ± 1.24 9.16 ± 0.86** 7.43 ± 1.15** 
C26:1-SM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.79 ± 0.19 0.75 ± 0.19 0.72 ± 0.19 
2 0.96 ± 0.15 0.82 ± 0.05 0.78 ± 0.07* 
4 0.98 ± 0.27 1.09 ± 0.29 0.89 ± 0.21 
8 0.76 ± 0.18 0.60 ± 0.14* 0.55 ± 0.13** 
16 0.74 ± 0.11 0.45 ± 0.04** 0.46 ± 0.11** 
Total SMs       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 74.90 ± 8.79 76.16 ± 10.25 73.90 ± 10.75 
2 88.18 ± 10.37 77.01 ± 3.10 75.69 ± 5.59* 
4 71.14 ± 5.94 73.84 ± 4.43 58.09 ± 0.88 
8 81.65 ± 1.86 64.89 ± 5.26** 52.50 ± 2.29** 





Dihydrosphingomyelins (pmol/µg PC)   
C16:0-dhSM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 6.60 ± 0.38 6.43 ± 0.27 6.53 ± 0.53 
2 8.42 ± 1.63 7.60 ± 1.52** 7.59 ± 1.38* 
4 8.12 ± 0.75 8.85 ± 1.61 7.57 ± 1.28 
8 9.18 ± 1.04 9.68 ± 0.65 8.24 ± 0.91* 
16 9.49 ± 0.98 10.73 ± 1.03 10.08 ± 1.68 
C18:0-dhSM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.14 ± 0.010 0.15 ± 0.012 0.14 ± 0.018 
2 0.18 ± 0.027 0.17 ± 0.041 0.16 ± 0.027** 
4 0.29 ± 0.078 0.28 ± 0.077 0.24 ± 0.071 
8 0.26 ± 0.065 0.24 ± 0.044 0.22 ± 0.052 
16 0.74 ± 0.078 0.58 ± 0.043 0.54 ± 0.083 
C20:0-dhSM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.13 ± 0.017 0.14 ± 0.025 0.14 ± 0.031 
2 0.15 ± 0.015 0.14 ± 0.022 0.13 ± 0.020 
4 0.22 ± 0.018 0.22 ± 0.032 0.20 ± 0.027 
8 0.18 ± 0.035 0.18 ± 0.029 0.16 ± 0.037* 
16 0.13 ± 0.032 0.16 ± 0.034** 0.14 ± 0.035 
C22:0-dhSM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.37 ± 0.067 0.39 ± 0.038 0.37 ± 0.039 
2 0.47 ± 0.061 0.46 ± 0.069 0.44 ± 0.072 
4 0.69 ± 0.12 0.67 ± 0.10 0.61 ± 0.11 
8 0.49 ± 0.061 0.55 ± 0.078 0.49 ± 0.079 
16 0.32 ± 0.051 0.59 ± 0.098** 0.50 ± 0.14 
C24:0-dhSM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 0.55 ± 0.13 0.49 ± 0.071 0.48 ± 0.071 
2 0.71 ± 0.080 0.61 ± 0.081* 0.64 ± 0.12 
4 1.05 ± 0.58 1.23 ± 0.71 0.89 ± 0.46 
8 0.46 ± 0.13 0.50 ± 0.086 0.40 ± 0.11 
16 0.45 ± 0.069 0.81 ± 0.12** 0.55 ± 0.18 
C26:0-dhSM       
Hours Control δT-13' 10 µM δT-13' 20 µM 




2 0.08 ± 0.011 0.08 ± 0.020 0.08 ± 0.017 
4 0.13 ± 0.061 0.13 ± 0.071 0.12 ± 0.057 
8 0.05 ± 0.024 0.05 ± 0.016 0.05 ± 0.014 
16 0.04 ± 0.010 0.12 ± 0.084 0.04 ± 0.013 
Total dhSMs       
Hours Control δT-13' 10 µM δT-13' 20 µM 
1 7.87 ± 0.61 7.65 ± 0.22 7.73 ± 0.51 
2 10.02 ± 1.76 9.06 ± 1.73** 9.03 ± 1.61* 
4 10.50 ± 1.01 11.38 ± 2.04 9.64 ± 1.40 
8 10.63 ± 1.30 11.20 ± 0.78 9.56 ± 1.12* 
16 10.58 ± 1.15 12.57 ± 1.29 11.49 ± 2.08 
 
 
Table 3.2 Effect of δT-13’-COOH on sphingolipid metabolism in MCF-7 cells. MCF-7 
cells were treated with 10 or 20 µM δT-13’-COOH for 4 and 8 h. The amount of each 
sphingolipid was determined by LC-MS/MS. Data are mean ± SEM of 2 independent 
experiments. 
 
Ceramides (pmol/µg PC)   
C16:0-Cer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 1.49 ± 0.082 1.30 ± 0.17 1.56 ± 0.006 
8 1.48 ± 0.14 1.23 ± 0.007 2.23 ± 0.23 
C18:0-Cer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 0.10 ± 0.015 0.084 ± 0.0004 0.086 ± 0.005 
8 0.094 ± 0.001 0.071 ± 0.001 0.11 ± 0.001 
C20:0-Cer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 0.020 ± 0.0018 0.021 ± 0.0005 0.026 ± 0.0014 
8 0.018 ± 0.0006 0.022 ± 0.0014 0.033 ± 0.0023 
C22:0-Cer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 0.056 ± 0.024 0.070 ± 0.051 0.068 ± 0.048 
8 0.060 ± 0.038 0.079 ± 0.057 0.11 ± 0.096 
C24:1-Cer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 13.19 ± 1.19 12.21 ± 1.59 18.75 ± 1.51 




C24:0-Cer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 2.34 ± 0.31 3.59 ± 0.24 2.56 ± 0.026 
8 2.34 ± 0.20 5.34 ± 0.092 4.00 ± 0.082 
C26:1-Cer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 0.26 ± 0.10 0.41 ± 0.031 0.45 ± 0.019 
8 0.27 ± 0.025 0.51 ± 0.0001 0.74 ± 0.035 
Total Cers       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 17..45 ± 1.67 17.68 ± 2.08 23.51 ± 1.56 
8 17.84 ± 2.12 19.85 ± 1.41 32.75 ± 3.69 
 
Dihydroceramides (pmol/µg PC)   
C16:0-dhCer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 0.093 ± 0.035 0.12 ± 0.027 0.14 ± 0.007 
8 0.11 ± 0.022 0.13 ± 0.030 0.29 ± 0.018 
C18:0-dhCer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 0.0019 ± 0.0005 0.0028 ± 0.0007 0.004 ± 0.0006 
8 0.0022 ± 0.0006 0.0036 ± 0.0009 0.0029 ± 0.0001 
C22:0-dhCer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 
0.00051 ± 
0.0003 0.0028 ± 0.0016 0.0039 ± 0.0012 
8 0.0019 ± 0.0004 0.0044 ± 0.00001 0.0091 ± 0.0009 
C24:1-dhCer       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 0.085 ± 0.0070 0.096 ± 0.018 0.24 ± 0.062 
8 0.055 ± 0.0067 0.11 ± 0.036 0.41 ± 0.088 
Total dhCers       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 0.18 ± 0.029 0.22 ± 0.011 0.39 ± 0.053 
8 0.16 ± 0.017 0.25 ± 0.0049 0.71 ± 0.071 
 




Sph       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 0.51 ± 0.11 0.43 ± 0.017 0.49 ± 0.11 
8 0.47 ± 0.0036 0.40 ± 0.045 0.46 ± 0.064 
S1P       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 0.010 ± 0.0004 0.016 ± 0.008 0.013 ± 0.001 
8 0.013 ± 0.005 0.010 ± 0.0001 0.012 ± 0.004 
 
Sphingomyelins (pmol/µg PC)   
C16:0-SM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 32.77 ± 4.04 31.70 ± 0.15 23.85 ± 0.34 
8 34.30 ± 0.38 30.49 ± 0.09 23.92 ± 1.44 
C18:0-SM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 1.73 ± 0.33 1.73 ± 0.13 1.29 ± 0.10 
8 1.79 ± 0.11 1.62 ± 0.17 1.25 ± 0.22 
C20:0-SM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 0.90 ± 0.18 0.93 ± 0.056 0.60 ± 0.019 
8 0.92 ± 0.023 0.86 ± 0.11 0.62 ± 0.094 
C22:0-SM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 2.09 ± 0.67 2.06 ± 0.25 1.30 ± 0.068 
8 1.92 ± 0.13 2.18 ± 0.30 1.43 ± 0.34 
C24:1-SM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 14.23 ± 3.11 12.96 ± 0.0033 8.88 ± 0.32 
8 12.66 ± 0.61 11.89 ± 0.13 9.36 ± 0.66 
C26:1-SM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 3.26 ± 0.88 2.58 ± 0.016 1.72 ± 0.12 
8 2.58 ± 0.12 2.51 ± 0.028 1.73 ± 0.13 
Total SMs       
Hours Control δT-13' 10 µM δT-13' 20 µM 




8 54.17 ± 0.85 49.55 ± 0.64 38.35 ± 2.87 
 
Dihydrosphingomyelins (pmol/µg PC)   
C16:0-dhSM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 3.84 ± 0.39 4.72 ± 0.027 3.30 ± 0.14 
8 4.38 ± 0.14 4.96 ± 0.14 3.85 ± 0.21 
C18:0-dhSM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 0.24 ± 0.040 0.28 ± 0.021 0.18 ± 0.006 
8 0.26 ± 0.010 0.30 ± 0.033 0.18 ± 0.026 
C20:0-dhSM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 0.18 ± 0.055 0.21 ± 0.020 0.12 ± 0.017 
8 0.18 ± 0.0005 0.23 ± 0.035 0.12 ± 0.030 
C22:0-dhSM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 0.16 ± 0..054 0.18 ± 0.021 0.10 ± 0.0026 
8 0.13 ± 0.0033 0.21 ± 0.024 0.12 ± 0.023 
C24:0-dhSM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 0.096 ± 0.029 0.11 ± 0.013 0.066 ± 0.0021 
8 0.080 ± 0.0017 0.13 ± 0.016 0.076 ± 0.015 
C26:0-dhSM       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 0.027 ± 0.0084 0.032 ± 0.0045 0.016 ± 0.0023 
8 0.021 ± 0.0003 0.031 ± 0.0017 0.020 ± 0.0057 
Total dhSMs       
Hours Control δT-13' 10 µM δT-13' 20 µM 
4 4.54 ± 0.58 5.55 ± 0.052 3.79 ± 0.12 
8 5.04 ± 0.13 5.86 ± 0.25 4.37 ± 0.31 
 
 
Table 3.3 Effect of δTE-13’-COOH on sphingolipid metabolism in HCT-116 cells. HCT-
116 cells were treated with 10 or 20 µM δTE-13’-COOH for 8 and 16 h. The amount of 






Ceramides (pmol/µg PC)   
C16:0-Cer       
Hours Control δTE-13' 10 µM δTE-13' 20 µM 
8 2.43  ± 0.036 1.79 ± 0.0047 2.20 ± 0.051 
16 2.82  ± 0.080 1.69 ± 0.070 3.04 ± 0.26 
C18:0-Cer       
Hours Control δTE-13' 10 µM δTE-13' 20 µM 
8 0.043 ± 0.003 0.035 ± 0.001 0.050 ± 0.002 
16 0.039 ± 0.001 0.030 ± 0.002 0.066 ± 0.010 
C20:0-Cer       
Hours Control δTE-13' 10 µM δTE-13' 20 µM 
8 0.025 ± 0.001 0.021 ± 0.002 0.052 ± 0.001 
16 0.027 ± 0.001  0.018 ± 0.002 0.064 ± 0.012 
C22:0-Cer       
Hours Control δTE-13' 10 µM δTE-13' 20 µM 
8 0.22 ± 0.016 0.24 ± 0.0004 0.49 ± 0.005 
16 0.23 ± 0.005 0.21 ± 0.001 0.55 ± 0.049 
C24:1-Cer       
Hours Control δTE-13' 10 µM δTE-13' 20 µM 
8 2.58 ± 0.27 1.92 ± 0.049 2.46 ± 0.12 
16 2.68 ± 0.029 1.49 ± 0.010 2.26 ± 0.15 
C24:0-Cer       
Hours Control δTE-13' 10 µM δTE-13' 20 µM 
8 2.64 ± 0.14 3.42 ± 0.22 3.12 ± 0.30 
16 3.40 ± 0.007 4.15 ± 0.026 3.22 ± 0.26 
C26:1-Cer       
Hours Control δTE-13' 10 µM δTE-13' 20 µM 
8 0.21 ± 0.007 0.17 ± 0.008 0.21 ± 0.014 
16 0.27 ± 0.008 0.16 ± 0.008 0.21 ± 0.004 
C26:0-Cer       
Hours Control δTE-13' 10 µM δTE-13' 20 µM 
8 0.16 ± 0.030 0.16 ± 0.003 0.16 ± 0.001 
16 0.23 ± 0.001 0.19 ± 0.003 0.13 ± 0.011 
Total Cers       
Hours Control δTE-13' 10 µM δTE-13' 20 µM 
8 8.31 ± 0.49 7.76 ± 0.28 8.74 ± 0.48 
16 9.70 ± 0.042 7.94 ± 0.098 9.55 ± 0.24 
 




C16:0-dhCer       
Hours Control δTE-13' 10 µM δTE-13' 20 µM 
8 0.19 ± 0.02 0.38 ± 0.03 0.85 ± 0.01 
16 0.42 ± 0.002 0.52 ± 0.02 1.86 ± 0.22 
C18:0-dhCer       
Hours Control δTE-13' 10 µM δTE-13' 20 µM 
8 0.0011 ± 0.0001 0.0017 ± 0.0004 0.0035 ± 0.00003 
16 0.0020 ± 0.0006 0.0020 ± 0.0001 0.0087 ± 0.0005 
C20:0-dhCer       
Hours Control δTE-13' 10 µM δTE-13' 20 µM 
8 0.0010 ± 0.0004 0.0010 ± 0.0002 0.0047 ± 0.0019 
16 0.0004 ± 0.0001 0.0013 ± 0.0002 0.0086 ± 0.0009 
C22:0-dhCer       
Hours Control δTE-13' 10 µM δTE-13' 20 µM 
8 0.0043 ± 0.0011 0.0076 ± 0.0013 0.022 ± 0.0019 
16 0.0080 ± 0.0002 0.013 ± 0.0010 0.053 ± 0.0029 
C24:1-dhCer       
Hours Control δTE-13' 10 µM δTE-13' 20 µM 
8 0.016 ± 0.001 0.035 ± 0.001 0.076 ± 0.010 
16 0.043 ± 0.001 0.050 ± 0.005 0.14 ± 0.001 
C24:0-dhCer       
Hours Control δTE-13' 10 µM δTE-13' 20 µM 
8 0.028 ± 0.007 0.083 ± 0.011 0.086 ± 0.007 
16 0.066 ± 0.005 0.16 ± 0.011 0.21 ± 0.019 
Total dhCers       
Hours Control δTE-13' 10 µM δTE-13' 20 µM 
8 0.24 ± 0.033 0.51 ± 0.040 1.04 ± 0.007 
16 0.54 ± 0.003 0.74 ± 0.018 2.28 ± 0.20 
 
Sphingoid bases (pmol/µg PC)   
Sph       
Hours Control δTE-13' 10µM δTE-13' 20µM 
8 0.52 ± 0.067 0.42 ± 0.009 0.39 ± 0.097 
16 0.37 ± 0.043 0.35 ± 0.008 0.39 ± 0.063 
dhSph       
Hours Control δTE-13' 10µM δTE-13' 20µM 
8 0.049 ± 0.006 0.054 ± 0.003 0.12 ± 0.00002 
16 0.043 ± 0.005 0.074 ± 0.004 0.15 ± 0.013 




Hours Control δTE-13' 10µM δTE-13' 20µM 
8 0.025 ± 0.007 0.025 ± 0.001 0.019 ± 0.003 
16 0.013 ± 0.007 0.019 ± 0.002 0.011 ± 0.004 
 
Sphingomyelins (pmol/µg PC)   
C16:0-SM       
Hours Control δTE-13' 10µM δTE-13' 20µM 
8 55.88 ± 8.96 54.47 ± 4.88 44.53 ± 0.39 
16 71.01 ± 2.01 60.66 ± 3.38 50.29 ± 2.19 
C18:0-SM       
Hours Control δTE-13' 10µM δTE-13' 20µM 
8 0.69 ± 0.16 0.70 ± 0.092 0.58 ± 0.037 
16 0.59 ± 0.060 0.65 ± 0.066 0.58 ± 0.043 
C20:0-SM       
Hours Control δTE-13' 10µM δTE-13' 20µM 
8 0.60 ± 0.21 0.63 ± 0.19 0.53 ± 0.085 
16 0.44 ± 0.037 0.57 ± 0.084 0.54 ± 0.094 
C22:0-SM       
Hours Control δTE-13' 10µM δTE-13' 20µM 
8 2.52 ± 0.83 2.85 ± 0.74 2.08 ± 0.25 
16 1.99 ± 0.25 2.97 ± 0.29 2.55 ± 0.27 
C24:1-SM       
Hours Control δTE-13' 10µM δTE-13' 20µM 
8 9.52 ± 2.93 9.30 ± 2.02 6.70 ± 0.28 
16 7.98 ± 0.68 8.85 ± 0.66 6.65 ± 0.29 
C26:1-SM       
Hours Control δTE-13' 10µM δTE-13' 20µM 
8 0.55 ± 0.22 0.47 ± 0.14 0.33 ± 0.028 
16 0.39 ± 0.049 0.43 ± 0.033 0.33 ± 0.038 
Total SMs       
Hours Control δTE-13' 10µM δTE-13' 20µM 
8 75.64 ± 15.77 74.35 ± 9.95 58.38 ± 0.62 
16 86.85 ± 3.84 81.38 ± 5.36 65.20 ± 1.17 
 
Dihydrosphingomyelins (pmol/µg PC)   
C16:0-dhSM       
Hours Control δTE-13' 10µM δTE-13' 20µM 
8 6.71 ± 1.44 8.80 ± 1.08 7.44 ± 0.32 




C18:0-dhSM       
Hours Control δTE-13' 10µM δTE-13' 20µM 
8 0.14 ± 0.045 0.17 ± 0.034 0.15 ± 0.009 
16 0.10 ± 0.019 0.18 ± 0.014 0.19 ± 0.023 
C20:0-dhSM       
Hours Control δTE-13' 10µM δTE-13' 20µM 
8 0.11 ± 0..037 0.11 ± 0.029 0.10 ± 0.020 
16 0.064 ± 0.011 0.14 ± 0.023 0.15 ± 0.026 
C22:0-dhSM       
Hours Control δTE-13' 10µM δTE-13' 20µM 
8 0.31 ± 0.12 0.37 ± 0.14 0.27 ± 0.052 
16 0.20 ± 0.039 0.60 ± 0.11 0.50 ± 0.080 
C24:0-dhSM       
Hours Control δTE-13' 10µM δTE-13' 20µM 
8 0.37 ± 0.17 0.40 ± 0.15 0.24 ± 0.035 
16 0.26 ± 0.061 0.78 ± 0.14 0.48 ± 0.018 
C26:0-dhSM       
Hours Control δTE-13' 10µM δTE-13' 20µM 
8 0.030 ± 0.013 0.023 ± 0.0084 0.017 ± 0.0068 
16 0.016 ± 0.0050 0.033 ± 0.0008 0.023 ± 0.0013 
Total dhSMs       
Hours Control δTE-13' 10µM δTE-13' 20µM 
8 8.55 ± 2.13 10.82 ± 1.68 8.90 ± 0.55 
16 9.21 ± 1.88 16.10 ± 1.00 12.44 ± 0.80 
 
 
Table 3.4 Effect of δT-13’-COOH on de novo sphingolipid biosynthesis in HCT-116 
cells. HCT-116 cells were treated with either 400 µM 13C3, 15N-labeled L-serine alone as 
control or with a combination of 400 µM 13C3, 15N-labeled L-serine and 20 µM δT-13’-
COOH for 0.5, 1, 1.5, 2, and 4 h. The amount of each labeled de novo sphingolipid was 
determined by LC-MS/MS. Data are mean ± SEM of 3 independent experiments. *p < 
0.05, **p < 0.01, significant difference between control and δT-13’-COOH-treated cells. 
 
Ceramides (pmol/µg PC) 
De novo C16:0-Cer   
Hours Control δT-13' 20 µM 
0.5 0.081 ± 0.016 0.023 ± 0.010** 
1 0.26 ± 0.015 0.10 ± 0.0074** 
1.5 0.33 ± 0.046 0.18 ± 0.036** 




4 0.63 ± 0.038 0.41 ± 0.010** 
De novo C24:1-Cer   
Hours Control δT-13' 20 µM 
0.5 0.17 ± 0.063 0.069 ± 0.038** 
1 0.40 ± 0.11 0.22 ± 0.060** 
1.5 0.53 ± 0.19 0.38 ± 0.16** 
2 0.65 ± 0.19 0.53 ± 0.18** 
4 0.72 ± 0.077 0.62 ± 0.041 
De novo C24:0-Cer   
Hours Control δT-13' 20 µM 
0.5 0.13 ± 0.052 0.048 ± 0.020** 
1 0.31 ± 0.064 0.13 ± 0.023** 
1.5 0.38 ± 0.12 0.22 ± 0.079** 
2 0.51 ± 0.15 0.32 ± 0.078** 
4 0.75 ± 0.021 0.54 ± 0.038** 
De novo total Cers   
Hours Control δT-13' 20 µM 
0.5 0.37 ± 0.13 0.14 ± 0.068** 
1 0.97 ± 0.15 0.45 ± 0.088** 
1.5 1.25 ± 0.36 0.78 ± 0.28** 
2 1.56 ± 0.39 1.11 ± 0.28** 
4 2.09 ± 0.071 1.58 ± 0.068* 
 
Dihydroceramides (pmol/µg PC) 
De novo C16:0-dhCer   
Hours Control δT-13' 20 µM 
0.5 0.013 ± 0.0029 0.0058 ± 0.0014* 
1 0.028 ± 0.0086 0.028 ± 0.010 
1.5 0.029 ± 0.0038 0.045 ± 0.0024* 
2 0.030 ± 0.0059 0.08 ± 0.0094** 
4 0.056 ± 0.014 0.24 ± 0.065** 
De novo total dhCers   
Hours Control δT-13' 20 µM 
0.5 0.013 ± 0.0029 0.0058 ± 0.0014* 
1 0.028 ± 0.0086 0.028 ± 0.010 
1.5 0.029 ± 0.0038 0.045 ± 0.0024* 
2 0.030 ± 0.0059 0.080 ± 0.0094** 





Sphingomyelins (pmol/µg PC) 
De novo C16:0-SM   
Hours Control δT-13' 20 µM 
0.5 0.56 ± 0.049 0.47 ± 0.045 
1 0.77 ± 0.034 0.55 ± 0.041* 
1.5 1.05 ± 0.078 0.67 ± 0.092** 
2 1.52 ± 0.11 0.99 ± 0.080** 
4 2.00 ± 0.66 0.89 ± 0.12** 
De novo C18:0-SM   
Hours Control δT-13' 20 µM 
0.5 0.017 ± 0.0043 0.026 ± 0.0092 
1 0.026 ± 0.0077 0.023 ± 0.0078 
1.5 0.027 ± 0.0078 0.022 ± 0.0046 
2 0.031 ± 0.0034 0.031 ± 0.0057 
4 0.030 ± 0.0038 0.026 ± 0.0014 
De novo C24:1-SM   
Hours Control δT-13' 20 µM 
0.5 0.12 ± 0.016 0.11 ± 0.015 
1 0.16 ± 0.028 0.11 ± 0.011** 
1.5 0.19 ± 0.025 0.12 ± 0.007** 
2 0.26 ± 0.031 0.17 ± 0.018** 
4 0.36 ± 0.10  0.17 ± 0.029** 
De novo total SMs   
Hours Control δT-13' 20 µM 
0.5 0.71 ± 0.058 0.62 ± 0.061 
1 0.97 ± 0.056 0.69 ± 0.025* 
1.5 1.31 ± 0.052 0.84 ± 0.078** 
2 1.85 ± 0.058 1.22 ± 0.062** 
4 2.59 ± 0.79 1.18 ± 0.15** 
 
Dihydrosphingomyelins (pmol/µg PC) 
De novo C16:0-dhSM   
Hours Control δT-13' 20 µM 
0.5 0.76 ± 0.0084 0.077 ± 0.011 
1 0.11 ± 0.012 0.090 ± 0.0031 
1.5 0.14 ± 0.011 0.12 ± 0.013 
2 0.17 ± 0.011 0.20 ± 0.014 




De novo total dhSMs   
Hours Control δT-13' 20 µM 
0.5 0.085 ± 0.010 0.086 ± 0.015 
1 0.12 ± 0.0053 0.10 ± 0.0056 
1.5 0.16 ± 0.0042 0.13 ± 0.012 
2 0.19 ± 0.016 0.22 ± 0.0034 







We show that vitamin E long-chain metabolites, δT- and δTE-13’-COOH, inhibit 
the proliferation and induce apoptosis and autophagy in human colon, breast and 
pancreatic cancer cells. In these anticancer effects, δT-13’-COOH appears to be more 
potent than δTE-13’-COOH, and both 13’-COOHs are much stronger than tocopherols 
and slightly stronger than γTE. Using a lipidomic approach with LC-MS/MS, we 
demonstrate for the first time that 13’-COOHs profoundly modulate sphingolipid 
metabolism. Specifically, 13’-COOH treatment quickly increased dhCers and dhSph, 
subsequently enhanced Cers and decreased SMs. The importance of sphingolipid 
modulation in 13’-COOH-induced anticancer effects is supported by three lines of 
evidence. First, 13’-COOH-caused increase of dhCers and dhSph took place prior to any 
manifestation of cell death, and subsequent elevation of Cers occurred prior to and 
coinciding with LC3-II increase and PARP cleavage. Secondly, dhCers, dhSph and Cers, 
which are enhanced by 13’-COOHs, have been shown to induce antiproliferation, cell 




Zheng et al., 2006). Furthermore, chemically blocking the increase of dhCers and dhSph 
by myriocin or Cers by suppressing SM hydrolysis partially reversed 13’-COOH-
mediated cell death.   
We identify DEGS in the de novo synthesis of sphingolipid pathway as an initial 
inhibitory target by 13’-COOHs based on their temporal modulation of endogenous and 
newly synthesized sphingolipids. Specifically, in the study with 13C3, 15N-labeled L-serine 
for tracing newly-made sphingolipids, 13’-COOHs caused rapid increase of dhCers, but 
profoundly decreased Cers like C16:0- and C24-Cers and SMs through de novo synthesis. 
This observation strongly suggests that DEGS-catalyzed conversion of dhCers to Cers is 
compromised. Consistently, the similar pattern of sphingolipid changes was reported in 
DEGS knockout model (Ruangsiriluk et al., 2012; Siddique et al., 2013). We further 
show that despite having no impact on DEGS protein expression, δT-13’-COOH 
inhibited the enzyme activity in an in vitro assay. On the other hand, we did not observe 
inhibition of DEGS when rat’s microsome was used, which may be caused by limited 
access of 13’-COOHs to microsomal membrane under cell-free condition possibly due to 
lack of proper transportation.   
DEGS was first proposed as a potential inhibitory target for γT that induced 
intracellular accumulation of dhCers and dhSph without changing total Cers in prostate 
cancer cells (Jiang et al., 2004). Similar effects on sphingolipids were observed by other 
known anticancer agents including γTE (Gopalan et al., 2012; Jiang et al., 2012), 
resveratrol (Signorelli et al., 2009), fenretinide (or 4-HPR) (Rahmaniyan et al., 2011) and 
celecoxib, a selective COX-2 inhibitor (Schiffmann et al., 2009b). Resveratrol and 




homogenates or intact cells, respectively (Schiffmann et al., 2009b; Signorelli et al., 
2009). Recently, DEGS activity was found to be inhibited by hydrogen peroxide 
(Idkowiak-Baldys et al., 2010) or during hypoxia (Devlin et al., 2011). Interestingly, 
phenolic compounds are known to have prooxidant effects including presumably 
increasing hydrogen peroxide in vitro and the prooxidant activity can be counteracted by 
N-acetylcysteine (NAC) (Babich et al., 2009; Fujisawa et al., 2004).  In our studies, we 
found that NAC did not reverse 13’-COOHs’-induced cell death (data not shown) or γTE-
induced modulation of sphingolipids (Jang Y and Jiang Q, unpublished data). We 
therefore conclude that the modulation of dhCers and inhibition of DEGS is not likely 
caused by prooxidant activity, which is also supported by the inhibition of DEGS by 
celecoxib that is not a prooxidant.  
The use of LC-MS/MS approach revealed that 13’-COOHs have differential 
effect on different forms of Cers. For instance, compared with controls, 13’-COOH 
initially decreased C16:0-Cer but enhanced it after longer treatment, while caused a 
continuous increase of C18:0-Cer. This is an intriguing observation because recent studies 
demonstrate that endogenous Cers with specific fatty acid chain lengths have distinct or 
sometimes opposed roles in proliferation and death (Hannun and Obeid, 2011; Senkal et 
al., 2010; Sentelle et al., 2012). For instance, C16:0-Cer and C18:0-Cer generated by Cer 
synthases 5/6 (CerS5/6) and CerS1 have been shown to have anti- and pro-apoptosis 
properties (Senkal et al., 2010), respectively. Besides proapoptotic, C18:0-Cer has been 
found to induce lethal autophagy (Sentelle et al., 2012). The increase of C18:0-Cer 
therefore may contribute to 13’-COOH-caused apoptosis and autophagy. In addition, the 




impact on CerS1 or CerS5/6 in addition to inhibition of DEGS. This is supported by an 
increase of dhSph, a key substrate of CerSs. Further investigation should be conducted to 
characterize the effect of 13’-COOH on these Cer synthases. 
 The observation that 13’-COOHs increased Cers and decreased SM during 
prolonged treatment is likely resulted from involvement of multi-pathways and enzymes.  
Cellular levels of Cers and SMs are determined by the balance between de novo synthesis 
and SM hydrolysis via SMases (Fig. 3.7A). Cers are de novo synthesized in the ER and 
then converted to SMs by SM synthases (SMS) in the Golgi. SMs are the most abundant 
sphingolipids located in membranes and can be hydrolyzed to regenerate Cers by acid or 
neutral SMases (Marchesini and Hannun, 2004). In the current study, given that 13’-
COOHs inhibited DEGS and therefore led to decrease in de novo synthesized Cers, we 
reason that an increase of Cers in the prolonged treatment is likely caused by SMase-
mediated SM hydrolysis, which resulted in further decrease of SMs in addition to the 
reduced synthesis via the de novo pathway. Acid SMases are known to be present in 
lysosomes and the outer membrane leaflet and have been shown to be activated by 
TNFα, oxidants, and UV radiation (Henry et al., 2013; Marchesini and Hannun, 2004; 
Zhang et al., 2001). Neutral SMases are found in the inner leaflet of the bilayer (Hannun 
and Obeid, 2008), and are stimulated by serum starvation (Jayadev et al., 1995), oxidative 
stress (Marchesini and Hannun, 2004), treatment of vitamin D (Okazaki et al., 1994) and 
curcumin (Abdel Shakor et al., 2014). Neutral SMase activation was also a necessary 
signaling event for the TNF-induced human MCF-7 breast cancer cell death (Luberto et 
al., 2002). Here we found that co-treatment with neutral SMase inhibitor GW4869 but not 




suggesting that neutral SMase-catalyzed SM hydrolysis may be involved. However, we 
cannot completely rule out the possibility that SMS was inhibited by 13’-COOHs so that 
Cers were accumulated with simultaneous decrease of SMs. 
Our finding that 13’-COOHs have potent anti-proliferation effect and induce cell 
death in various types of cancer cells has physiological implications. Previous studies 
have demonstrated that γT and mixed tocopherols are effective in suppression of colon 
tumorigenesis in preclinical mouse models (Jiang et al., 2013; Ju et al., 2009; Newmark 
et al., 2006). Interestingly, 13’-COOHs have been identified as a predominant fecal 
excreting vitamin E metabolite and found at relatively high levels in feces of mice fed γT 
or δT supplementation (Bardowell et al., 2012a; Bardowell et al., 2012b; Jiang et al., 
2013). Since 13’-COOHs appear to be much stronger than un-metabolized tocopherols in 
induction of death in colon cancer cells, 13’-COOHs likely contribute to the anticancer 
effects of tocopherol supplements against colon cancer in vivo. Furthermore, given the 
anticancer and anti-inflammatory activities possessed by 13’-COOHs, these compounds 
are potentially excellent agents for chemoprevention. Consistently, our animal studies 
showed that δTE-13’-COOH effectively attenuated DSS-caused colon inflammation and 
AOM/DSS-induced tumor development in mice, which mimic colitis and colitis-
promoted colon cancer, respectively.   
In summary, we have demonstrated for the first time that 13’-COOHs, long-chain 
metabolites of vitamin E, induce apoptosis and autophagy by modulating sphingolipids in 
various types of cancer cells. Our results indicate that 13’-COOHs initially targets DEGS 
and subsequently activate SM hydrolysis possibly via neutral SMase during cell death 




strongly suggest that 13’-COOHs likely play significant roles in the chemoprevention 
effect by vitamin E forms in vivo and that long-chain carboxychromanols may be novel 









CHAPTER 4. TARGETING SPHINGOLIPID METABOLISM FOR THE 
ANTICANCER EFFECTS OF VARIOUS CHEMOPREVENTIVE COMPOUNDS 
4.1 Abstract 
 
Phytochemicals have been shown to exert anticancer activities, but the underlying 
mechanisms; in particular, the first important target has not been completely identified 
yet. We have earlier shown that specific vitamin E forms, phenolic compounds in various 
classes of phytochemicals, and 13’-carboxychromanols, long-chain vitamin E metabolites 
induced cancer cell death by modulation of sphingolipid metabolism as an initial primary 
target. In this study, we investigated whether other chemopreventive compounds 
including representative phytochemicals (curcumin, resveratrol, epigallocatechin gallate 
(EGCG), quercetin, sulforaphane), ER stress inducers (dithiothreitol, thapsigargin), and 
chemotherapeutic drugs (doxorubicin, camptothecin) also show anticancer effects by 
modulation of sphingolipid metabolism using a sphingolipidomic analysis via employing 
liquid chromatography tandem mass spectrometry (LC-MS/MS) in human colon cancer 
HCT-116 cells. We show that all the tested compounds modulated sphingolipid 
metabolism in HCT-116 cells. Specifically, while the effects of individual compounds on 
different Ceramide (Cer) species with distinct chain-length of fatty acyl-CoA were 
different, all tested compounds increased the levels of dihydroceramides (dhCers) 




Cer, and resveratrol and DTT decreased the levels of all different species of Cers. On the 
other hand, while sulforaphane, quercentin, thapsigargin, doxorubicin and camptothecin 
increased all Cers, EGCG did not affect on the Cer levels during our tested treatment 
times. Moreover, we found that curcumin and quercetin significantly inhibited DEGS 
enzyme activities. Interestingly, these changes in sphingolipid metabolism by the tested 
compounds occurred quickly and prior to any manifestation of cell death. These data 
demonstrated that modulation of sphingolipid metabolism might be a general mechanism 
for the anticancer effects of various chemopreventive compounds against cancer, and 




Colon cancer is one of the leading causes of cancer-related deaths in the United 
States (Siegel et al., 2015). Since there are no effective treatment for advanced cancer, 
chemoprevention becomes a promising strategy to reduce cancer-caused death. 
Chemoprevention against cancer includes antiproliferation and induction of death in 
malignant cells, and therefore stops or delays the onset of metastasis. Epidemiological 
studies have consistently shown that intake of high levels of fruits and vegetables is 
inversely associated with cancer incidence (Block et al., 1992; Steinmetz and Potter, 
1996). Recently, numerous dietary plant phytochemicals have been extensively studied 
and have exhibited cancer preventive activities through modulation of multiple signaling 
pathways and proteins, which are involved in cellular proliferation, differentiation, and 




mechanisms especially the first primary target of their anticancer effects is not 
understood yet. 
 Cellular metabolism, including sphingolipid metabolism, is emerging as 
promising targets as sphingolipids are closely associated with cell survival and death 
(Hannun and Obeid, 2008; Ryland et al., 2011; Zheng et al., 2006). Sphingolipids are 
structural components of cell membranes and play important roles in signal transduction. 
De novo sphingolipid biosynthesis starts in the endoplasmic reticulum with the 
condensation of palmitoyl-CoA and serine into 3-ketosphinganine by serine 
palmitoyltransferase, which rapidly reduced to dihydrosphingosine (dhSph) by 3-
ketosphinganine reductase. A family of (dihydro)ceramide synthases (CerSs) attached 
fatty acyl-CoA with variable chain lengths to dhSph to generate the corresponding 
dihydroceramide (dhCer) subspecies. DhCer desaturase (DEGS) introduces a 4,5-trans 
double bond in dhCer, thus generating ceramide (Cer). The Cer is transported to the 
Golgi apparatus to generate more complex sphingolipids such as glycosyl-, or galactosyl-
Cers and sphingomyelin (SM) by the actions of enzymes glucosyl-Cer synthase, Cer 
galactosyltransferase, or SM synthases, respectively (Hannun and Obeid, 2008). 
 DhCers were believed to be a non-signaling molecule and an inactive precursor of 
Cer, which is a well-known sphingolipid metabolite, especially involved in the regulation 
of apoptosis (Kolesnick, 2002; Radin, 2001; Woodcock, 2006). However, the potential 
effectiveness of dhCers has become recognized with the development of the new 
technology, LC-MS/MS, which can identify and distinguish the different species of Cer 
and dhCer. Since then, several recent studies reported that the increase of dhCers is 




al., 2012; Jiang et al., 2012; Stiban et al., 2006), and autophagy (Jiang et al., 2012; 
Signorelli et al., 2009; Zheng et al., 2006), and some compounds and environmental 
factors such as vitamin E forms (γT and γTE) (Gopalan et al., 2012; Jiang et al., 2012; 
Jiang et al., 2004), fenretinide (Rahmaniyan et al., 2011), resveratrol (Signorelli et al., 
2009), celecoxib (Schiffmann et al., 2009b), oxidative stress (Idkowiak-Baldys et al., 
2010), and hypoxia (Devlin et al., 2011) are known to induce accumulation of 
intracellular dhCers. In addition, the regulation of DEGS, an enzyme that converts dhCer 
into Cer, thus controls the levels of each sphingolipid metabolite became important, as 
genetic or chemical inhibition of DEGS was reported to induce accumulation of dhCer 
(Kraveka et al., 2007; Ruangsiriluk et al., 2012; Siddique et al., 2013). 
We have previously shown that γTE and 13’-carboxychromanol, a long-chain 
vitamin E metabolite, induced colon cell death by inhibition of DEGS as an initial target, 
resulting in the accumulation of intracellular dhCers (Jang Y and Jiang Q, unpublished 
data). Therefore, the objectives of this study were to investigate whether like vitamin E 
forms, other chemopreventive compounds also modulate sphingolipid metabolism as a 
general pathway, and to determine whether this modulation is an initial primary target for 
their anticancer activities. Here, we demonstrated that various chemopreventive 
compounds (Fig. 4.1) including representative phytochemicals (curcumin, resveratrol, 
epigalloatecin gallate (EGCG), quercetin, sulforaphane), endoplasmic reticulum (ER) 
stress inducers (dithiothreitol (DTT), thapsigargin), and chemotherapeutic drugs 
(doxorubicin, camptothecin) induced increases of dhCers and modulation of Cers by 







Figure 4.1 The structures of (A) representative phytochemicals, (B) ER stress inducers 
and (C) cancer chemotherapeutic drugs. (A) Representative phytochemicals: curcumin, 
resveratrol, quercetin, EGCG, and sulforaphane. (B) ER stress inducers: DTT and 
thapsigargin. (C) Cancer chemotherapeutic drugs: doxorubicin and camptothecin. 
 
4.3 Materials and Methods 
 
4.3.1 Materials and reagents 
Curcumin (≥90%), resveratrol (≥98%), and epigallocatechin gallate (EGCG; 
≥98%) were purchased from Sigma (St Louis, MO). Quercetin (≥95%), sulforaphane 
(≥90%), dithiothreitol (DTT; ≥99%), thapsigargin (≥98%), doxorubicin (98-102%), and 




sphingolipid standards were obtained from Avanti Polar Lipids (Alabaster, AL). C8-
cyclopropenylceramide (C8-CPPC) was purchased from Matreya LLC (Pleasant Gap, 
PA). 13C3, 15N-labeled L-serine, Dimethyl sulfoxide (DMSO), [3-(4,5)-dimethylthiazol-2-
yl]-2,5-diphenyl tetrazolium bromide] (MTT), and all other chemicals were from Sigma.  
 
4.3.2 Cell culture and treatment 
Human colon cancer HCT-116 cells were obtained from American Type Culture 
Collection (Manassas, VA). Cells were routinely cultured in McCoy’s 5A modified 
growth medium containing 10% fetal bovine serum (FBS) at 37 °C in 5% CO2. For 
experiments, cells were seeded in the growth medium with 10% FBS either at a density 
of 4 x 104 cells/well in 24-well plates or at a density of 7-8 x 105 cells in 10-cm dishes. 
After overnight attachment, media were replaced with fresh Dulbecco’s modified eagle 
medium (DMEM) containing 1% FBS with tested compounds. All the treatment solutions 
were freshly prepared for each experiment. All the tested compounds were dissolved in 
DMSO and the same amount of DMSO was added to control group. 
 
4.3.3 MTT assay 
Cell viability was examined by the estimation of mitochondrial dehydrogenase 
activity that reduces MTT to form formazan which was dissolved in DMSO and 
measured the absorbance at 570 nm by using a microplate reader (SpectraMax 190, 





4.3.4 Lipid extraction 
Lipids were extracted according to a previously published method (Merrill et al., 
2005). Briefly, cell pellets were resuspended in methanol/chloroform/water (10:5:1 
[v/v/v]), after the addition of internal standard mixture containing 0.5 nmol of C12:0-Cer, 
C25:0-Cer, C17-sphingosine, C17-dhSph, and C12:0-SM (Avanti Polar Lipids, Alabaster, 
AL). The suspension was tip sonicated and then incubated overnight at 48 °C. A total of 
100 µL of suspension was used to determine the amount of total choline-containing 
phospholipids by an enzymatic colorimetric assay (Wako chemicals, Osaka, Japan) (Jiang 
et al., 2004) 75 µL of 1M KOH in methanol was added to the rest of the suspension and 
sonicated for 30 min. Samples were incubated at 37 °C for 2 h and evaporated under a 
stream of nitrogen. 
 
4.3.5 Measurement of sphingolipids using liquid chromatography tandem mass 
spectrometry (LC-MS/MS) 
Immediately before the LC-MS/MS analyses, the prepared samples above were 
resolved in methanol, sonicated, and then briefly centrifuged. The LC-MS/MS analyses 
were performed using the Agilent 6460 triple quadrupole mass spectrometer coupled with 
the Agilent 1200 Rapid Resolution HPLC (Agilent Technologies, Santa Clara, CA) with 
identification of each sphingolipid in positive mode by multiple reaction monitoring 
(MRM) technique (Merrill et al., 2005). The HPLC mobile phases consisted of methanol-
H2O-formic acid (74:25:1, v/v/v; RA) and methanol-formic acid (99:1, v/v; RB); both RA 
and RB contain 5 mM ammonium formate. For measurement of Cers and sphingoid 




with isocratic run (100% B) or gradient (0-1 min, 20% B, 10-13 min, 100% B and 15-20 
min at 20% B), respectively. For measurement of SMs, Agilent Zorbax XDB-C8 (2.1 x 
50 mm) with particle size of 3.5 µm, was used with gradient (0-1 min, 20% B, 10-20 min, 
100% B, 22-30 min, 20% B). The MS/MS parameters were as follows: gas temperature, 
325-350 °C; gas flow rate, 7-10 L/min; nebulizer pressure, 45-50 psi; capillary voltage, 
3500 V; The fragmentor voltage was 100 V and collision energy was 12-20 V. Precursor-
to-product ion transitions for each sphingolipid were used according to the method of 
Merrill et al. (Merrill et al., 2005). 
 
4.3.6 De novo sphingolipids anlaysis 
HCT-116 cells were treated with either 400 µM 13C3, 15N-labeled L-serine alone 
or with a combination of 400 µM 13C3, 15N-labeled L-serine and 10 µM of curcumin for 
20, 30, 60 and 90 min. Lipids were extracted and de novo synthesized sphingolipids were 
measured using LC-MS/MS. 
 
4.3.7 Dihydroceramide desaturase (DEGS) assays 
In Vitro DEGS assay - HCT-116 cells were treated with either a tested compound 
or 1 µM C8-CPPC as a positive control for 1 or 2 h. Cells were collected and 
homogenized in a buffer (5 mM Hepes, pH 7.4, containing 50 mM sucrose) followed by 
10 min incubation on ice. The cell homogenate was centrifuged at 250 x g for 5 min at 
4 °C to remove unbroken cells. Reaction was started by addition of C8:0-dihydroceramide 




cofactor at 37 °C for an hour. Immediately after the reaction, lipids were extracted and 
the products (C8:0-Cer and C8:0-SM) were quantified by LC-MS/MS. 
In Situ DEGS assay - HCT-116 cells were pretreated with either a tested 
compound or C8-CPPC, and then added 10 μM of C8:0-dhCer as a substrate for the DEGS 
enzyme, followed by 1h incubation. The cells were collected and lipids were extracted. 
The levels of products (C8:0-Cer and C8:0-SM) were measured by LC-MS/MS. 
 
4.3.8 Statistics 
Statistical significance was determined using a Student’s t-test.  P < 0.05 was 




4.4.1 Curcumin increased dhCers, dhSph, and C24-Cers, but decreased C16:0-Cer by 
DEGS inhibition 
We first investigated the effects of curcumin, which is a polyphenolic compound 
isolated from a rhizome of the plant Curcuma longa and a promising phytochemical for 
cancer chemoprevention and therapy, on sphingolipid metabolism using LC-MS/MS in 
human colon HCT-116 cancer cells. HCT-116 cells were treated with 10 μM of curcumin 
for 1, 2, and 4 hours. During the treatment times, curcumin caused significant increases 
of dhCers including C16:0-, C24:1-, and C24:0-dhCers, and dhSph, compared with controls 
(Fig. 4.2B). While C16:0-Cer was significantly decreased as early as 1 h incubation with 




were no apparent changes of SM and dhSM species after 4 h incubation with curcumin 
(Fig. 4.2D; Table 4.1). Since treatment of curcumin induced accumulations of dhCers and 
dhSph, which are important sphingolipid metabolites in the de novo sphingolipid 
biosynthesis pathway (Fig. 4.3A), we used 13C3, 15N-labeled L-serine to only trace the 
effect of curcumin on de novo synthesized sphingolipids. Curcumin treatment induced 
significant increases in labeled dhCers, but decreases in C16:0-Cer as early as 20 min to 90 
min (Figs. 4.3C and D), without affecting the amount of total de novo-syntheized 
sphingolipids (Fig. 4.3B; Table 4.2). The increases of de novo dhCers but decreases of de 
novo Cers suggest the inhibition of DEGS-catalyzed reaction by curcumin treatment. 
Therefore, we next examined the effect of curcumin on the DEGS enzyme activity. In the 
in vitro DEGS assay with cell homogenates, 1 h incubation with 10 or 20 μM of 
curcumin showed ~76% and ~92% inhibition of DEGS enzyme activity, respectively 
(Fig. 4.4A). In another assay, in situ DEGS assay also showed significant inhibition of 
DEGS activity with 10 or 20 μM of curcumin after 2-3 hours incubation, though the 
inhibitory effects in this assay were much lower than those in the in vitro assay (Fig. 
4.4B). In both assays, C8-CPPC, a known competitive inhibitor of DEGS (Triola et al., 
2003), inhibited the enzyme activity by about 85~95%. Interestingly, these all modulation 
of sphingolipid metabolism was occurred prior to any signs of cell death determined by 
















Figure 4.2 Effects of curcumin on sphingolipid metabolism in HCT-116 cells. (A) The 
anti-proliferative effects of curcumin on human colon HCT-116 cancer cells. Relative 
cell viability was measured after treatment with curcumin at the stated concentrations and 
time by MTT assay compared with control. The data are mean ± SD for 3 independent 
experiments, each performed in duplicate. HCT-116 cells were treated with 10 μM of 
curcumin for 1, 2, and 4 hours. The sphingolipid levels including (B) dhCers; C16:0-, 
C24:1-, and C24:0-dhCers and dhSph, (C) Cers; C16:0-, C24:1-, and C24:0-Cers, (D) dhSM; 
C16:0- and C24:0-dhSMs, and SMs; C16:0- and C24:1-SMs were determined by LC-MS/MS. 
Results are shown as mean ± SD for 3-4 independent experiments. *p < 0.05 and **p < 






















Figure 4.3 Effects of curcumin on de novo sphingolipid biosynthesis in HCT-116 cells. 
(A) The de novo biosynthesis pathway of sphingolipids (SMS, sphingomyelin synthase; 
SMase, sphingomyelinase). HCT-116 cells were treated with either 400 μM 13C3, 15N-
labeled L-serine alone as control or with a combination of 400 μM 13C3, 15N-labeled L-
serine and 10 μM curcumin for 20, 30, 60, and 90 min. The amount of each labeled de 
novo sphingolipid including (B) total amounts of all the de novo synthesized 
sphingolipids, (C) de novo total dhCer and de novo C16:0-dhCer, (D) de novo total Cers, 
de novo C16:0-Cer, and de novo C24:1-Cer were determined by LC-MS/MS. Results are 
shown as mean ± SEM for 3-4 independent experiments. *p < 0.05 and **p < 0.01 








Figure 4.4 Effects of curcumin on DEGS activity. HCT-116 cells were treated with either 
10 or 20 μM curcumin or 1 μM C8-CPPC as a positive control. (A) In vitro DEGS assay: 
After 1 h of treatment, cells were collected and homogenized. Using the homogenates, 
reaction was started by addition of C8:0-dhCer as a substrate for DEGS with NADH for an 
hour in 37 °C. The levels of products which are C8:0-sphingolipids were analyzed by 
using LC-MS/MS. The data are mean ± SD of 1-2 independent experiments. (B) In situ 
DEGS assay: After 1-2 hours of pretreatment, cells were incubated with 10 μM C8:0-
dhCer as a substrate for DEGS for additional 1 h. The cells were collected and the levels 
of products which are C8:0-sphingolipids were analyzed by using LC-MS/MS. The data 
are mean ± SD of three independent experiments. *p < 0.05 and **p < 0.01 indicate a 













4.4.2 Resveratrol and DTT increased dhCers, dhSph, but decreased C16:0-Cer and C24-
Cers 
We next examined the modulation of sphingolipid using another naturally 
occurring, well-recognized cancer chemopreventive polyphenolic compound, resveratrol, 
found in grapes and wine. Reseveratrol has been shown to induce autophagy by inhibition 
of DEGS activity followed by dhCer accumulation in gastric cancer cells (Signorelli et 
al., 2009). Consistently, 50 μM of resveratrol treatment for 2-4 hours significantly 
enhanced intracelluar levels of dhCers and dhSph (Fig. 4.5B). Compared with controls, 
resveratrol treatment induced decreases in C16:0- and C24:1-Cers (Fig. 4.5C). While C16:0-
SM was decreased, C16:0-dhSM was increased by 4 h incubation with resveratrol (Fig. 
4.5D; Table 4.3). 
 In addition, we tested the effects of ER stress inducers including DTT and 
thapsigargin on sphingolipid metabolism. Since de novo synthesis pathway occurs in the 
ER, we hypothesized that disruption of ER environment by ER stress induction may also 
induce interruption of sphingolipid metabolism. As we expected, similar to resveratrol, 2 
mM of DTT treatment for 2-4 hours elevated dhCers and dhSph, but decreased in C16:0- 
and C24-Cers (Figs. 4.6A and B). DTT treatment also tends to decrease in C16:0-SM but 











Figure 4.5 Effects of resveratrol on sphingolipid metabolism in HCT-116 cells. (A) The 
anti-proliferative effects of resveratrol on human colon HCT-116 cancer cells. Relative 
cell viability was measured after treatment with resveratrol at the stated concentrations 
and time by MTT assay compared with control. The data are mean ± SD for 1 duplicate 
experiment. HCT-116 cells were treated with 50 μM of resveratrol for 2 and 4 hours. The 
sphingolipid levels including (B) dhCers; C16:0-, C24:1-, and C24:0-dhCers and dhSph, (C) 




and C24:1-SMs were determined by LC-MS/MS. Results are shown as mean ± SD for 
three independent experiments. *p < 0.05 and **p < 0.01 indicate a significant difference 
between treated and control cells.  
 
 
Figure 4.6 Effects of DTT on sphingolipid metabolism in HCT-116 cells. HCT-116 cells 
were treated with 2 mM of DTT for 2 and 6 hours. The sphingolipid levels including (A) 
dhCers; C16:0-, C24:1-, and C24:0-dhCers and dhSph, (B) Cers; C16:0-, C24:1-, and C24:0-Cers, 
(C) dhSM; C16:0- and C24:0-dhSMs, and SMs; C16:0- and C24:1-SMs were determined by 








4.4.3 Sulforaphane, quercetin, thapsigargin, doxorubicin and camptothecin increased 
Cers and dhCers 
We then investigated to see whether sulforaphane also modulates sphingolipid 
metabolism as it belongs to a class of organosulfur compounds in phytochemical groups. 
Different with phenolic compounds that contain one or more hydroxyl groups attached to 
one or more aromatic rings, organosulfur compounds contain sulfur in their structure. 
Treatment of cells with 20 μM of sulforaphane for 2-4 hours also modulated sphingolipid 
metabolism by increasing the levels of Cers as well as the levels of dhCers compared 
with controls (Fig. 4.7; Table 4.5). Another phenolic compound, quercetin modulated the 
levels of sphingolipid metabolites as similar way with sulforaphane (Fig. 4.8; Table 4.6). 
Since 20 μM of quercetin elevated not only dhCers, but also Cers, we tested the effects of 
quercetin on DEGS enzyme activity. In the in situ DEGS assay, incubation of cells with 
20 μM of quercetin for 2-3 hours significantly inhibited the DEGS activity by 42% (Fig. 
4.8E). Interestingly, thapsigargin, another ER stress inducer, also induced accumulation 
of intracellular C16:0-dhCer after 6 h treatment with 1 μM concentration, but different 
with DTT, it did not decrease the levels of Cers (Fig. 4.9; Table 4.7). 
 Furthermore, to evaluate whether cancer chemotherapeutic drugs modulate 
sphingolipid metabolism or not, we used two well-known drugs, doxorubicin and 
camptothecin. Treatment of cells with 5 μM of doxorubicin or 1 μM of camptothecin 









Figure 4.7 Effects of sulforaphane on sphingolipid metabolism in HCT-116 cells. HCT-
116 cells were treated with 20 μM of sulforaphane for 2 and 4 hours. The sphingolipid 
levels including (A) dhCers; C16:0-, C24:1-, and C24:0-dhCers and dhSph, (B) Cers; C16:0-, 
C24:1-, and C24:0-Cers, (C) dhSM; C16:0- and C24:0-dhSMs, and SMs; C16:0- and C24:1-SMs 















Figure 4.8 Effects of quercetin on sphingolipid metabolism in HCT-116 cells. (A) The 
anti-proliferative effects of quercetin on human colon HCT-116 cancer cells. Relative cell 
viability was measured after treatment with quercetin at the stated concentrations and 
time by MTT assay compared with control. The data are mean ± SD for 1 duplicate 
experiment. HCT-116 cells were treated with 20 μM of quercetin for 2 and 4 hours. The 
sphingolipid levels including (B) dhCers; C16:0-, C24:1-, and C24:0-dhCers and dhSph, (C) 
Cers; C16:0-, C24:1-, and C24:0-Cers, (D) dhSM; C16:0- and C24:0-dhSMs, and SMs; C16:0- 
and C24:1-SMs were determined by LC-MS/MS. Results are shown as mean ± SD for two 
independent experiments. (E) The effect of quercetin on DEGS activity was measured by 
in situ assay. HCT-116 cells were preincubated with either 20 μM quercetin or 1 μM C8-
CPPC for 2-3 hours followed by 10 μM C8:0-dhCer treatment for 1 h. The cells were 
collected and the levels of products which are C8:0-sphingolipids were analyzed by using 
LC-MS/MS. The data are mean ± SD of three independent experiments. *p < 0.05 and 









Figure 4.9 Effects of thapsigargin on sphingolipid metabolism in HCT-116 cells. HCT-
116 cells were treated with 1 μM of thapsigargin for 6 hours. The sphingolipid levels 
including (A) dhCers; C16:0-, C24:1-, and C24:0-dhCers and dhSph, (B) Cers; C16:0-, C24:1-, 
and C24:0-Cers, (C) dhSM; C16:0- and C24:0-dhSMs, and SMs; C16:0- and C24:1-SMs were 
















Figure 4.10 Effects of cancer chemotherapeutic drugs (doxorubicin and camptothecin) on 
sphingolipid metabolism in HCT-116 cells. (A) The anti-proliferative effects of 
doxorubicin on human colon HCT-116 cancer cells. Relative cell viability was measured 
after treatment with doxorubicin at the stated concentrations and time by MTT assay 
compared with control. The data are mean ± SD for 1 duplicate experiment. HCT-116 
cells were treated with 5 μM of doxorubicin or 1 μM of camptothecin for 24 hours. The 




dhSph, (C and F) Cers; C16:0-, C24:1-, and C24:0-Cers, (D and G) dhSM; C16:0- and C24:0-
dhSMs, and SMs; C16:0- and C24:1-SMs were determined by LC-MS/MS. Results are 
shown as mean ± SD for one independent experiment.  
 
 
4.4.4 EGCG increased dhCer, but did not affect other sphingolipids 
The effects of EGCG, the major polyphenolic compound found in green tea, on 
sphingolipid metabolism were investigated in human colon HCT-116 cancer cells. 
Treatment of cells with 50 μM of EGCG for 4 h elevated dhCers including C16:0-, C24:1-, 
and C24:0-dhCers compared with controls, but not in 2 h incubation with EGCG (Fig. 
4.11B). Even in 4 h incubation, EGCG did not change the levels of Cer species (Fig. 
4.11C). While EGCG tends to increase C24:1-SM at 2 h, it did not affect SM and dhSM 










Figure 4.11 Effects of EGCG on sphingolipid metabolism in HCT-116 cells. (A) The 
anti-proliferative effects of EGCG on human colon HCT-116 cancer cells. Relative cell 
viability was measured after treatment with EGCG at the stated concentrations and time 
by MTT assay compared with control. The data are mean ± SD for 1 duplicate 
experiment. HCT-116 cells were treated with 50 μM of EGCG for 2 and 4 hours. The 
sphingolipid levels including (B) dhCers; C16:0-, C24:1-, and C24:0-dhCers and dhSph, (C) 
Cers; C16:0-, C24:1-, and C24:0-Cers, (D) dhSM; C16:0- and C24:0-dhSMs, and SMs; C16:0- 
and C24:1-SMs were determined by LC-MS/MS. Results are shown as mean ± SD for 
three independent experiments. *p < 0.05 and **p < 0.01 indicate a significant difference 







Table 4.1 Effect of curcumin on sphingolipid metabolism in HCT-116 cells. HCT-116 
cells were treated with 10 µM curcumin for 1, 2, and 4 h. The amount of each 
sphingolipid was determined by LC-MS/MS. Data are mean ± SEM of 3-4 independent 
experiments. *p < 0.05, **p < 0.01, significant difference between control and curcumin-
treated cells. Cer, ceramide; dhCer, dihydroceramide; Sph, sphingosine; dhSph, 
dihydrosphingosine; S1P, sphingosine-1-phosphate; SM, sphingomyelin; dhSM, 
dihydrosphingomyelin 
 
Ceramides (pmol/µg PC) 
C16:0-Cer     
Hours Control Cur 10 µM 
1 2.36 ± 0.29 1.65 ± 0.13** 
2 3.29 ± 0.38 1.53 ± 0.11** 
4 3.46 ± 0.42 1.66 ± 0.12** 
C18:0-Cer     
Hours Control Cur 10 µM 
1 0.069 ± 0.008 0.10 ± 0.020 
2 0.083 ± 0.009 0.093 ± 0.011 
4 0.084 ± 0.019 0.11 ± 0.022* 
C20:0-Cer     
Hours Control Cur 10 µM 
1 0.046 ± 0.009 0.072 ± 0.013** 
2 0.057 ± 0.006 0.080 ± 0.008* 
4 0.058 ± 0.016 0.099 ± 0.026** 
C22:0-Cer     
Hours Control Cur 10 µM 
1 0.49 ± 0.11 0.71 ± 0.13* 
2 0.64 ± 0.032 0.87 ± 0.092 
4 0.58 ± 0.15 1.03 ± 0.20** 
C24:1-Cer     
Hours Control Cur 10 µM 
1 2.43 ± 0.43 3.18 ± 0.85* 
2 2.39 ± 0.31 2.77 ± 0.31** 
4 1.98 ± 0.33 2.57 ± 0.45* 
C24:0-Cer     
Hours Control Cur 10 µM 
1 2.54 ± 0.41 3.23 ± 0.74* 
2 2.61 ± 0.19 2.97 ± 0.21** 




C26:1-Cer     
Hours Control Cur 10 µM 
1 0.24 ± 0.041 0.45 ± 0.11** 
2 0.24 ± 0.026 0.45 ± 0.052** 
4 0.20 ± 0.029 0.50 ± 0.089** 
C26:0-Cer     
Hours Control Cur 10 µM 
1 0.14 ± 0.054 0.21 ± 0.088** 
2 0.19 ± 0.019 0.28 ± 0.030** 
4 0.15 ± 0.024 0.32 ± 0.060** 
Total Cers     
Hours Control Cur 10 µM 
1 8.32 ± 0.61 9.61 ± 1.55 
2 9.51 ± 0.88 9.05 ± 0.80 
4 8.61 ± 0.96 8.36 ± 0.94 
 
Dihydroceramides (pmol/µg PC) 
C16:0-dhCer     
Hours Control Cur 10 µM 
1 0.067 ± 0.009 0.11 ± 0.011** 
2 0.11 ± 0.015 0.16 ± 0.023 
4 0.11 ± 0.011 0.29 ± 0.039** 
C18:0-dhCer     
Hours Control Cur 10 µM 
1 0.0016 ± 0.0001 0.0035 ± 0.0006* 
2 0.0020 ± 0.0004 0.0035 ± 0.0006** 
4 0.0019 ± 0.0004 0.0071 ± 0.0012** 
C20:0-dhCer     
Hours Control Cur 10 µM 
1 0.00080 ± 0.0002 0.0021 ± 0.0004 
2 0.0011 ± 0.0001 0.0017 ± 0.0001** 
4 0.0012 ± 0.0002 0.0054 ± 0.0014** 
C22:0-dhCer     
Hours Control Cur 10 µM 
1 0.0036 ± 0.001 0.009 ± 0.003** 
2 0.0037 ± 0.001 0.011 ± 0.002 
4 0.0049 ± 0.001 0.03 ± 0.007** 




Hours Control Cur 10 µM 
1 0.0055 ± 0.001 0.015 ± 0.003** 
2 0.0055 ± 0.001 0.017 ± 0.003 
4 0.0069 ± 0.043 0.043 ± 0.004** 
C24:0-dhCer     
Hours Control Cur 10 µM 
1 0.0069 ± 0.001 0.014 ± 0.003** 
2 0.0060 ± 0.0009 0.016 ± 0.002** 
4 0.0081 ± 0.0003 0.046 ± 0.004** 
C26:1-dhCer     
Hours Control Cur 10 µM 
1 0.00041 ± 0.0002 0.0012 ± 0.0007 
2 0.00081 ± 0.0001 0.0020 ± 0.0006 
4 0.00085 ± 0.0002 0.0060 ± 0.0005** 
Total dhCers     
Hours Control Cur 10 µM 
1 0.085 ± 0.010 0.15 ± 0.014** 
2 0.13 ± 0.019 0.21 ± 0.030 
4 0.13 ± 0.010 0.42 ± 0.044** 
 
Sphingoid bases (pmol/µg PC) 
Sph     
Hours Control Cur 10 µM 
1 0.94 ± 0.16 1.25 ± 0.30 
2 1.40 ± 0.15 1.27 ± 0.17 
4 1.02 ± 0.25 1.03 ± 0.17 
dhSph     
Hours Control Cur 10 µM 
1 0.057 ± 0.012 0.14 ± 0.025** 
2 0.082 ± 0.007 0.16 ± 0.027* 
4 0.071 ± 0.011 0.18 ± 0.010* 
S1P     
Hours Control Cur 10 µM 
1 0.022 ± 0.006 0.025 ± 0.013 
2 0.018 ± 0.004 0.011 ± 0.001 
4 0.017 ± 0.005 0.0091 ± 0.003 
 




C16:0-SM     
Hours Control Cur 10 µM 
1 54.91 ± 3.13 59.54 ± 4.97* 
2 64.14 ± 4.06 56.92 ± 2.24* 
4 66.1 ± 4.76 65.24 ± 3.01 
C18:0-SM     
Hours Control Cur 10 µM 
1 0.69 ± 0.048 0.81 ± 0.064* 
2 1.06 ± 0.14 1.02 ± 0.076 
4 0.90 ± 0.075 1.42 ± 0.11* 
C20:0-SM     
Hours Control Cur 10 µM 
1 0.57 ± 0.065 0.70 ± 0.076** 
2 1.04 ± 0.24 1.12 ± 0.18 
4 0.95 ± 0.21 1.49 ± 0.18 
C22:0-SM     
Hours Control Cur 10 µM 
1 3.19 ± 0.62 3.77 ± 0.61* 
2 4.77 ± 0.93 4.95 ± 0.55 
4 4.06 ± 1.15 6.49 ± 1.01 
C24:1-SM     
Hours Control Cur 10 µM 
1 14.09 ± 2.57 16.35 ± 2.76 
2 22.00 ± 5.07 21.88 ± 2.62 
4 19.56 ± 5.76 28.11 ± 4.06 
C26:1-SM     
Hours Control Cur 10 µM 
1 0.72 ± 0.15 0.89 ± 0.17 
2 1.41 ± 0.37 1.42 ± 0.25 
4 1.23 ± 0.42 1.78 ± 0.39 
Total SMs     
Hours Control Cur 10 µM 
1 74.16 ± 6.26 82.05 ± 8.59* 
2 94.42 ± 10.73 87.31 ± 5.17 
4 92.81 ± 7.20 107.21 ± 5.95* 
 
Dihydrosphingomyelins (pmol/µg PC) 




Hours Control Cur 10 µM 
1 7.14 ± 0.60 7.63 ± 0.68 
2 13.42 ± 3.22 11.47 ± 2.39* 
4 10.91 ± 1.33 12.06 ± 2.32 
C18:0-dhSM     
Hours Control Cur 10 µM 
1 0.16 ± 0.018 0.19 ± 0.029 
2 0.38 ± 0.10 0.37 ± 0.089 
4 0.31 ± 0.033 0.54 ± 0.083** 
C20:0-dhSM     
Hours Control Cur 10 µM 
1 0.14 ± 0.012 0.18 ± 0.033 
2 0.32 ± 0.083 0.34 ± 0.092 
4 0.25 ± 0.054 0.46 ± 0.050 
C22:0-dhSM     
Hours Control Cur 10 µM 
1 0.38 ± 0.047 0.46 ± 0.057 
2 0.84 ± 0.15 0.86 ± 0.15 
4 0.78 ± 0.16 1.37 ± 0.14 
C24:0-dhSM     
Hours Control Cur 10 µM 
1 0.56 ± 0.094 0.67 ± 0.11 
2 1.44 ± 0.30 1.44 ± 0.32 
4 1.24 ± 0.32 5.63 ± 3.20 
C26:0-dhSM     
Hours Control Cur 10 µM 
1 0.067 ± 0.006 0.075 ± 0.010 
2 0.19 ± 0.058 0.19 ± 0.070 
4 0.14 ± 0.052 0.17 ± 0.011 
Total dhSMs     
Hours Control Cur 10 µM 
1 8.44 ± 0.71 9.21 ± 0.83 
2 16.58 ± 3.55 14.66 ± 2.93 
4 13.63 ± 0.98 20.23 ± 5.73 
 
 
Table 4.2 Effect of curcumin on de novo sphingolipid biosynthesis in HCT-116 cells. 
HCT-116 cells were treated with either 400 µM 13C3, 15N-labeled L-serine alone as 




for 20, 30, 60, and 90 min. The amount of each labeled de novo sphingolipid was 
determined by LC-MS/MS. Data are mean ± SEM of 3-4 independent experiments. *p < 
0.05, **p < 0.01, significant difference between control and curcumin-treated cells. 
 
Ceramides (pmol/µg PC) 
De novo C16:0-Cer   
Minutes Control Cur 10 µM 
20 0.045 ± 0.014 0.027 ± 0.008** 
30 0.15 ± 0.035 0.078 ± 0.022** 
60 0.27 ± 0.035 0.13 ± 0.023** 
90 0.38 ± 0.065 0.18 ± 0.031** 
De novo C24:1-Cer   
Minutes Control Cur 10 µM 
20 0.063 ± 0.032 0.056 ± 0.029 
30 0.16 ± 0.070 0.18 ± 0.082 
60 0.25 ± 0.094 0.31 ± 0.11** 
90 0.40 ± 0.15 0.53 ± 0.21* 
De novo total Cers   
Minutes Control Cur 10 µM 
20 0.11 ± 0.046 0.082 ± 0.038* 
30 0.33 ± 0.10 0.27 ± 0.10* 
60 0.55 ± 0.13 0.47 ± 0.14 
90 0.86 ± 0.22 0.79 ± 0.23 
 
Dihydroceramides (pmol/µg PC) 
De novo C16:0-dhCer   
Minutes Control Cur 10 µM 
20 0.0076 ± 0.002 0.0059 ± 0.001 
30 0.018 ± 0.003 0.019 ± 0.001 
60 0.027 ± 0.005 0.037 ± 0.010 
90 0.030 ± 0.005 0.045 ± 0.007** 
 
Sphingomyelins (pmol/µg PC) 
De novo C16:0-SM   
Minutes Control Cur 10 µM 
20 0.26 ± 0.043 0.27 ± 0.051 
30 0.34 ± 0.025 0.31 ± 0.040 




90 0.64 ± 0.052 0.56 ± 0.033 
De novo C18:0-SM   
Minutes Control Cur 10 µM 
20 0.0095 ± 0.007 0.0038 ± 0.002 
30 0.024 ± 0.019 0.028 ± 0.024 
60 0.018 ± 0.015 0.045 ± 0.038 
90 0.018 ± 0.009 0.018 ± 0.009 
De novo C24:1-SM   
Minutes Control Cur 10 µM 
20 0.14 ± 0.073 0.13 ± 0.076 
30 0.15 ± 0.054 0.11 ± 0.052** 
60 0.13 ± 0.048 0.17 ± 0.058 
90 0.18 ± 0.076 0.21 ± 0.066 
De novo total SMs   
Minutes Control Cur 10 µM 
20 0.41 ± 0.079 0.41 ± 0.061 
30 0.51 ± 0.043 0.45 ± 0.049 
60 0.57 ± 0.077 0.62 ± 0.064 
90 0.83 ± 0.12 0.79 ± 0.070 
 
Dihydrosphingomyelins (pmol/µg PC) 
De novo C16:0-dhSM   
Minutes Control Cur 10 µM 
20 0.094 ± 0.019 0.071 ± 0.005 
30 0.11 ± 0.012 0.088 ± 0.008 
60 0.094 ± 0.004 0.11 ± 0.010 
90 0.12 ± 0.005 0.17 ± 0.023 
 
Table 4.3 Effect of resveratrol on sphingolipid metabolism in HCT-116 cells. HCT-116 
cells were treated with 50 µM resveratrol for 2 and 4 h. The amount of each sphingolipid 
was determined by LC-MS/MS. Data are mean ± SEM of 3 independent experiments. *p 
< 0.05, **p < 0.01, significant difference between control and resveratrol-treated cells. 
 
Ceramides (pmol/µg PC) 
C16:0-Cer     
Hours Control Res 50 µM 
2 3.29 ± 0.38 1.46 ± 0.11** 




C18:0-Cer     
Hours Control Res 50 µM 
2 0.083 ± 0.009 0.068 ± 0.005** 
4 0.098 ± 0.018 0.069 ± 0.003* 
C20:0-Cer     
Hours Control Res 50 µM 
2 0.057 ± 0.006 0.049 ± 0.004 
4 0.069 ± 0.016 0.049 ± 0.006* 
C22:0-Cer     
Hours Control Res 50 µM 
2 0.64 ± 0.032 0.64 ± 0.067 
4 0.70 ± 0.13 0.78 ± 0.046 
C24:1-Cer     
Hours Control Res 50 µM 
2 2.39 ± 0.31 1.60 ± 0.18** 
4 2.18 ± 0.38 1.29 ± 0.26** 
C24:0-Cer     
Hours Control Res 50 µM 
2 2.61 ± 0.19 2.43 ± 0.27 
4 2.31 ± 0.39 2.62 ± 0.58 
C26:1-Cer     
Hours Control Res 50 µM 
2 0.24 ± 0.026 0.24 ± 0.036 
4 0.22 ± 0.034 0.25 ± 0.043 
C26:0-Cer     
Hours Control Res 50 µM 
2 0.19 ± 0.019 0.19 ± 0.023 
4 0.17 ± 0.023 0.21 ± 0.035* 
Total Cers     
Hours Control Res 50 µM 
2 9.51 ± 0.88 6.66 ± 0.65** 
4 9.52 ± 0.44 6.64 ± 0.92* 
 
Dihydroceramides (pmol/µg PC) 
C16:0-dhCer     
Hours Control Res 50 µM 




4 0.12 ± 0.011 0.92 ± 0.029** 
C18:0-dhCer     
Hours Control Res 50 µM 
2 0.0020 ± 0.0004 0.012 ± 0.0005** 
4 0.0021 ± 0.0005 0.011 ± 0.002** 
C20:0-dhCer     
Hours Control Res 50 µM 
2 0.0011 ± 0.0001 0.014 ± 0.0003 
4 0.0014 ± 0.0003 0.013 ± 0.0035** 
C22:0-dhCer     
Hours Control Res 50 µM 
2 0.0037 ± 0.001 0.14 ± 0.011** 
4 0.0055 ± 0.002 0.17 ± 0.028** 
C24:1-dhCer     
Hours Control Res 50 µM 
2 0.0055 ± 0.0014 0.16 ± 0.016* 
4 0.0069 ± 0.0004 0.15 ± 0.0058** 
C24:0-dhCer     
Hours Control Res 50 µM 
2 0.0060 ± 0.0009 0.23 ± 0.019** 
4 0.0083 ± 0.0002 0.29 ± 0.019** 
C26:1-dhCer     
Hours Control Res 50 µM 
2 0.00081 ± 0.0001 0.022 ± 0.0034 
4 0.0010 ± 0.0002 0.020 ± 0.0003 
Total dhCers     
Hours Control Res 50 µM 
2 0.13 ± 0.019 1.62 ± 0.12** 
4 0.14 ± 0.008 1.56 ± 0.007** 
 
Sphingoid bases (pmol/µg PC) 
Sph     
Hours Control Res 50 µM 
2 1.40 ± 0.15 1.24 ± 0.10 
4 1.17 ± 0.27 0.91 ± 0.17* 
dhSph     




2 0.082 ± 0.007 0.29 ± 0.014** 
4 0.074 ± 0.016 0.27 ± 0.040** 
S1P     
Hours Control Res 50 µM 
2 0.018 ± 0.004 0.018 ± 0.004 
4 0.020 ± 0.006 0.013 ± 0.002 
 
Sphingomyelins (pmol/µg PC) 
C16:0-SM     
Hours Control Res 50 µM 
2 64.14 ± 4.06 58.89 ± 5.65* 
4 66.68 ± 6.68 51.39 ± 5.09* 
C18:0-SM     
Hours Control Res 50 µM 
2 1.06 ± 0.14 0.93 ± 0.13 
4 0.92 ± 0.10 0.83 ± 0.11* 
C20:0-SM     
Hours Control Res 50 µM 
2 1.04 ± 0.24 1.05 ± 0.25 
4 0.96 ± 0.30 1.02 ± 0.19 
C22:0-SM     
Hours Control Res 50 µM 
2 4.77 ± 0.93 5.07 ± 1.06* 
4 4.01 ± 1.62 5.43 ± 0.99 
C24:1-SM     
Hours Control Res 50 µM 
2 22.00 ± 5.07 22.84 ± 5.11 
4 19.51 ± 8.14 22.94 ± 3.91 
C26:1-SM     
Hours Control Res 50 µM 
2 1.41 ± 0.37 1.49 ± 0.41 
4 1.30 ± 0.58 1.57 ± 0.31 
Total SMs     
Hours Control Res 50 µM 
2 94.42 ± 10.73 90.27 ± 12.59 





Dihydrosphingomyelins (pmol/µg PC) 
C16:0-dhSM     
Hours Control Res 50 µM 
2 13.42 ± 3.22 13.73 ± 1.23 
4 11.70 ± 1.52 16.18 ± 1.52* 
C18:0-dhSM     
Hours Control Res 50 µM 
2 0.38 ± 0.10 0.45 ± 0.087 
4 0.34 ± 0.019 0.64 ± 0.023** 
C20:0-dhSM     
Hours Control Res 50 µM 
2 0.32 ± 0.083 0.43 ± 0.11* 
4 0.28 ± 0.069 0.65 ± 0.076 
C22:0-dhSM     
Hours Control Res 50 µM 
2 0.84 ± 0.15 1.48 ± 0.30** 
4 0.79 ± 0.22 2.70 ± 0.23 
C24:0-dhSM     
Hours Control Res 50 µM 
2 1.44 ± 0.30 1.79 ± 0.44 
4 1.19 ± 0.44 3.15 ± 0.33 
C26:0-dhSM     
Hours Control Res 50 µM 
2 0.19 ± 0.058 0.22 ± 0.057* 
4 0.15 ± 0.071 0.35 ± 0.034 
Total dhSMs     
Hours Control Res 50 µM 
2 16.58 ± 3.55 18.11 ± 1.65 
4 14.44 ± 0.77 23.67 ± 0.91** 
 
Table 4.4 Effect of DTT on sphingolipid metabolism in HCT-116 cells. HCT-116 cells 
were treated with 2 mM DTT for 2 and 6 h. The amount of each sphingolipid was 
determined by LC-MS/MS. Data are mean ± SEM of 1 (6 h) or 2 (2 h) independent 
experiments.  
 
Ceramides (pmol/µg PC) 




Hours Control DTT 2 mM 
2 2.59 ± 0.20 1.75 ± 0.059 
6 1.76 1.55 
C18:0-Cer     
Hours Control DTT 2 mM 
2 0.055 ± 0.002 0.043 ± 0.004 
6 0.038 0.036 
C20:0-Cer     
Hours Control DTT 2 mM 
2 0.034 ± 0.0001 0.027 ± 0.0007 
6 0.029 0.023 
C22:0-Cer     
Hours Control DTT 2 mM 
2 0.27 ± 0.002 0.15 ± 0.007 
6 0.10 0.059 
C24:1-Cer     
Hours Control DTT 2 mM 
2 2.07 ± 0.90 1.05 ± 0.51 
6 0.12 0.054 
C24:0-Cer     
Hours Control DTT 2 mM 
2 1.95 ± 0.94 1.15 ± 0.49 
6 0.17 0.069 
C26:1-Cer     
Hours Control DTT 2 mM 
2 0.22 ± 0.069 0.11 ± 0.046 
6 0.019 0.0076 
Total Cers     
Hours Control DTT 2 mM 
2 7.20 ± 2.12 4.28 ± 1.11 
6 2.23 1.80 
 
Dihydroceramides (pmol/µg PC) 
C16:0-dhCer     
Hours Control DTT 2 mM 
2 0.15 ± 0.049 2.30 ± 0.89 




C18:0-dhCer     
Hours Control DTT 2 mM 
2 0.00066 ± 0.0007 0.0052 ± 0.0052 
6 0.0018 0.028 
C22:0-dhCer     
Hours Control DTT 2 mM 
2 0.0017 0.023 
6 0.0022 0.096 
C24:1-dhCer     
Hours Control DTT 2 mM 
2 0.0080 ± 0.006 0.27 ± 0.12 
6 0.0018 0.063 
C24:0-dhCer     
Hours Control DTT 2 mM 
2 0.015 ± 0.007 0.22 ± 0.10 
6 0.0040 0.070 
Total dhCers     
Hours Control DTT 2 mM 
2 0.17 ± 0.034 2.81 ± 0.64 
6 0.17 6.23 
 
Sphingoid bases (pmol/µg PC) 
Sph     
Hours Control DTT 2 mM 
2 0.68 ± 0.059 0.56 ± 0.068 
6 1.69 1.06 
dhSph     
Hours Control DTT 2 mM 
2 0.088 ± 0.016 0.15 ± 0.018 
6 0.19 0.62 
S1P     
Hours Control DTT 2 mM 
2 0.042 ± 0.003 0.035 ± 0.005 
6 0.037 0.020 
 
Sphingomyelins (pmol/µg PC) 




Hours Control DTT 2 mM 
2 38.08 ± 4.13 33.91 ± 3.57 
6 28.09 19.89 
C18:0-SM     
Hours Control DTT 2 mM 
2 1.54 ± 0.091 0.64 ± 0.075 
6 0.53 0.40 
C20:0-SM     
Hours Control DTT 2 mM 
2 0.33 ± 0.054 0.49 ± 0.015 
6 0.64 0.44 
C22:0-SM     
Hours Control DTT 2 mM 
2 0.90 ± 0.29 1.41 ± 0.33 
6 0.77 0.55 
C24:1-SM     
Hours Control DTT 2 mM 
2 3.16 ± 0.89 4.68 ± 1.02 
6 4.29 2.99 
C26:1-SM     
Hours Control DTT 2 mM 
2 0.68 ± 0.017 0.28 ± 0.10 
6 0.43 0.33 
Total SMs     
Hours Control DTT 2 mM 
2 44.69 ± 5.47 41.41 ± 5.08 
6 34.75 24.59 
 
Dihydrosphingomyelins (pmol/µg PC) 
C16:0-dhSM     
Hours Control DTT 2 mM 
2 10.36 ± 0.79 10.76 ± 1.18 
6 5.15 6.30 
C18:0-dhSM     
Hours Control DTT 2 mM 
2 0.27 ± 0.005 0.35 ± 0.022 




C20:0-dhSM     
Hours Control DTT 2 mM 
2 0.11 ± 0.002 0.30 ± 0.010 
6 0.17 0.20 
C22:0-dhSM     
Hours Control DTT 2 mM 
2 0.19 ± 0.090 0.37 ± 0.029 
6 0.12 0.23 
C24:0-dhSM     
Hours Control DTT 2 mM 
2 0.20 ± 0.045 0.41 ± 0.054 
6 0.27 0.57 
Total dhSMs     
Hours Control DTT 2 mM 
2 11.13 ± 0.91 12.20 ± 1.30 
6 5.96 7.61 
 
Table 4.5 Effect of sulforaphane on sphingolipid metabolism in HCT-116 cells. HCT-116 
cells were treated with 20 µM sulforaphane for 2 and 4 h. The amount of each 
sphingolipid was determined by LC-MS/MS. Data are mean ± SEM of 2 independent 
experiments. 
 
Ceramides (pmol/µg PC) 
C16:0-Cer     
Hours Control SFN 20 µM 
2 2.40 ± 0.18 3.13 ± 0.073 
4 2.85 ± 0.36 3.83 ± 0.010 
C18:0-Cer     
Hours Control SFN 20 µM 
2 0.038 ± 0.001 0.054 ± 0.009 
4 0.042 ± 0.0002 0.061 ± 0.006 
C20:0-Cer     
Hours Control SFN 20 µM 
2 0.022 ± 0.003 0.035 ± 0.006 
4 0.025 ± 0.002 0.042 ± 0.010 
C22:0-Cer     
Hours Control SFN 20 µM 




4 0.21 ± 0.0003 0.30 ± 0.025 
C24:1-Cer     
Hours Control SFN 20 µM 
2 4.45 ± 0.42 5.61 ± 0.35 
4 4.76 ± 0.26 6.68 ± 0.58 
C24:0-Cer     
Hours Control SFN 20 µM 
2 4.41 ± 0.59 4.31 ± 0.40 
4 4.67 ± 0.67 4.41 ± 0.50 
C26:1-Cer     
Hours Control SFN 20 µM 
2 0.37 ± 0.051 0.47 ± 0.017 
4 0.43 ± 0.037 0.47 ± 0.024 
Total Cers     
Hours Control SFN 20 µM 
2 11.88 ± 1.23 13.87 ± 0.65 
4 12.99 ± 1.32 15.79 ± 1.04 
 
Dihydroceramides (pmol/µg PC) 
C16:0-dhCer     
Hours Control SFN 20 µM 
2 0.053 ± 0.006 0.078 ± 0.007 
4 0.072 ± 0.018 0.11 ± 0.019 
C24:1-dhCer     
Hours Control SFN 20 µM 
2 0.0078 ± 0.008 0.012 ± 0.012 
4 0.0074 ± 0.007 0.016 ± 0.016 
Total dhCers     
Hours Control SFN 20 µM 
2 0.061 ± 0.002 0.090 ± 0.004 
4 0.079 ± 0.011 0.12 ± 0.003 
 
Sphingoid bases (pmol/µg PC) 
Sph     
Hours Control SFN 20 µM 
2 0.57 ± 0.018 0.50 ± 0.013 




dhSph     
Hours Control SFN 20 µM 
2 0.10 ± 0.011 0.081 ± 0.005 
4 0.10 ± 0.001 0.10 ± 0.006 
S1P     
Hours Control SFN 20 µM 
2 0.013 ± 0.007 0.016 ± 0.003 
4 0.010 ± 0.002 0.014 ± 0.004 
 
Sphingomyelins (pmol/µg PC) 
C16:0-SM     
Hours Control SFN 20 µM 
2 83.97 ± 19.12 62.22 ± 15.81 
4 90.58 ± 20.91 67.94 ± 22.24 
C18:0-SM     
Hours Control SFN 20 µM 
2 1.59 ± 0.26 0.65 ± 0.17 
4 1.61 ± 0.13 0.60 ± 0.14 
C20:0-SM     
Hours Control SFN 20 µM 
2 0.37 ± 0.17 0.50 ± 0.13 
4 0.28 ± 0.084 0.50 ± 0.13 
C22:0-SM     
Hours Control SFN 20 µM 
2 1.32 ± 0.63 1.77 ± 0.29 
4 1.03 ± 0.33 1.84 ± 0.47 
C24:1-SM     
Hours Control SFN 20 µM 
2 4.80 ± 2.52 5.98 ± 1.14 
4 3.86 ± 1.53 6.31 ± 1.74 
C26:1-SM     
Hours Control SFN 20 µM 
2 2.12 ± 0.12 0.25 ± 0.040 
4 2.15 ± 0.048 0.27 ± 0.064 
Total SMs     
Hours Control SFN 20 µM 




4 99.51 ± 23.04 77.45 ± 24.79 
 
Dihydrosphingomyelins (pmol/µg PC) 
C16:0-dhSM     
Hours Control SFN 20 µM 
2 6.22 ± 0.15 6.78 ± 0.46 
4 5.50 ± 0.42 6.24 ± 0.12 
C18:0-dhSM     
Hours Control SFN 20 µM 
2 0.11 ± 0.019 0.16 ± 0.005 
4 0.082 ± 0.016 0.13 ± 0.008 
C20:0-dhSM     
Hours Control SFN 20 µM 
2 0.033 ± 0.005 0.078 ± 0.016 
4 0.025 ± 0.011 0.068 ± 0.007 
C22:0-dhSM     
Hours Control SFN 20 µM 
2 0.081 ± 0.006 0.17 ± 0.034 
4 0.053 ± 0.026 0.15 ± 0.004 
C24:0-dhSM     
Hours Control SFN 20 µM 
2 0.063 ± 0.010 0.12 ± 0.026 
4 0.045 ± 0.029 0.11 ± 0.012 
C26:0-dhSM     
Hours Control SFN 20 µM 
2 0.0052 ± 0.001 0.010 ± 0.002 
4 0.0036 ± 0.002 0.011 ± 0.003 
Total dhSMs     
Hours Control SFN 20 µM 
2 6.51 ± 1.16 7.30 ± 0.17 
4 5.71 ± 0.00002 6.71 ± 0.84 
 
Table 4.6 Effect of quercetin on sphingolipid metabolism in HCT-116 cells. HCT-116 
cells were treated with 20 µM quercetin for 2 and 4 h. The amount of each sphingolipid 
was determined by LC-MS/MS. Data are mean ± SEM of 2 independent experiments. 
 




C16:0-Cer     
Hours Control Quer 20 µM 
2 2.59 ± 0.20 3.79 ± 0.29 
4 3.04 ± 0.32 4.10 ± 0.11 
C18:0-Cer     
Hours Control Quer 20 µM 
2 0.055 ± 0.002 0.082 ± 0.003 
4 0.058 ± 0.009 0.085 ± 0.004 
C20:0-Cer     
Hours Control Quer 20 µM 
2 0.034 ± 0.0001 0.052 ± 0.001 
4 0.038 ± 0.005 0.050 ± 0.003 
C22:0-Cer     
Hours Control Quer 20 µM 
2 0.27 ± 0.002 0.32 ± 0.022 
4 0.25 ± 0.025 0.32 ± 0.010 
C24:1-Cer     
Hours Control Quer 20 µM 
2 2.07 ± 0.90 2.19 ± 1.08 
4 2.31 ± 1.07 2.10 ± 0.89 
C24:0-Cer     
Hours Control Quer 20 µM 
2 1.95 ± 0.94 2.28 ± 1.03 
4 2.23 ± 1.07 2.48 ± 0.98 
C26:1-Cer     
Hours Control Quer 20 µM 
2 0.22 ± 0.069 0.17 ± 0.10 
4 0.21 ± 0.085 0.16 ± 0.086 
Total Cers     
Hours Control Quer 20 µM 
2 7.20 ± 2.12 8.88 ± 2.52 
4 8.14 ± 2.59 9.30 ± 2.06 
 
Dihydroceramides (pmol/µg PC) 
C16:0-dhCer     
Hours Control Quer 20 µM 




4 0.19 ± 0.055 0.68 ± 0.18 
C24:1-dhCer     
Hours Control Quer 20 µM 
2 0.0080 ± 0.006 0.020 ± 0.008 
4 0.025 ± 0.015 0.060 ± 0.029 
C24:0-dhCer     
Hours Control Quer 20 µM 
2 0.015 ± 0.007 0.048 ± 0.020 
4 0.016 ± 0.009 0.12 ± 0.063 
Total dhCers     
Hours Control Quer 20 µM 
2 0.17 ± 0.034 0.42 ± 0.064 
4 0.24 ± 0.028 0.87 ± 0.081 
 
Sphingoid bases (pmol/µg PC) 
Sph     
Hours Control Quer 20 µM 
2 0.68 ± 0.059 1.13 ± 0.31 
4 0.75 ± 0.029 0.77 ± 0.017 
dhSph     
Hours Control Quer 20 µM 
2 0.088 ± 0.016 0.11 ± 0.008 
4 0.11 ± 0.021 0.14 ± 0.037 
S1P     
Hours Control Quer 20 µM 
2 0.042 ± 0.003 0.039 ± 0.001 
4 0.033 ± 0.008 0.026 ± 0.019 
 
Sphingomyelins (pmol/µg PC) 
C16:0-SM     
Hours Control Quer 20 µM 
2 38.08 ± 4.13 39.18 ± 2.96 
4 43.38 ± 5.40 35.33 ± 4.79 
C18:0-SM     
Hours Control Quer 20 µM 
2 1.54 ± 0.091 0.68 ± 0.021 




C20:0-SM     
Hours Control Quer 20 µM 
2 0.33 ± 0.054 0.51 ± 0.069 
4 0.33 ± 0.092 0.60 ± 0.070 
C22:0-SM     
Hours Control Quer 20 µM 
2 0.90 ± 0.29 1.55 ± 0.23 
4 0.93 ± 0.30 1.33 ± 0.40 
C24:1-SM     
Hours Control Quer 20 µM 
2 3.16 ± 0.89 5.24 ± 0.92 
4 3.25 ± 1.13 4.77 ± 1.25 
C26:1-SM     
Hours Control Quer 20 µM 
2 0.68 ± 0.017 0.34 ± 0.083 
4 0.78 ± 0.099 0.30 ± 0.065 
Total SMs     
Hours Control Quer 20 µM 
2 44.69 ± 5.47 47.51 ± 4.28 
4 50.37 ± 7.10 42.93 ± 6.72 
 
Dihydrosphingomyelins (pmol/µg PC) 
C16:0-dhSM     
Hours Control Quer 20 µM 
2 10.36 ± 0.79 11.25 ± 0.92 
4 10.56 ± 1.01 9.13 ± 1.95 
C18:0-dhSM     
Hours Control Quer 20 µM 
2 0.27 ± 0.005 0.40 ± 0.012 
4 0.36 ± 0.11 0.33 ± 0.072 
C20:0-dhSM     
Hours Control Quer 20 µM 
2 0.11 ± 0.002 0.21 ± 0.054 
4 0.087 ± 0.010 0.17 ± 0.021 
C22:0-dhSM     
Hours Control Quer 20 µM 




4 0.17 ± 0.046 0.32 ± 0.095 
C24:0-dhSM     
Hours Control Quer 20 µM 
2 0.20 ± 0.045 0.35 ± 0.046 
4 0.16 ± 0.004 0.38 ± 0.18 
Total dhSMs     
Hours Control Quer 20 µM 
2 11.13 ± 1.72 12.56 ± 1.73 
4 11.34 ± 1.62 10.33 ± 3.30 
 
Table 4.7 Effect of thapsigargin on sphingolipid metabolism in HCT-116 cells. HCT-116 
cells were treated with 1 µM thapsigargin for 6 h. The amount of each sphingolipid was 
determined by LC-MS/MS. Data are mean ± SEM of 2 independent experiments. 
 
Ceramides (pmol/µg PC) 
C16:0-Cer     
Hours Control TG 1 µM 
6 2.21 ± 0.45 3.43 ± 0.93 
C18:0-Cer     
Hours Control TG 1 µM 
6 0.045 ± 0.007 0.088 ± 0.020 
C20:0-Cer     
Hours Control TG 1 µM 
6 0.031 ± 0.003 0.059 ± 0.004 
C22:0-Cer     
Hours Control TG 1 µM 
6 0.16 ± 0.059 0.31 ± 0.15 
C24:1-Cer     
Hours Control TG 1 µM 
6 0.68 ± 0.56 0.81 ± 0.66 
C24:0-Cer     
Hours Control TG 1 µM 
6 0.72 ± 0.55 0.90 ± 0.73 
Total Cers     
Hours Control TG 1 µM 





Dihydroceramides (pmol/µg PC) 
C16:0-dhCer     
Hours Control TG 1 µM 
6 0.20 ± 0.035 0.67 ± 0.19 
C24:1-dhCer     
Hours Control TG 1 µM 
6 0.0059 ± 0.0041 0.0094 ± 0.0068 
C24:0-dhCer     
Hours Control TG 1 µM 
6 0.0054 ± 0.0015 0.017 ± 0.010 
Total dhCers     
Hours Control TG 1 µM 
6 0.21 ± 0.038 0.71 ± 0.20 
 
Sphingoid bases (pmol/µg PC) 
Sph     
Hours Control TG 1 µM 
6 1.12 ± 0.56 1.03 ± 0.27 
dhSph     
Hours Control TG 1 µM 
6 0.13 ± 0.060 0.11 ± 0.048 
S1P     
Hours Control TG 1 µM 
6 0.032 ± 0.005 0.030 ± 0.003 
 
Sphingomyelins (pmol/µg PC) 
C16:0-SM     
Hours Control TG 1 µM 
6 28.09 ± 1.52 31.20 ± 3.89 
C18:0-SM     
Hours Control TG 1 µM 
6 1.60 ± 0.023 0.63 ± 0.085 
C20:0-SM     
Hours Control TG 1 µM 




C22:0-SM     
Hours Control TG 1 µM 
6 0.40 ± 0.12 1.03 ± 0.25 
C24:1-SM     
Hours Control TG 1 µM 
6 2.25 ± 0.25 4.32 ± 0.17 
C26:1-SM     
Hours Control TG 1 µM 
6 0.85 ± 0.089 0.41 ± 0.10 
Total SMs     
Hours Control TG 1 µM 
6 33.54 ± 1.16 38.18 ± 3.85 
 
Dihydrosphingomyelins (pmol/µg PC) 
C16:0-dhSM     
Hours Control TG 1 µM 
6 5.15 ± 0.97 7.23 ± 1.63 
C18:0-dhSM     
Hours Control TG 1 µM 
6 0.20 ± 0.021 0.24 ± 0.070 
C20:0-dhSM     
Hours Control TG 1 µM 
6 0.17 ± 0.003 0.19 ± 0.014 
C22:0-dhSM     
Hours Control TG 1 µM 
6 0.12 ± 0.059 0.19 ± 0.059 
C24:0-dhSM     
Hours Control TG 1 µM 
6 0.14 ± 0.038 0.29 ± 0.045 
Total dhSMs     
Hours Control TG 1 µM 
6 5.86 ± 0.98 8.21 ± 1.78 
 
Table 4.8 Effect of cancer chemotherapeutic drugs (doxorubicin and camptothecin) on 
sphingolipid metabolism in HCT-116 cells. HCT-116 cells were treated with 5 µM 
doxorubicin or 1 µM camptothecin for 24 h. The amount of each sphingolipid was 





Ceramides (pmol/µg PC)  
C16:0-Cer       
Hours Control Dox 5 µM CPT 1 µM 
24 2.03 3.93 6.04 
C18:0-Cer       
Hours Control Dox 5 µM CPT 1 µM 
24 0.025 0.064 0.094 
C20:0-Cer       
Hours Control Dox 5 µM CPT 1 µM 
24 0.022 0.039 0.062 
C22:0-Cer       
Hours Control Dox 5 µM CPT 1 µM 
24 0.16 0.24 0.27 
C24:1-Cer       
Hours Control Dox 5 µM CPT 1 µM 
24 1.18 2.03 2.08 
C24:0-Cer       
Hours Control Dox 5 µM CPT 1 µM 
24 1.87 1.51 1.75 
C26:1-Cer       
Hours Control Dox 5 µM CPT 1 µM 
24 0.16 0.11 0.22 
C26:0-Cer       
Hours Control Dox 5 µM CPT 1 µM 
24 0.15 0.11 0.24 
Total Cers       
Hours Control Dox 5 µM CPT 1 µM 
24 5.60 8.03 10.77 
 
Dihydroceramides (pmol/µg PC)  
C16:0-dhCer       
Hours Control Dox 5 µM CPT 1 µM 
24 0.26 0.57 0.38 
C24:1-dhCer       




24 0.024 0.088 0.021 
Total dhCers       
Hours Control Dox 5 µM CPT 1 µM 
24 0.28 0.66 0.40 
 
Sphingoid bases (pmol/µg PC)  
Sph       
Hours Control Dox 5 µM CPT 1 µM 
24 0.88 0.96 2.10 
dhSph       
Hours Control Dox 5 µM CPT 1 µM 
24 0.08 0.10 0.16 
S1P       
Hours Control Dox 5 µM CPT 1 µM 
24 0.011 0.029 0.034 
 
Sphingomyelins (pmol/µg PC)  
C16:0-SM       
Hours Control Dox 5 µM CPT 1 µM 
24 62.19 66.74 68.25 
C18:0-SM       
Hours Control Dox 5 µM CPT 1 µM 
24 0.51 0.65 0.68 
C20:0-SM       
Hours Control Dox 5 µM CPT 1 µM 
24 0.45 0.55 0.55 
C22:0-SM       
Hours Control Dox 5 µM CPT 1 µM 
24 1.58 1.99 1.94 
C24:1-SM       
Hours Control Dox 5 µM CPT 1 µM 
24 7.02 9.60 8.38 
C26:1-SM       
Hours Control Dox 5 µM CPT 1 µM 
24 0.37 0.57 0.48 




Hours Control Dox 5 µM CPT 1 µM 
24 72.12 80.11 80.28 
 
Dihydrosphingomyelins (pmol/µg PC)  
C16:0-dhSM       
Hours Control Dox 5 µM CPT 1 µM 
24 10.19 13.65 12.52 
C18:0-dhSM       
Hours Control TG 1 µM CPT 1 µM 
24 0.23 0.38 0.38 
C20:0-dhSM       
Hours Control TG 1 µM CPT 1 µM 
24 0.15 0.26 0.24 
C22:0-dhSM       
Hours Control TG 1 µM CPT 1 µM 
24 0.26 0.42 0.38 
C24:0-dhSM       
Hours Control TG 1 µM CPT 1 µM 
24 0.31 0.50 0.38 
C26:0-dhSM       
Hours Control TG 1 µM CPT 1 µM 
24 0.03 0.06 0.06 
Total dhSMs       
Hours Control TG 1 µM CPT 1 µM 
24 11.17 15.26 13.96 
 
 
Table 4.9 Effect of EGCG on sphingolipid metabolism in HCT-116 cells. HCT-116 cells 
were treated with 50 µM EGCG for 2 and 4 h. The amount of each sphingolipid was 
determined by LC-MS/MS. Data are mean ± SEM of 3 independent experiments. *p < 
0.05, **p < 0.01, significant difference between control and EGCG-treated cells. 
 
Ceramides (pmol/µg PC) 
C16:0-Cer     
Hours Control EGCG 50 µM 
2 3.29 ± 0.38 3.80 ± 0.10 




C18:0-Cer     
Hours Control EGCG 50 µM 
2 0.083 ± 0.009 0.080 ± 0.008 
4 0.098 ± 0.018 0.085 ± 0.009 
C20:0-Cer     
Hours Control EGCG 50 µM 
2 0.057 ± 0.006 0.058 ± 0.006 
4 0.069 ± 0.016 0.064 ± 0.008 
C22:0-Cer     
Hours Control EGCG 50 µM 
2 0.64 ± 0.032 0.63 ± 0.069 
4 0.70 ± 0.13 0.59 ± 0.031 
C24:1-Cer     
Hours Control EGCG 50 µM 
2 2.39 ± 0.31 2.47 ± 0.28 
4 2.18 ± 0.38 1.76 ± 0.38 
C24:0-Cer     
Hours Control EGCG 50 µM 
2 2.61 ± 0.19 2.76 ± 0.35 
4 2.31 ± 0.39 2.21 ± 0.42 
C26:1-Cer     
Hours Control EGCG 50 µM 
2 0.24 ± 0.026 0.22 ± 0.036 
4 0.22 ± 0.034 0.16 ± 0.028* 
C26:0-Cer     
Hours Control EGCG 50 µM 
2 0.19 ± 0.019 0.17 ± 0.026 
4 0.17 ± 0.023 0.15 ± 0.022 
Total Cers     
Hours Control EGCG 50 µM 
2 9.51 ± 0.88 10.18 ± 0.86 
4 9.52 ± 0.44 9.24 ± 0.87 
 
Dihydroceramides (pmol/µg PC) 
C16:0-dhCer     
Hours Control EGCG 50 µM 




4 0.12 ± 0.011 0.24 ± 0.037* 
C18:0-dhCer     
Hours Control EGCG 50 µM 
2 0.0020 ± 0.0004 0.0019 ± 0.0002 
4 0.0021 ± 0.0005 0.0037 ± 0.0004* 
C20:0-dhCer     
Hours Control EGCG 50 µM 
2 0.0011 ± 0.0001 0.00092 ± 0.0001 
4 0.0014 ± 0.0003 0.0019 ± 0.0002 
C22:0-dhCer     
Hours Control EGCG 50 µM 
2 0.0037 ± 0.0006 0.0034 ± 0.0007 
4 0.0055 ± 0.0019 0.012 ± 0.0027* 
C24:1-dhCer     
Hours Control EGCG 50 µM 
2 0.0055 ± 0.0014 0.0058 ± 0.0002 
4 0.0069 ± 0.0004 0.013 ± 0.0011** 
C24:0-dhCer     
Hours Control EGCG 50 µM 
2 0.0060 ± 0.0009 0.0056 ± 0.0010 
4 0.0083 ± 0.0002 0.020 ± 0.0025** 
C26:1-dhCer     
Hours Control EGCG 50 µM 
2 0.00081 ± 0.0001 0.0009 ± 0.0001 
4 0.0010 ± 0.0002 0.0015 ± 0.0002 
Total dhCers     
Hours Control EGCG 50 µM 
2 0.13 ± 0.019 0.13 ± 0.003 
4 0.14 ± 0.008 0.29 ± 0.041* 
 
Sphingoid bases (pmol/µg PC) 
Sph     
Hours Control EGCG 50 µM 
2 1.40 ± 0.15 1.24 ± 0.16 
4 1.17 ± 0.27 0.96 ± 0.20* 
dhSph     




2 0.082 ± 0.007 0.067 ± 0.003 
4 0.074 ± 0.016 0.045 ± 0.019 
S1P     
Hours Control EGCG 50 µM 
2 0.018 ± 0.004 0.022 ± 0.003 
4 0.020 ± 0.006 0.017 ± 0.004 
 
Sphingomyelins (pmol/µg PC) 
C16:0-SM     
Hours Control EGCG 50 µM 
2 64.14 ± 4.06 66.62 ± 9.12 
4 66.68 ± 6.68 55.12 ± 1.34 
C18:0-SM     
Hours Control EGCG 50 µM 
2 1.06 ± 0.14 1.34 ± 0.25 
4 0.92 ± 0.10 0.99 ± 0.088* 
C20:0-SM     
Hours Control EGCG 50 µM 
2 1.04 ± 0.24 1.30 ± 0.37 
4 0.96 ± 0.30 1.05 ± 0.12 
C22:0-SM     
Hours Control EGCG 50 µM 
2 4.77 ± 0.93 5.90 ± 1.51 
4 4.01 ± 1.62 4.99 ± 0.55 
C24:1-SM     
Hours Control EGCG 50 µM 
2 22.00 ± 5.07 25.67 ± 6.43** 
4 19.51 ± 8.14 23.25 ± 2.37 
C26:1-SM     
Hours Control EGCG 50 µM 
2 1.41 ± 0.37 1.65 ± 0.47** 
4 1.30 ± 0.58 1.53 ± 0.15 
Total SMs     
Hours Control EGCG 50 µM 
2 94.42 ± 10.73 102.48 ± 17.82 





Dihydrosphingomyelins (pmol/µg PC) 
C16:0-dhSM     
Hours Control EGCG 50 µM 
2 13.42 ± 3.22 12.75 ± 1.58 
4 11.70 ± 1.52 10.46 ± 2.02 
C18:0-dhSM     
Hours Control EGCG 50 µM 
2 0.38 ± 0.10 0.44 ± 0.10 
4 0.34 ± 0.019 0.40 ± 0.044 
C20:0-dhSM     
Hours Control EGCG 50 µM 
2 0.32 ± 0.083 0.40 ± 0.11 
4 0.28 ± 0.069 0.35 ± 0.031 
C22:0-dhSM     
Hours Control EGCG 50 µM 
2 0.84 ± 0.15 1.08 ± 0.22** 
4 0.79 ± 0.22 1.08 ± 0.12 
C24:0-dhSM     
Hours Control EGCG 50 µM 
2 1.44 ± 0.30 1.62 ± 0.34 
4 1.19 ± 0.44 1.65 ± 0.16 
C26:0-dhSM     
Hours Control EGCG 50 µM 
2 0.19 ± 0.058 0.22 ± 0.059* 
4 0.15 ± 0.071 0.27 ± 0.059 
Total dhSMs     
Hours Control EGCG 50 µM 
2 16.58 ± 3.55 16.51 ± 2.07 











We show that various anticancer compounds including representative 
chemopreventive phytochemicals against cancer (phenolics: curcumin, resveratrol, 
quercetin, EGCG; organosulfur compound: sulforaphane), ER stress inducers (DTT, 
thapsigargin), and cancer chemotherapeutic drugs (doxorubicin, camptothecin), all 
modulated sphingolipid metabolism in human colon HCT-116 cancer cells. Specifically, 
while the effects of individual compounds on Cer species with specific fatty acid chain 
lengths were different, all tested compounds increased the levels of dhCers compared 
with controls. For instance, curcumin increased C24-Cers, but decreased C16:0-Cer, and 
resveratrol and DTT decreased the levels of all different species of Cers. On the other 
hand, while sulforaphane, quercentin, thapsigargin, doxorubicin and camptothecin 
increased all Cers, EGCG did not affect on the Cer levels during our tested treatment 
times. Moreover, we found that curcumin and quercetin significantly inhibited DEGS 
enzyme activities. Interestingly, these changes of sphingolipid by the tested compounds 
occurred quickly and took place prior to any manifestation of cell death. These data 
demonstrated that modulation of sphingolipid metabolism might be a general mechanism 
for the anticancer effects of chemopreventive compounds against cancer, and inhibition 
of DEGS enzyme might be the initial primary target of their anticancer actions. 
We suggests DEGS in the de novo sphingolipid biosynthesis pathway as an initial 
inhibitory target of various cancer chemopreventive compounds based on the quick 
increase of intracellular dhCers after treatment of all the tested compounds in human 




a double bond in dhCer, thus regulating the levels of dhCer as well as Cer in the cell. As 
well as the elevation of dhCers, various compounds seem to have different effects on the 
regulation of individual Cer species. Recent studies have shown that individual Cers with 
specific fatty acid chain lengths have distinct roles in cell proliferation and death 
(Hannun and Obeid, 2011; Ryland et al., 2011). For instance, C18:0-Cer generated by 
CerS1 has been found to induce apoptosis (Senkal et al., 2010) or lethal autophagy 
(Sentelle et al., 2012). The roles of C16:0-Cer generated by CerS5/6 are still debatable as it 
has shown anti- or pro-apoptotic properties (Mullen et al., 2011; Schiffmann et al., 
2009b; Senkal et al., 2010; White-Gilbertson et al., 2009). In this study, in contrast to 
dhCer, the effects of various cancer chemopreventive or chemotherapeutic compounds on 
Cer varied with treatment time and specific Cer species. Therefore, further studies are 
needed to verify their specific effects on CerS enzymes and the roles of individual Cers in 
the regulation of cell fate. 
 Plant-derived phytochemicals were thought to act as only antioxidants to exhibit 
their chemopreventive effects against cancer. However, interestingly, these compounds 
have been found to show dual roles as pro-oxidants as well as antioxidants depending on 
various environmental factors. They can generate reactive oxygen species and cause 
oxidative stress (Babich et al., 2011; Fujisawa et al., 2004; Galati et al., 2002). Recently, 
DEGS activity was found to be inhibited by hydrogen peroxide (Idkowiak-Baldys et al., 
2010). The mechanism whether the inhibition of DEGS and modulation of sphingolipid 
metabolism by our tested compounds are caused by their pro-oxidant effects is not 
understood, which warrants further investigation. In addition, the concentrations of 




bioavailability due to rapid metabolism and excretion. Although many studies reported 
anticancer effects of phytochemicals in vitro and in vivo, the effects of phytochemicals in 
humans will need to be assessed in the future studies.  
The current results also showed that ER stress inducers, DTT and thapsigargin, 
modulated sphingolipid metabolism in cancer cells. The ER is an important organelle that 
plays roles in the folding and maturation of newly synthesized transmembrane and 
secretory proteins. Disruption of ER function causes an accumulation of unfolded and 
misfolded proteins in the ER lumen, a condition termed ER stress, which then activates 
unfolded protein response (UPR) to recover the condition. However, the excessive and 
unresolvable ER stress induces apoptosis of the cell (Sano and Reed, 2013). DTT is an 
ER stress inducer as it is a strong reducing compound and blocks disulfide-bond 
formation. Thapsigargin is another well-known ER stress inducer and it acts as a specific 
inhibitor of the sarcoplasmic/ER Ca2+-ATPase (SERCA), resulting in a decrease in 
calcium levels in the ER. The decreased calcium levels in the ER lead to the 
accumulation of unfolded protein followed by ER stress induction due to the loss of 
activities of calcium-dependent ER chaperones (Oslowski and Urano, 2011). Since the de 
novo sphingolipid biosynthesis pathway occurs in the ER, we hypothesized that ER stress 
inducers may interrupt this sphingolipid metabolism. We found that both ER stress 
inducers, DTT and thapsigargin enhanced dhCers and modulated sphingolipid 
metabolism. Their mechanism of actions on sphingolipid metabolism is not completely 
identified yet, but DTT has been shown to strongly inhibit DEGS activity, probably by 
elevating cellular thiol contents or/and interfering with disulfide bonds in enzyme, 




 In summary, we have shown that various compounds with cancer preventive or 
therapeutic properties all induced accumulation of dhCers and modulation of sphingolipid 
metabolism in human colon HCT-116 cancer cells. Our results indicate that these 
compounds initially target DEGS and induce subsequent increase of dhCer species as 
these responses took place very quickly and prior to any signs of cell death. Although 
further studies to identify the clear mechanisms and the different effects of 
chemopreventive compounds on individual CerSs are needed, we have demonstrated that 


















CHAPTER 5.  SUMMARY AND FUTURE DIRECTION 
5.1 Effects and Mechanisms of γTE on Sphingolipid Metabolism 
 
Sphingolipids are structural components of cell membranes and play important 
roles in cellular signal transduction. Using sphingolipidomic approach by LC-MS/MS, 
we demonstrated that γTE, a vitamin E form abundant in palm oil, modulated 
sphingolipid metabolism as an initial primary target and led to induction of apoptosis, 
autophagy and death of cancer cells. Specifically, γTE induced accumulation of 
intracellular dhCers and dhSph, which are important sphingolipid intermediates in the de 
novo biosynthesis pathway and appear to mediate cell death, but decreased in total Cers 
during the initial phase. In the study with 13C3, 15N-labeled L-serine for tracing newly-
synthesized sphingolipids, γTE caused rapid increase of dhCers, but decreases of Cers, 
suggesting that DEGS-catalyzed reaction is likely inhibited by γTE. Consistently, we 
found the inhibition of DEGS activity by γTE, but not the expression. In addition, γTE 
treatment caused increases of endogenous Cer levels with still lower levels of de novo 
Cers during prolonged incubation, suggesting hydrolysis of SM via SMases activation by 
γTE treatment. Blocking the γTE-induced increases of dhCers/dhSph or Cers from SM by 
using myriocin (a specific inhibitor of the first enzyme in the de novo sphingolipid 




significantly reversed the γTE-induced cancer cell death. Overall, our results indicate that 
γTE modulated enzyme activities in sphingolipid metabolism, specifically by inhibition 
of DEGS as an initial target and activation of SM hydrolysis, and this modulation of 
sphingolipid plays an important role in γTE-induced cancer cell death. 
 We showed that γTE also modulated Cer levels, although the effects of γTE on 
individual Cers were varied in cancer cells. For instance, γTE treatment led to significant 
decrease in C16:0-Cer during the initial phase, but increase in the longer time treatment. 
While γTE caused an increase in C18:0-Cer, it led to continuous decreases in C24:1- and 
C24:0-Cers. Interestingly, emerging results suggest that endogenous Cers with different 
fatty acyl-chain lengths appear to have distinct bioactivities. C18:0-Cer generated by 
CerS1 has been found to induce apoptosis and lethal autophagy (Senkal et al., 2010; 
Sentelle et al., 2012). However, the roles of C16:0-Cer and C24-Cers in the regulation of 
cell death are still debatable. C16:0-Cer generated by CerS5/6 have been proposed to have 
antiapoptotic roles (Senkal et al., 2010), but several other studies found that this Cer also 
plays important roles in apoptotic cell death (Mullen et al., 2011; Schiffmann et al., 
2009b; White-Gilbertson et al., 2009). Therefore, further investigation should be 
conducted to determine the role of individual Cer species and to characterize the effects 
of γTE on individual CerSs and Cers. 
 Although our study provided a mechanistic explanation of anticancer activity of 
γTE, the underlying mechanisms by which γTE modulates sphingolipid metabolism are 
not completely understood. Since sphingolipid metabolism is a dynamic and complex 




it remains to be investigated regarding how γTE inhibits DEGS enzyme activity and 
activates acid SMase. In addition, whether this mechanistic study can be translated in 
preclinical models also warrants further investigation. 
 
5.2 Anticancer Effects and Mechanisms of 13’-carboxychromanols, Long-chain 
Metabolites of Vitamin E 
 
Cancer is one of the leading causes of death worldwide. Natural forms of vitamin E 
are potentially good chemoprevention agents as they are known to be safe and specific 
forms of vitamin E have been shown to have cancer prevention effects. Among them, αT, 
which is the predominant vitamin E form in tissues, is the most extensively studied in 
relation to prevention of cancer. However, the human clinical studies as well as numerous 
animal studies of αT in cancer prevention resulted in inconsistent and disappointing 
outcomes. On the other hand, recent mechanistic and preclinical studies using preclinical 
animal models have demonstrated that other forms of vitamin E appear to have different 
and stronger biological properties for cancer prevention and therapy compared with αT. 
Despite these exciting findings, the anticancer effects may not directly be rooted in non-
αT form of vitamin E per se because most vitamin E forms are readily metabolized in 
vivo. Recently, long-chain carboxychromanols are found at high levels in feces from mice 
fed diet supplemented with γT or δT, and 13’-carboxychromanols (13’-COOHs) were 
major fecal excreted carboxychromanols (Bardowell et al., 2012a; Bardowell et al., 
2012b; Jiang et al., 2007; Jiang et al., 2013). Interestingly, 13’-COOHs appear to have 




inhibitory effects toward COXs and LOX activities (Jiang et al., 2008; Jiang et al., 2011). 
Since chronic inflammation has been recognized to be an important risk factor in cancer 
development, 13’-COOHs could be potential cancer preventive agents due to their strong 
anti-inflammatory properties. Birringer et al. recently found that 13’-COOHs 
metabolized from αT or δT induced apoptosis in human liver cells, but the underlying 
mechanism was not completely understood (Birringer et al., 2010). 
 We showed that 13’-COOHs derived from δT or δTE inhibited the growth and 
induced apoptosis and autophagy in human colon, breast, and pancreatic cancer cells. In 
these activities, 13’-COOHs were much stronger than natural forms of vitamin E. Using 
LC-MS/MS method, we found that δT-13’-COOH increased intracellular dhSph and 
dhCers but decreased C16:0-Cer within 2 h treatment. During longer treatment, δT-13’-
COOH enhanced all sphingoid bases including Cers while decreased SMs. Modulation of 
sphingolipids by 13’-COOHs was observed prior to or coinciding with biochemical 
manifestation of cell death including PARP cleavage and LC3-II increase. The 
importance of sphingolipid modulation was supported by the observation that 
pharmaceutically blocking the increase of these sphingolipids partially counteracted 13’-
COOH-induced cell death. Further mechanistic studies indicated that 13’-COOH 
inhibited DEGS without affecting its protein expression and may activate SM hydrolysis 
to enhance Cers. In agreement with these cell-based studies, δTE-13’-COOH 
significantly decreased colon tumor multiplicity induced by AOM with two cycles of 
1.5% DSS without any apparent toxicity even when the dietary supplementation was 




anticancer effects by modulating enzyme activities in sphingolipid metabolism in cancer 
cells. 
 Current study demonstrated that 13’-COOHs have potent anticancer effects in 
various human cancer cells, even stronger than their unmetabolized vitamin E forms. 
However, as 13’-COOHs are relatively newly found compounds, studies to investigate 
the effects and mechanisms of 13’-COOHs are scarce. Therefore, many further studies 
are needed to understand the properties of these compounds using cell culture studies, 
animal models and human studies. First of all, although our study provides mechanistic 
insight into 13’-COOHs-mediated anticancer effects, underlying mechanisms by which 
13’-COOHs modulate enzyme activities in sphingolipid metabolism and exert anticancer 
effects are not completely understood. Moreover, investigation and comparison of the 
anticancer effects of other 13’-COOHs would be interesting. Second, in our AOM-DSS 
colon cancer animal study, supplementation of δTE-13’-COOH significantly attenuated 
DSS-caused colon inflammation and decreased the number of large-sized tumors. To 
better understand the underlying mechanisms of the anticancer effects of 13’-COOHs, we 
can analyze other cancer biomarkers such as β-catenin and Ki67 as a proliferation marker 
as well as inflammatory markers such as PGE2 and LTB4 from plasma. Further 
measurement of the levels of 13’-COOHs in plasma, feces, and other tissues also needed 
to be conducted. In addition, further researches are needed to investigate bioavailability 
of 13’-COOHs in animals and humans. Although we know that relative high levels of 
13’-COOHs can be found in feces after vitamin E supplementation and we can speculate 
that 13’-COOHs may exert their anticancer effects when they pass through the colon 




Therefore, future studies are needed to investigate their anticancer effects and underlying 
mechanisms as well as bioavailability in other cancer tissues. 
 
5.3 Phytochemicals as Chemopreventive Agents 
 
Carcinogenesis is generally recognized as a multistep process including tumor 
initiation, promotion and progression, and cancer cell growth is driven by multiple altered 
signaling pathways to gain unlimited growth potential. Therefore, blocking only one 
signaling transduction pathway might not be sufficient to suppress the growth of cancer 
cells.  
Dietary phytochemicals have been used for the prevention as well as treatment of 
cancer for a long time due to their safety and general availability. Chemopreventive 
phytochemicals can block or reverse the multistep carcinogenesis by targeting multiple 
signaling pathways and proteins. Despite their beneficial properties against cancers, the 
underlying mechanisms are not completely understood. Although many studies have 
shown the multiple targets of chemopreventive phytochemicals, if we can find the initial 
primary target of their anticancer effects, it would be more useful information to 
understand their mechanism. 
 We demonstrate that various representative phytochemicals including curcumin, 
resveratrol, EGCG, quercetin and sulforaphane show anticancer effects by modulation of 
sphingolipid metabolism using LC-MS/MS technology. Specifically, while the effects of 
individual compounds on different Cer species with distinct chain-length of fatty acyl-




with controls. Interestingly, these changes of sphingolipids by the tested phytochemicals 
occurred quickly and took place prior to any signs of cell death. These data demonstrated 
that modulation of sphingolipid metabolism might be a general mechanism for the 
anticancer effects of various chemopreventive compounds against cancer, and inhibition 
of DEGS enzyme might be the initial primary target of their anticancer actions. 
 Although several phytochemicals have been extensively studied and have 
exhibited potent anticancer activities through alteration of various mechanisms, and our 
study demonstrates the modulation of sphingolipid metabolism as an initial and primary 
target for anticancer activity of them, there are still a number of key weaknesses and 
further researches to be conducted. First weakness of the current researches of 
phytochemicals is that most studies have been conducted in vitro and little is known 
about the bioavailability of the compounds. Although numerous cell-culture studies have 
evaluated and defined the anticancer effects and mechanisms of several phytochemicals, 
most in vitro studies used supraphysiological concentrations, which might not be 
achievable when the phytochemicals are administered as a diet. In addition, 
phytochemicals generally show very low bioavailability as the small proportion of these 
compounds is absorbed and it further has extensive metabolism before going to target 
organs. Moreover, their bioavailability might become further lower as they are present as 
glycosides or converted to other conjugated forms after absorption. Finally, although 
many reports have suggested health benefits and molecular targets of dietary 
phytochemicals in cell culture and animal models, the effects of phytochemicals in 




agents in humans, further investigations of pharmacokinetics and bioavailability, and the 
anticancer effects and mechanisms of the compounds should be conducted carefully. 
 
5.4 Dietary Vitamin E in Colon Cancer Prevention 
 
Colon cancer is one of the leading causes of cancer-related deaths in the US (Siegel 
et al., 2015). Because advanced colon cancer is a devastating disease for patients, 
intervening before the development of tumor can prevent cancer-associated deaths. Early 
detection of dysplasia and prevention of colon cancer progression in high-risk population 
as secondary prevention, which is the treatment for patients who already have developed 
risk factors or disease, will be a key strategy to reduce its incidence. Given that chronic 
inflammation has been directly associated with the malignant transformation and 
development of colon cancer, patients with long-standing inflammatory bowel disease 
(IBD), which can be divided into two major disorders such as ulcerative colitis and 
Chrohn’s disease, have an increased risk of developing colon cancer and have been 
known to be a high-risk population for colon cancer. Although IBD-associated colon 
cancer accounts for only about 1~2% of all cases of colon cancer, patients with IBD are 
six times more likely to develop colon cancer than the general population (Lennard-Jones 
et al., 1983). Thus, secondary prevention must be considered in this population to prevent 
the risk.  
The ideal chemopreventive agent would be safe, inexpensive, and effective. In this 
regard, natural forms of vitamin E are considered as potentially promising 




forms such as γT and γTE, and δT-13’-COOH, a long-chain metabolite of δT exert anti-
inflammatory activities (Jiang, 2014; Jiang et al., 2000; Wang and Jiang, 2013; Wang et 
al., 2015). In addition, results from previous studies in our lab and this study have 
demonstrated that supplementation of vitamin E forms (Jiang et al., 2013) or its long-
chain metabolite results in a significant reduction of carcinogen-induced colon tumor 
incidence or the fecal scores in AOM-DSS colon cancer model and DSS colitis model in 
mice, respectively, suggesting that vitamin E may play important roles in preventing 
colon tumorigenesis.  
Although the doses of vitamin E used in the current study had no adverse effects in 
mice, more researches are needed to translate the dose of vitamin E and the timing to 
begin vitamin E supplementation in animal studies into clinical trials in humans. Overall, 
our data from the in vivo studies as well as in vitro studies support that dietary vitamin E 
reduces the risk of colon tumorigenesis and may contribute to the establishment of 
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